Functional aspects of thrombolytic therapy by Gemmill, John Douglas










LIST OF FIGURES 7
LIST OF TABLES 10
DECLARATION 1 1
ACKNOWLEDGEMENTS 12
CHAPTER ONE 1 4
A Historical Overview of Myocardial Infarction 14
CHAPTER TWO 29
A Review of Thrombolytic Therapy in the Management; 29
of Acute Myocardial Infarction
Early Experience with streptokinase 30
Early experience of intravenous streptokinase 31
Experience with intracoronary streptokinase 41
Metanalysis of previous studies of streptokinase 45
Intravenous or intracoronary streptokinase? 50




ASSESSMENT OF THROMBOLYTIC EFFICACY 62
A. Coronary Reperfusion 62
Streptokinase 63
Anistreplase 67
Tissue-type plasminogen activator 72
2







Comparison of the Pharmacokinetic Properties of 96
Streptokinase and Anistreplase







CHAPTER FOUR 1 12
Pre-dosing Antibody Levels and Efficacy of 112
Streptokinase-containing Thrombolytic Agents
Introduction 113




Hypotensive Responses Following Thrombolytic 130
Therapy with Streptokinase-containing Agents








The Time Course of Acquired Resistance 156
to Streptokinase-containing Thrombolytic Agents
in Acute Myocardial Infarction
Introduction 157
Methods 159
Clot lysis assay 160
Data Analysis 161
Results 161
Streptokinase Resistance Titre 162
Anti-SK IgG Concentrations 170
Clot Lysis Assay on Pooled Plasma Samples 175
Discussion 182
CHAPTER SEVEN 1 89
The Efficacy and Safety of Two 35 sag Boluses of 189
Alteplase in Acute Myocardial Infarction
Introduction 190








Low Dose Bolus Alteplase in 209
Acute Myocardial Infarction
Introduction 210








Time to treatment: Pharmacokinetic 229
considerations and early treatment
Limitations of the streptokinase-containing 230
thrombolytic agents: the role of acquired
resistance and haemodynamic responses
Rt-PA bolus dosing 237
Future developments 239
REFERENCES 242
APPENDIX I - PATIENT DEMOGRAPHY 261
APPENDIX II - DEFINITION OF TIMI SCORES 268
APPENDIX III - STUDY PROTOCOLS 270




The benefits of thrombolytic therapy in acute myocardial
infarction are established, yet there remain important
questions, including the safe interval for effective
readmistration of the streptokinase-containing thrombolytic
agents, and how to expedite the administration of therapy
and the restoration of coronary patency. The work in this
thesis addresses some aspects of these questions.
The administration of thrombolytic agents by bolus
injection has practical attractions. The pharmacokinetic
properties of streptokinase (SK) and anistreplase in their
standard administration regimens are compared, and
demonstrate the significantly earlier, higher plasma
concentrations and longer half-life achieved by bolus
administration of anistreplase.
The significance of antibodies to the SK-containing
thrombolytic agents is largely unknown. Pretreatment SK
resistance titre and anti-SK IgG concentrations were
measured in 128 patients with acute myocardial infarction
treated with SK or anistreplase. A significant minor
negative influence of SK resistance titre on coronary
patency was observed. The haemodynamic responses to these
agents were observed in detail, and blood pressure falls
found to be usually short-lived and not require specific
intervention. An association was sought between
hypotensive episodes and markers of immunological
resistance, markers of thrombin activity, and plasma
viscosity. No relationship was found, refuting their
implication in the hypotensive mechanism.
The time course of the development of changes in SK
resistance titre and anti-SK IgG concentration were
documented in detail in the same patients over 30 months.
Both indices peaked at 2 weeks following therapy, and
declined slowly, with 50 & 58% respectively of the
population returning to within two standard deviations of
pretreatment levels within 2 years. The functional
sequelae of these antibody responses were studied in vitro
using a pooled clot lysis assay. These data demonstrated
near complete inhibition of lysis up to 9 months, with 75%
recovery at 30 months.
Two novel administration regimens of alteplase, as 2
intravenous boluses of 35mg, or 3 of 20mg, were assessed by
their ability to achieve high plasma concentrations of t-PA
and coronary patency. The former regimen achieved coronary
patency in 87% at 90 minutes, but while the latter achieved
high early patency there was a 30% reocclusion rate, making
this regimen unlikely to be suitable for clinical use.
The use of SK-containing thrombolytic agents may be limited
by haemodynamic and immunological reactions, and bolus
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A HISTORICAL OVERVIEW OF MYOCARDIAL INFARCTION AND CORONARY
THROMBOSIS
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"The heart is a firm, thick mass so richly supplied
with fluid that it does not suffer harm or manifest pain."
Hippocrates (460 - 370 BC)
The heart in itself is not the beginning of life, but it is
a vessel made of dense muscle, vivified and nourished by the
artery and vein, as are the other muscles."
Leonardo da Vinci (1452 - 1519)
In early times, the heart was thought to be the origin of
life and the seat of the soul. Although the function of
this essential organ was not recognised by Hippocrates, he
taught the concept that the heart was not affected by
disease processes - "cor non aegrotaro potest". It was not
until the second century that Galen (130 - 200 AD)
recognised the motor power of the heart and first termed the
arteries of the heart coronary arteries.
Knowledge of the heart advanced little during the Middle
Ages, until the time of the celebrated English physician,
William Harvey (1578 - 1657) who first described the
circulation of the blood in "de Motu Cordis" in 1628.
Harvey also described rupture of the left ventricle
coincident with thrombosis in a calcified coronary artery in
"Exercitationes II ad Riolanum" in 1660, probably the
earliest description of acute myocardial infarction.
"Ossification of the coronary arteries" was described in the
late seventeenth and early eighteenth centuries by
Drelincourt (1633 - 97), Bellini (1643 - 1704) and
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Thebesius (1708). Lancini of Rome (1654 - 1720) included
calcified coronary arteries as one cause of "aneurysm of the
heart", a term used at that time to describe cardiomegaly.
In 1749, Senac again described ossified coronary arteries
associated with thin-walled parietal aneurysms of the left
ventricle. Morgagni in "De Sedibus et Causis Morborum"
(1761) described patients who in life had typical symptoms
of angina pectoris and myocardial infarction, and who at
autopsy had obstructed coronary arteries, although the
connection between these findings was not made.
William Heberden (1710 - 1801) in 1768 and again in 1782
gave perfect graphical accounts of the symptom complex of
angina pectoris, although he did not offer an explanation of
the pathophysiology of this syndrome. The connection
between angina pectoris and the heart and in particular the
coronary arteries was first suggested by three men -
Fothergill, Parry and Jenner.
John Fothergill (1712 - 80) was a graduate of Edinburgh
university who described a case of a man with angina
pectoris who proceeded to a sudden death, and attributed his
symptoms and demise to the heart. After an autopsy was
performed by the famous dissector, John Hunter, on a 63 year
old man with angina, Fothergill described the heart as being
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of "a ligamentous consistence and in many parts of the left
ventricle almost white and hard"...."the two coronary
arteries from their origin to many of their ramifications
upon the heart were become one piece of bone."
Edward Jenner (1749 - 1823) and Caleb Hillier Parry (1755 -
1822) claimed that myocardial ischaemia due to coronary
obstruction was the cause of angina, and Parry in 1799
described "syncope anginosa", although undoubtedly some of
his cases of angina had suffered myocardial infarction.
Publication of some of these theories was delayed until
after the death of the dissector, John Hunter, in 1793. In
life he suffered from angina pectoris, and his friends were
reluctant to predict his demise due to coronary obstruction,
but after his death, as predicted, he indeed had extensively
calcified coronary vasculature.
On the experimental front, in 1809 Allan Burns, proved that
deprivation of blood flow caused pain by occluding the
brachial artery with a ligature. He suggested that
ischaemic pain of the heart was the cause of angina
pectoris.
Latham (1789 - 1875) was probably the first to differentiate
patients with chronic stable angina pectoris from those with
a shorter, less effort-related history of greater severity
and associated with early death, probably due to myocardial
infarction. However, he did not relate these events to the
coronary arteries.
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The late eighteenth and nineteenth centuries were the era of
"physical medicine", led by Laennec (1781 - 1826) and
Corvisart (1755 - 1821), when the recognition and
demonstration of physical signs was considered all-
important. In this atmosphere, because of the absence of
physical signs, angina was largely dismissed as either a
"rheumatic" or "nervous" complaint. Rokitansky and Virchow
both regarded left ventricular aneurysms as inflammatory in
origin and the pain of angina due to "nervousness".
It was Richard Quain (1816 - 1889) in 1850 who clearly
related diseased coronary arteries to angina and myocardial
changes in "On Fatty Diseases of the Heart". He wrote of
"local modification of nutrition" and described again
ossification of the coronary arteries. He also wrote that,
in the absence of anastamoses between the coronary arteries,
"obstruction from any cause in one will not admit of the
deficiency being compensated for by the supply of the
other". He described localised fatty degeneration of the
myocardium in the context of alteration of the coronary
artery to this part: "I have seen the coronary extensively
ossified, going directly to the only part of the heart
affected" and "at least, arteries proceeding to the
principal seat of the disease, are found more or less
obstructed." He understood the basic pathophysiology of
ischaemic heart disease, writing that ossification of the
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coronary arteries "caused interference with the nutritive
function of the artery and thus produced the softening which
was attended by pain on effort."
The late nineteenth century German physicians had an
understanding of ischaemic heart disease not dissimilar to
that of the modern era. Karl Weigert in 1880 wrote "in
atheromatous changes of the coronary arteries not
infrequently thrombotic or embolic obstructions form in the
branches of the arteries. If the obstruction forms slowly,
or at least in such wise that collateral channels exist, but
not enough to keep up nutrition, a slow atrophy occurs with
destruction of the muscle fibres without injury to the
connective tissue. The muscle fibres that disappear are
replaced by fibrous connective tissue, and the so-called
chronic myocarditis is no more than such a process." In
1882, Karl Huber clearly described the process by which
atheroma of the artery caused diminution of myocardial blood
supply leading to anaemic, atrophic or necrotic lesions
which ultimately become areas of fibrosis. Two years later
in 1884, Ernst Leyden described differing rates of
development of coronary obstruction causing a spectrum of
clinical disorders, from angina pectoris through myocardial
infarction and sudden death to incipient congestive cardiac
failure.
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In 1842, Marshall Hall speculated that sudden death was
often due to arrest of the coronary circulation and John
Erichsen showed that ligation of a major coronary artery in
the dog caused syncope. Further experiments in dogs were
reported by Connheim in 1881, who showed that ligation of
large coronary arteries caused death within two minutes.
Although he also showed that ligation of smaller coronary
vessels or more gradual obstruction caused much lesser or
indeed no ill effects, the medical world concentrated on the
sudden death aspects of coronary occlusion and extending the
conclusions of these observations to man, decided that
coronary occlusion was incompatible with life and therefore
not worthy of further major investigation. It was
unfortunate that this opinion dominated at the time of the
major surge in matters medical led by the innovative work of
Koch and the pioneer surgeons, with the effect that
cardiological knowledge was not substantially advanced by
this wave of medical enthusiasm (from Herrick, 1942).
Herrick in 1912 described in detail two patients with
myocardial infarction who survived 52 hours and seven days,
the first case having suffered a thrombotic occlusion of the
proximal left anterior descending coronary artery (Herrick,
1912). He also reviewed the historical literature,
emphasising experiments where the animal survived in the
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short term following coronary occlusion, and the occasional
description of patients coming to autopsy with evidence of
previous coronary occlusions and myocardial infarctions
which they had survived for some time.
However, even after it was accepted that it was possible to
survive a coronary occlusion and ensuing myocardial
infarction, there remained one major argument which raged
for at least half a century, namely the question of whether
coronary thrombosis was the cause or effect of myocardial
infarction. Numerous papers concerning this controversy
were published, supporting both sides of the argument.
Early in the discussion, there had always been difficulty in
accepting that coronary thrombus was an important initiating
event in vivo, as coronary thrombosis had previously been
observed as an incidental finding in autopsies, notably in
the nineteenth century. At that time, medical teaching
instructed that coronary occlusion was incompatible with
life and it therefore followed that these findings were an
irrelevant post-mortem artifact. However, once it was
accepted that man was able to survive coronary occlusion,
and indeed that such an event could be asymptomatic, this
argument was no longer valid.
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There remained, however, other arguments favouring coronary
thrombosis as a secondary phenomenon (Roberts & Buja, 1972,
Silver et al., 1980, Baroldi et al., 1979, Roberts, 1974,
Hellstrom, 1979). Coronary thrombosis had been documented
in the absence of myocardial infarction. This can be
explained by the presence of sufficient coronary
collateralisation (Blumgart et al., 1940) and a slow onset
of coronary occlusion.
Post-mortem studies in sudden death failed to demonstrate
coronary thrombus (Roberts et al., 1972). This argument is
only valid if it is assumed that myocardial infarction is
the cause of sudden cardiac death. However, other studies
have demonstrated that patients resuscitated from sudden
death do not necessarily develop evidence of myocardial
infarction (Cobb et al., 1975, Liberthson et al., 1974a,
Liberthson et al., 1974b). It was subsequently revealed
that sudden death in ischaemic heart disease was due to
primary ventricular arrhythmias, often associated with an
acute ischaemic event, but not necessarily with major
coronary occlusion and myocardial infarction, or else due to
primary arrhythmia in chronic ischaemic heart disease in the
absence of acute ischaemia.
Estimates of the incidence of coronary thrombosis as judged
by post-mortem studies vary enormously. For example,
Branwood et al., 1956, reported an incidence of 21%, and at
the other extreme, Ridolfi et al. , (1977) 93%. Several
authors have reported cases of myocardial infarction in the
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absence of coronary thrombosis (Ehrlich et al., 1964, Maseri
et al., 1978a,b). This finding can be explained in a number
of ways. Not all myocardial infarctions are necessarily due
to occlusive coronary thrombus. Other causes of coronary
obstruction causing myocardial infarction without primary
coronary thrombosis include coronary artery spasm (Maseri et
al., 1978a, Braunwald ,1978), coronary embolism (Ehrlich et
al., 1964), coronary dissection, and rupture of and
haemorrhage into an atherosclerotic plaque (Willerson et
al., 1980). It is important to differentiate between
anatomically discrete, regional myocardial infarction and
more diffuse global, subendocardial or laminar myocardial
infarctions or multiple micro-infarcts. This distinction is
not always clearly made in the literature. Diffuse
myocardial infarction is more likely to be due to systemic
causes such as severe hypotension, anoxia, anaemia, coronary
embolus or conditions of increased myocardial oxygen demand,
such as tachycardia or hypertensive crises (Buja et al.,
1981), although systemic causes on the background of a
critical coronary stenosis may precipitate a discrete
myocardial infarction. Obversely, in general, discrete
segmental infarcts are more likely to be associated with
acute coronary thrombosis, probably superadded to a coronary
stenosis, possibly precipitated by atherosclerotic plaque
rupture.
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This view was supported by Ehrlich and Shinohara in 1964 in
a careful pathological study with block dissection of
coronary arteries in 38 patients dying after myocardial
infarction and 29 controls dying from unrelated causes.
Although coronary thrombus was identified in only 50% of all
38 patients with myocardial infarction, the prevalence was
94% (17 of 18) of patients with unicentric myocardial
infarction, compared to 10% (2 of 20) of patients with
multicentric infarction. Similar post-mortem studies have
confirmed these findings (Buja et al., 1981). In addition,
post-mortem studies take no account of the possibility of
ante-mortem recanalisation (deWood et al., 1980), post¬
mortem thrombolysis or clot retraction after death.
The incidence of coronary thrombosis found at post-mortem
studies may depend on the rigour of the pathological and
histological techniques employed (Ehrlich et al., 1964) and
also the delay between the onset of myocardial infarction
and pathological examination. Although some authors have
found higher incidence of thrombus in older myocardial
infarctions (Spain and Bradess, 1960), this would not be in
keeping with the data of deWood (1980) - vide infra. It is
important to note that post-mortem studies are by definition
performed on a selected sub-group of patients with
myocardial infarction, and it would hardly be surprising if
some systematic bias was introduced to these studies.
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The pathological studies also made efforts to differentiate
post-mortem clots from in vivo thrombus, and although they
can be differentiated histologically, they are easily
confused on naked eye examination. This differentiation may
have added a further confounding factor to the pathologists'
studies.
The observation that larger and transmural infarcts,
especially if associated with cardiogenic shock, or severe
congestive cardiac failure, had a higher incidence of
coronary thrombus was also used to suggest that coronary
thrombosis was secondary to myocardial infarction. These
studies are flawed by the patient selection inherent in
these studies and it is not surprising that larger infarcts
are associated with larger, more proximal and more
persistent coronary thrombus, and therefore more likely to
be identified in pathological studies.
Early studies with radio-labelled fibrinogen injected
several hours after the onset of myocardial infarction
showed that fibrinogen continued to be incorporated into the
coronary thrombus, and this was interpreted as meaning that
coronary thrombosis was secondary to myocardial infarction
(Erhardt et al., 1973 & 1976). However, subsequent studies
with radio-labelled fibrinogen have suggested that the label
may continue to be incorporated into clot formed prior to
the injection of the tracer (Salimi et al., 1977) and that a
radio-negative core can be demonstrated in most human
thrombi (Fulton et al., 1977). These later findings
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illustrate that coronary thrombus occurs before the
injection of radio-label and that formed thrombus remains in
a dynamic state of equilibrium after its formation in the
coronary arteries.
By 1980, there had been a number of post-mortem and
clinicopathological studies published which showed that
there was a strong association between acute coronary artery
occlusion in the infarct related artery and regional
myocardial infarcts, and a temporal relationship between the
age of the thrombus and the age of the infarct, albeit
recognising the limitations of the histological techniques
in this regard (Willerson et al., 1980). Thus it was
reasonably clear that coronary thrombosis was an associated
event, rather than a post-mortem artifact in acute
myocardial infarction, and it was thought that the thrombus
was a major factor in the causation of myocardial
infarction.
In 1980, deWood and his colleagues published a classical
paper which to a great extent resolved many of the previous
arguments, as well as establishing the safety and
feasibility of coronary angiography in the early stages of
myocardial infarction. They performed selective coronary
angiography on 322 patients with proven acute myocardial
infarction within 24 hours of onset of chest pain. It was
shown that if the artery was examined within 4 hours of
onset of myocardial infarction, coronary occlusion could be
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demonstrated in 87% with a subtotal lesion in a further 10%.
However if arteriography was delayed to at least 12 hours,
the occlusion rate had fallen to 65%, with subtotal lesions
in 16%. Patients with cardiogenic shock showed a strong,
but not significant trend towards persistent total occlusion
(86%) throughout 24 hours.
This important study demonstrated the central role of
coronary occlusion due to thrombosis in acute myocardial
infarction and the occurrence of spontaneous reperfusion.
It also suggested the application of thrombolytic drug by
the intracoronary route of administration in myocardial
infarction, and stressed the essential elements of
pretreatment patency and influence of time on coronary
patency in the interpretation of future patency/reperfusion
studies of thrombolytic therapy in acute myocardial
infarction.
Since this work, coronary angiography has been performed
early in the course of acute myocardial infarction in many
patients, both for confirmation of diagnosis and
administration of therapy. The findings confirm the high
incidence of coronary occlusion early in the process of
infarction, being 74-86% in the first 12 hours of myocardial
infarction (Rentrop et al., 1981, Anderson et al. , 1983,
Kennedy et al., 1983, TIMI-1, 1985, Simoons et al., 1985,
Blanke et al., 1985, Williams et al., 1986).
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Once the causative role of coronary thrombosis in myocardial
infarction was accepted, the way was open for the logical
trial of thrombolytic therapy, and the next chapter




A REVIEW OF THROMBOLYTIC THERAPY IN THE MANAGEMENT
OF ACUTE MYOCARDIAL INFARCTION
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Early experience with streptokinase in acute
myocardial infarction
Streptokinase is derived from streptococci and was first
used to dissolve collections of sanguineous, fibrinous, and
purulent fluid in man {Tillett and Sherry, 1949) and was
subsequently used experimentally to lyse in vivo
intravascular blood clots (Johnson and Tillett, 1952).
From an early stage in the drug's development it was
appreciated that streptokinase exerted its effects by
stimulation of the intrinsic lytic cascade by activating
plasminogen, which it does with great efficacy (Sherry,
1 954 ) .
In 1959, Ruegsegger et al. reported on the experimental use
of fibrinolytic therapy with intravenous and intracoronary
infusions of thrombin to lyse thrombi, formed in coronary
arteries in dogs by the introduction of serum into a
restricted segment of coronary artery. They followed
events by serial coronary arteriography and demonstrated
lysis of the intracoronary clots, after 3 to 7 hours in 4
of 5 dogs. Histological examination of the treated and
control animals' myocardium showed less oedema and
capillary damage in the lysed group, and perhaps more
importantly did not find any evidence of damage induced by
the thrombin therapy, and a little surprisingly did not
even identify intramyocardial haemorrhage. Although this
study was performed in small numbers of surviving animals,
and used a drug which could not be widely applied because
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of its scarcity, it did demonstrate that systemic treatment
with a thrombolytic agent was feasible and possibly
beneficial. This latter point, although far from proven,
at least opposed previous work which suggested that
coronary occlusion of 30 minutes produced ischaemic damage
equivalent to that of permanent coronary occlusion
(Blumgart et al., 1941).
In the same year, Fletcher et al. , (1959) published on the
maintenance of a sustained thrombolytic state in man with
streptokinase. They treated 22 patients with myocardial
infarction with an intravenous regimen of streptokinase
over 30 hours in a dose designed to cause an intense lytic
state. Their therapy was initiated very late by modern
standards with 19 patients being treated at a mean time
delay of 9 hours, and the remaining three receiving therapy
from 34 to 65 hours after onset of symptoms. Although this
study was essentially observational, and no conclusions
could be drawn from it concerning any putative benefits, it
was very important in that it demonstrated that a lytic
state could be maintained in man without serious
haemorrhagic complications.
Early experience of intravenous streptokinase in acute
myocardial infarction
Between 1959 and 1966, there were 21 other feasibility
studies of thrombolytic agents in myocardial infarction,
with series of 5 to 100 patients, using streptokinase,
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urokinase and plasmin (Simon, 1973). The first large-scale
controlled trial was completed in 1966. This was a German-
Swiss trial comparing streptokinase with heparin in 558
patients treated within 12 hours of onset of myocardial
infarction (Schmutzler et al. , 1966). They gave a loading
dose of streptokinase to overcome resistance to
streptokinase, guided by a pretreatment streptokinase
resistance test, followed by an infusion lasting 18 hours
with a variable dose designed to maintain a thrombolytic
state. Although they showed a significant improvement in
mortality in the streptokinase treated group (14.1% vs
21.7% at 40 days, p<0.01), their conclusions were flawed by
their failure to adhere to their randomisation schedule and
their breaking of an intention-to-treat analysis, thereby
introducing potential selection biases, severely
compromising the conclusions of the study.
The same group set up a second German-Swiss trial
(Schmutzler et al., 1966), this time treating 269 patients
with a fixed loading dose of 250,000 units, followed by
167,000 unit/hour for 18 hours compared to an alternately
assigned, but non-blinded placebo group. All patients
recruited were included in the analysis. Clearly, this
allocation regimen is far from ideal, and although the
baseline patient characteristics in the two groups were
similar, a selection bias again cannot be ruled out. Their
40 day mortality was significantly better in the
streptokinase treated group (14.5% vs 26%, p<0.01), as was
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the 24 hour mortality rate (2% vs 10%, pcO.001). This
benefit was confined to those patients treated within 6
hours of onset of symptoms. Interestingly, statistical
significance was not achieved in the sub-group of patients
treated in a coronary care unit rather than in a general
ward.
The First European Working Party trial was established in
1963, and reported in 1969 (Amery et al., 1969) and
recruited 167 patients presenting up to 72 hours after
onset of symptoms of myocardial infarction. Patients
received either heparin or streptokinase as a 1.25 MIU
loading dose and 104,000 units/hour for 72 hours. In this
study mortality was higher in the streptokinase group,
although this trend did not reach statistical significance.
Cardiac rupture was higher in the treatment group and there
was a high incidence of side effects attributed to
streptokinase.
The Second European Working Party trial in 1966 (European
Working Party, 1971) recruited a more substantial 730
patients, presenting within 24 hours of chest pain. This
study was randomised and double-blind, with patients
receiving either streptokinase 250,000 units loading, then
100,000 units/hour for 24 hours, or heparin. On this
occasion, mortality was significantly lower in the
streptokinase group at 40 days (18.5% vs 26.3%, p<0.01).
A contemporary Finnish study addressing the same question
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showed no evidence of treatment benefit, but the study was
flawed by a number of design faults. In particular,
different centres within the study used differing treatment
regimens, and generally the doses of streptokinase used
were smaller than previously, and again patients were
recruited up to 72 hours following onset of symptoms. In
addition, there were differences in the pretreatment
characteristics of the two groups, with a higher incidence
of heart failure in the streptokinase group. Lastly, the
control mortality rate was low, and the study lacked the
necessary power to detect a treatment benefit.
The first high-dose short duration study of streptokinase
in myocardial infarction was performed in Frankfurt in
1972, using an intravenous infusion of 750,000 units of
streptokinase over 3 hours in 216 patients within 12 hours
of chest pain, in a double-blind randomised protocol.
Mortality was markedly improved in the streptokinase group
(12.7% vs 27.9%, p<0.01 ) .
Dioguardi et al. published in 1971 the results of a
comparison of streptokinase and heparin, administered in a
coronary care unit setting. They recruited 321 patients
within 12 hours of symptoms, and the treatment group
received 250,000 units streptokinase loading, then 150,000
units/hour for 12 hours. Although their study protocol
appeared sound, they did not find any treatment effect,
with near identical mortality rates in the two groups.
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This may in part be accounted for by the relatively low
numbers recruited, and a low mortality rate in the control
group making a significant improvement difficult to
demonstrate. The latter limitation recurs in later studies
(v.i.).
The Australian multi-centre trial (Bett et al., 1973)
treated 534 patients within 24 hours of onset of myocardial
infarction, with the prolonged infusion regimen of
streptokinase of 250,000 units loading, then 100,000
units/hour for 17.5 hours. Although none of their
differences in mortality reached statistical significance,
they found a trend to improvement in the streptokinase
group (9.8% vs 12.6% at 3 months, NS) and identified
relatively greater benefit in patients in high risk
categories by sub-group analysis. Clearly, interpretation
of this type of analysis must be qualified. In their
discussion, the authors commented on the possibility of a
Type II error, and felt that a positive result favouring
streptokinase could not be ruled out, and elected to
continue to recruit a further 500 patients. The second
phase of this study reported in 1977 on a total of 747
patients, followed up for twelve months, but still found no
significant difference in mortality between the two groups
(Bett et al., 1977) .
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A United Kingdom coronary care unit based, multi-centre,
placebo-controlled, randomised study of streptokinase was
performed between 1971 and 1974 (Aber et al., 1976). They
recruited 595 patients within 24 hours of onset of pain
with a clinical diagnosis of myocardial infarction. The
treatment group received 2.5 MIU of streptokinase over 24
hours, and follow-up was for 6 months. Mortality at
discharge was 12.6% vs 13.7%, and at six months, 15.9% vs
17.8%, neither difference reaching significance.
A controlled trial of 512 patients randomised to a 24 hour
intravenous infusion of either streptokinase (total of 2.65
MIU) or glucose, was carried out by the European
Cooperative Study Group in 1979. Mortality was
significantly lower in the streptokinase group at six
months (15.6% vs 30.6%, p<0.01), this improved mortality
becoming apparent statistically only after three weeks.
They reported a much higher bleeding complication rate in
the streptokinase group, with 18% of the streptokinase
group suffering from gastrointestinal haemorrhage or oozing
from puncture sites compared to only one of 157 control
patients, with 3% requiring cessation of their
streptokinase infusion. Two patients had cerebral bleeds,
both in the streptokinase group.
Unfortunately, interpretation of the results were a little
compromised by a higher prevalence of recognised risk
factors in the control group and the fact that only 13.5%
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of all their patients with myocardial infarction screened
were admitted to the study. Nevertheless, the study did
reach a statistically significant result in favour of
streptokinase in a good-sized study population.
Ganz et al., in 1984, treated 81 patients within 3 hours of
onset of myocardial infarction with a 15-30 minutes
intravenous infusion of 0.75 or 1.5 MIU of streptokinase.
They assessed reperfusion by immediate non-invasive
criteria, with follow-up coronary angiography at 3-7 days.
Their results suggested that this intravenous regimen could
achieve coronary patency in 78 of the 81 patients although
this was almost certainly an over-estimate.
There were several influential experimental papers
published at the time of these early studies of prolonged
intravenous infusion of streptokinase, which altered
contemporary thinking about the use of thrombolytic therapy
in acute myocardial infarction. Maroko et al. , in 1972,
published the results of experiments on dogs undergoing
reperfusion after 3 hours of coronary artery occlusion.
They demonstrated that reperfusion at this time was
associated with myocardial salvage as reflected in less
creatine kinase depletion, less marked histological changes
and preservation of contractile function. The same group
37
in similar experiments, showed that reperfusion after three
hours resulted in preservation of the subendocardial region
of the myocardium, apparent histopathologically a week
after occlusion, and reflected by preservation of
myocardial creatine kinase activity (Ginks et al. , 1972).
In the early 1970s, there was also discussion concerning
the "no-reflow" phenomenon. This concept was originally
applied to the cerebral and renal circulations and
described the failure of even perfusion to a vascular bed
following a period of arterial occlusion. This phenomenon
was extended to the coronary circulation by Kloner et al.,
(1974) and led to further confusion regarding whether
thrombolytic therapy and coronary reperfusion could
possibly be beneficial, or may even be detrimental, on
theoretical grounds. The histological study in dogs
undergoing temporary coronary occlusion and reperfusion,
showed that periods of ischaemia lasting less than 40
minutes were not associated with permanent
histopathological features, but that if the duration of
ischaemia was extended to 90 minutes, extensive capillary
damage and myocyte swelling occurred in the affected area,
increasing the tissue pressure and preventing flow of blood
into the region - the "no-reflow" phenomenon. The study
also confirmed a previous finding which had been a cause of
much concern in early thrombolytic experiments, namely the
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high incidence of reperfusion arrhythmias in dogs, notably
ventricular tachycardia and fibrillation. In this series
24 of 57 dogs died either on coronary occlusion or
immediately after sudden reperfusion.
Although this study also showed that the region in which
the "no-reflow" phenomenon occurred was entirely contained
within an area of irreversible myocardial cell necrosis,
and therefore could be considered of little relevance,
there followed much debate as to whether the
reestablishment of coronary blood patency was worthwhile if
no functional perfusion could be obtained. This and
similar studies illustrated that relatively short periods
of absolute ischaemia resulted in irreversible damage to
myocardial cell, and therefore questioned the relevance of
previous clinical thrombolytic studies with their
exceptionally long treatment window. It also raised doubts
as to whether thrombolytic therapy could be feasibly
applied to the general population if such a short
therapeutic window was available.
Further animal experimental studies by Reimer et al.,
(1977) provided valuable insight into the realistic time
window for salvage of ischaemic myocardium, and
demonstrated that restoration of coronary flow did diminish
myocardial damage. It was a simple experiment, relating
the duration of coronary occlusion in dogs to the degree
and distribution of myocardial necrosis. They showed that
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longer intervals of ischaemia resulted in a "wavefront" of
ischaemic cell death proceeding from the endocardial to the
epicardial region, and that reperfusion after 3 hours, and
possibly as long as 6 hours resulted in the salvage of a
rim of epicardial myocardium. Clearly this time window for
intervention might be applicable to worthwhile clinical
use, with the possibility of limiting myocardial damage in
patients with myocardial infarction, but it also
illustrated one explanation as to why the early
thrombolytic studies failed to reveal any advantage of
streptokinase treatment, namely that many of the patients
were recruited to the studies with episodes of myocardial
ischaemia which were so long that all vulnerable myocardium
had already been irreversibly damaged.
Interpretation of these clinical studies of prolonged
intravenous infusion of streptokinase in myocardial
infarction was confounded by factors such as the small
numbers involved in individual studies, allowing a Type II
error; differing dosage regimens of streptokinase, where
the benefits of a regimen may have been obscured by the
diluting effects of ineffective doses; differing entry
criteria, in particular differing duration of symptoms, and
inadequate randomisation procedures in some of the studies.
In addition to this, the impact of the introduction of
coronary care units in the early 1970s confused the issue
further by changing the mortality rate of acute myocardial
infarction. This influence was cited as an explanation for
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the apparent benefits of streptokinase in the earliest
studies, which could not be reproduced in later studies,
largely based in coronary care units (Simon et al., 1973).
Later metanalysis studies (Stampfer et al., 1982, Yusuf et
al., 1985) however suggested that many of these
discrepancies could be explained by a Type II error (v.i.).
In some of these studies, the mortality rates in the
control group were small, and on statistical grounds it
would be difficult to show a difference in this context
unless the benefit of the agent was immense, or the sample
size enormous. In addition, any small benefit present in
the sub-groups of patients treated early, would have been
swamped by the larger numbers of patients treated who had
already suffered a completed myocardial infarction. These
small studies however did reach a positive result for
streptokinase when grouped together in a metanalysis.
Experience with intracoronary streptokinase in acute
myocardial infarction
A seminal paper by deWood and his colleagues in 1980
radically influenced the subsequent development of
thrombolytic therapy in the management of acute myocardial
infarction. They assessed the prevalence of coronary
obstruction in a series of 322 patients admitted within 24
hours of onset of acute transmural myocardial infarction.
87% of patients studied within 4 hours of onset showed
coronary occlusion, decreasing to 65% of patients studied
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12-24 hours after onset. In 52 of 59 patients with
angiographic features of coronary thrombosis, they were
able to retrieve thrombus using a Fogarty catheter.
This study established several important landmarks in acute
myocardial infarction. Firstly, it demonstrated the
central role of coronary thrombosis in the aetiology of
myocardial infarction, and determined the incidence of
spontaneous coronary recanalisation, thus explaining many
of the discrepancies in the previous studies. Moreover, it
showed that coronary angiography was feasible and safe so
early in the course of myocardial infarction. This
established the rationale for thrombolytic therapy beyond
doubt, opened the way for intracoronary administration and
acute angiographic assessment of efficacy, and emphasised
the importance of time in the assessment of patency.
In the early 1980s interest centred on the use of
streptokinase in acute myocardial infarction administered
by the intracoronary route, and several studies looking at
this were published. Unfortunately many of the published
studies were not randomised, which although understandable
from the ethical viewpoint, confounded the interpretation
of the results.
Mathey et al. published a paper in Circulation in 1981,
treating 41 patients with 2000 units/minute of
streptokinase, along with attempted mechanical
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recanalisation with a guide-wire, and intracoronary
plasminogen. Using this technique, firstly they showed
that at presentation, 39 of their 41 patients had occluded
coronary arteries, with subtotal lesions in the remaining
two. Coronary patency was reestablished in 73% within one
hour using this combined treatment approach. Repeat
angiography at 7-21 days showed persistent coronary patency
in 12 of 15 patients. A significant improvement in left
ventricular ejection by left ventriculography was
demonstrated in those patients who successfully reperfused.
In a similar study, Ganz et al., in 1981, achieved coronary
reperfusion in 19 of 20 patients treated within 3 hours of
onset of myocardial infarction with Thrombolysin
(streptokinase and plasmin) at an intracoronary
subselective infusion rate of 2000-4000lU/minute. They
also showed that improvement in left ventricular function
was associated with patency. Similar reperfusion rates of
22 of 29 patients (76%) were achieved by Rentrop et al.
(1981), and of 74 of 84 (88%) by Timmis et al. (1982).
Although there were other similar studies performed at this
time, none helped resolve the question of the efficacy or
benefits of streptokinase because of the lack of
randomisation and placebo control.
Some studies (Smalling et al., 1982, Ganz et al., 1981,
Mathey et al. , 1981) did however show a difference in left
ventricular function between responders and non-responders
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to intracoronary streptokinase. In the Smalling paper,
reperfused patients showed a progressive improvement in
left ventricular ejection fraction with time, which was not
apparent in those remaining occluded. It was even more
surprising that this observed benefit was observed up to
eighteen hours after onset of symptoms. The lack of
adequate trial design was emphasised in an editorial by
Muller et al., in 1981, which called for placebo-controlled
studies in what was increasingly recognised as an important
and potentially beneficial area.
The first randomised study was published by Anderson et
al., in 1983. It was however not placebo-controlled or
blinded, the patients receiving active therapy of either
intracoronary streptokinase and intravenous heparin, or
control therapy of subcutaneous heparin. This study cannot
be said to be an adequate test of intracoronary
streptokinase, as the analysis is confused by these other
issues. They achieved coronary patency in 19 of 24 (79%)
of the streptokinase group, and compared changes in
echocardiographic and radionuclide left ventricular
function and clinical grading scores in the treated and
control groups between days 1 and 10. They demonstrated an
immediate and prolonged improvement in ventricular function
and in the Killip clinical class following thrombolytic
reperfusion.
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Khaja et al. (1983) published a placebo controlled,
randomised study of intracoronary streptokinase in 40
patients within 6 hours of onset of myocardial infarction.
They showed a low 60% reperfusion rate with streptokinase
compared to a reperfusion rate of 10% with placebo. They
were unable to demonstrate any benefit associated with
reperfusion in terms of preservation of left ventricular
function.
A similar publication in 1984 (Leiboff et al., 1984) again
showed the efficacy of intracoronary streptokinase in
achieving coronary artery patency, this time using
intracoronary nitroglycerine as a control therapy.
Reperfusion of the infarct related coronary artery was
achieved in 69% of the streptokinase group compared to only
17% of the nitroglycerine group in 43 patients. However,
once again the authors failed to demonstrate any advantage
of streptokinase therapy with respect to improvement of
left ventricular ejection fraction acutely or at 7-10
days.
Metanalysis of previous studies of streptokinase
A variety of studies had shown that thrombolytic therapy
administered by either the intravenous or intracoronary
route was feasible and safe, at least in small numbers
within the confines of a study protocol, and that the
therapy could successfully reperfuse coronary arteries.
However, up to this point although several studies had
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shown benefit on mortality, all these studies had been
based on small numbers of subjects and equally there were
numerous other studies which had failed to show any
benefit. Thus the literature was conflicting and it was
unclear whether reperfusion was translated into benefit to
the patients, either in preserving left ventricular
function or in the ultimate gold standard of reduction in
mortality. Two review and metanalytic papers published by
the same statistically based group of workers helped to
clarify the situation and thus stimulate the further
investigation and use of thrombolytic agents.
The first article was published in 1982 by Stampfer et al.
They pooled the results of eight randomised trials of
intravenous streptokinase, where the control group was
either placebo or anticoagulation, using mortality at
approximately 40 days as their end point. The results of
most of these trials have been discussed individually
above. They calculated the risk ratio for each group, that
is the proportion of deaths in the streptokinase group
compared with the proportion of deaths in the control group
for each trial, with a risk ratio less than one indicating
a beneficial effect of streptokinase. Using this method of
analysis, they found that six of their original eight
studies showed a benefit of streptokinase, with a tendency
for the larger studies to more clearly show benefit.
Pooling the results, appropriately weighting the studies,
they found an overall risk ratio of 0.8, which was
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significantly less than one (p=0.01), with a 95% confidence
interval of 0.68 to 0.95. Excluding the two studies which
recruited patients with duration of symptoms up to 72
hours, the pooled risk ratio became less, and more
significant (0.74, p=0.001, 95% confidence limits 0.62 to
0.89), indicative of a very beneficial effect of
intravenous streptokinase in patients treated within 24
hours of onset of symptoms of myocardial infarction, with a
reduction in mortality from myocardial infarction by 26%, a
figure remarkably similar to that found later in large
mortality studies in the late 1980s.
The second publication in 1985 (Yusuf et al., 1985) pooled
results from a total of 33 studies using intravenous and
intracoronary thrombolytic agents in the treatment of acute
myocardial infarction. Of the 24 trials of intravenous
thrombolytic therapy they reviewed, only five achieved
statistical significance at the 5% level in their own
right, 11 showed a non-significant trend in favour of
thrombolytic therapy, while the remaining eight showed a
non-significant trend toward an adverse effect. Using
similar methods as used in their earlier paper, they
derived an "average" risk, or odds ratio of 0.78, with a
95% significance interval of 0.68 to 0.89, which suggested
a highly significant (p<0.001) reduction in mortality of
22%.
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They applied similar techniques to nine studies of
intracoronary streptokinase, which between them recruited
less than 1000 patients. However, there were only 128
deaths in the entire study group, and it is hardly
surprising that statistical significance was not achieved
even using the pooled results. The calculated pooled
average odds ratio was 0.8 or a mortality reduction of 20%.
They also attempted to address the question of the
influence of delay in institution of therapy on efficacy of
therapy. Dividing the time intervals in the different
studies where the information was available, they were
unable to show that earlier treatment with intravenous
thrombolytic agents was associated with lower mortality.
The intracoronary studies all tended to have short
intervals between onset of symptoms and treatment, and
therefore analysis of this effect was somewhat limited.
Although some studies had suggested that earlier treatment
was associated with higher patency rates following
intracoronary streptokinase, using their overview
techniques, there could not confirm these findings.
Embracing the use of streptokinase in coronary care units,
they were able to provide evidence that coronary care units
did not negate the benefits of thrombolytic therapy.
Although this is not surprising, this question had been
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seriously raised. It is likely that the apparent negation
of the advantages of streptokinase can be attributed to the
smaller overall mortality and hence a larger chance of a
Type II error.
There are clearly limitations to this statistical overview
methodology in the objective assessment of the value of a
therapy. Notably, such analyses assume that all the data
from all performed studies are included in the metanalysis.
Exclusion of any relevant data, or a selection bias can
radically influence the conclusions of any overview, and
given the tendency in the literature for negative studies
to be considered less important than positive studies, this
possible influence cannot be ignored. In addition,
inevitably this approach must include studies with
differing protocols in terms of inclusion and exclusion
criteria, and I have alluded to one or two of these
differences above. All these considerations lead to
difficulties in the interpretation of the finer details of
the results, and the population to which these results can
reliably be applied. Nevertheless, these papers did
provide relatively crude evidence of a beneficial effect of
thrombolytic agents in the treatment of acute myocardial
infarction, and undoubtedly provided a stimulus to further
research into these agents which up until that time,
although they had been available for a number of years,
were hardly used at all as a routine measure in this
context.
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Intravenous or intracoronary streptokinase?
It had been at least provisionally established that
thrombolytic therapy, at this stage almost exclusively
using streptokinase, was beneficial in the treatment of
acute myocardial infarction in terms of short term
mortality, and possibly in terms of preservation of left
ventricular function due to myocardial salvage. However
the optimal dosage and route of administration was unclear,
questions which remain unresolved to this day.
The intracoronary route offered visualisation of the
affected coronary artery, and immediate assessment of
therapeutic success in achieving patency, and therefore
gave the opportunity to achieve subsequent coronary patency
by additional mechanical methods. In addition, there was
the attraction of giving a smaller dose of streptokinase,
and possibly causing fewer haemorrhagic side effects.
However, there were also obvious drawbacks to this route of
administration. Coronary angiography is a highly skilled,
invasive and expensive procedure. The necessity of
arterial cannulation in this group of patients in a lytic
state was associated with an increase in bleeding
complications (Merx et al., 1981). The procedure was
associated with other risks, such as the provocation of
serious arrhythmias and embolic phenomena, and although its
risks in patients currently undergoing myocardial
infarction had been overestimated, it was felt that such
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added risk was detrimental to the patients' welfare. In
addition, it was difficult to see how this procedure could
be offered on a large scale to the general population.
Lastly, although benefits of earlier administration of
thrombolytic therapy were yet to be conclusively proven, it
was still intuitively felt that therapy should be
administered as early as possible in the course of
myocardial infarction, and the organisation of coronary
angiography must inherently be associated with a delay in
the institution of therapy, in most studies of the order of
40-60 minutes.
Therefore, although intracoronary administration of
streptokinase could continue as a research tool, it would
only be feasible for general application if it were shown
to have a major advantage over the intravenous route. In
1984, there was a randomised comparison of intracoronary
and intravenous streptokinase published by Alderman and
colleagues. In this study intracoronary streptokinase
(total dose of 343,375 IU) achieved a reperfusion rate of
73% (11 of 15), taking a mean of 28 minutes, and
intravenous streptokinase (total dose 725,505 IU) a
reperfusion rate of 62% (8 of 13), taking a mean of 39
minutes. These differences were not significant, which is
not surprising in this small sample. This did however show
that in a direct comparison there was no marked difference
between the two treatment regimens. These results were
comparable to similar published studies (Blunda et al.,
1982, Tebbe et al., 1982).
Moreover this study found that the group which achieved
reperfusion had significantly lowered fibrinogen levels
early in the course of the infusion, immaterial of the
route and dose of streptokinase received, and that the two
treatment regimens were associated with similar falls in
fibrinogen. These results implied that reperfusion was
related to the intensity of systemic lytic changes, rather
than local concentrations of streptokinase. This would be
consistent with streptokinase's known indirect action
requiring binding of circulating plasmin or plasminogen.
This study also found that bleeding complications were
related not to the route of administration and therefore
total dose of streptokinase, but to the likelihood of
reperfusion, and therefore the fall in fibrinogen and the
administration of heparin, which was administered to those
patients with patent arteries following angiography.
These findings relating a systemic lytic state to
successful coronary reperfusion were supported by Rothbard
and colleagues (1985) who found a systemic lytic state to
be almost exclusively associated with reperfusion and
occurring in most patients receiving "standard"
intracoronary doses of streptokinase. It had also been
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shown that mean intracoronary doses of streptokinase of
201,000 IU caused a fall in fibrinogen in excess of 70%, in
88% of patients (Cowley et al., 1983). However, there were
other studies which did not find a fall in fibrinogen
following comparable intracoronary doses of streptokinase
(Rentrop et al., 1981).
Thus one major putative advantage was rejected, in that if
intracoronary streptokinase caused systemic lytic effects,
and these effects were possibly central to the mechanism of
reperfusion, then there was no value in using the more
invasive and cumbersome intracoronary route.
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THROMBOLYTIC AGENTS
In the years following the studies described above, the
principle of thrombolytic therapy in acute myocardial
infarction became increasingly accepted, until following
the very large mortality studies of GISSI (1986), ISIS-2
(1988) and AIMS (1988) the benefits of this treatment were
unequivocally proven. However, there remained and remains
debate as to the best available thrombolytic agent.
The next section looks at these influential studies in the
context of some of the individual thrombolytic agents
available, comparing their pharmacological properties, and
outlining the evidence available in support of their
efficacy in acute myocardial infarction.
Three main drug classes have been developed namely
streptokinase, anistreplase and tissue-type plasminogen
activator (rt-PA). The pharmacological advantages of each
drug and the evidence for their efficacy are discussed
below. No mention of urokinase or pro-urokinase is made in
this discussion, as this thesis does not contain work
relating to these agents.
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Streptokinase
Streptokinase is a single chain protein with a molecular
weight of 47,000 daltons, which is produced by Group C
beta-haemolytic streptococci. In the circulation it
combines with plasmin or plasminogen to form a complex
which is a potent activator of plasminogen to plasmin
(Anderson et al., 1987).
There are one or two major considerations with the clinical
use of streptokinase in terms of efficacy and safety.
Being a foreign protein, streptokinase is antigenic, and is
neutralised by circulating antibodies which may have been
stimulated by previous streptococcal infections, and in
addition itself will stimulate a further antibody reaction.
There is a small incidence of anaphylactoid reactions to
streptokinase, and it is possible that their incidence may
also be influenced by previously stimulated immunological
responses. In many studies, this possibility has been
catered for by the routine prophylactic use of
chlorpheniramine and hydrocortisone, although the evidence
for their efficacy in this context is not strong (Dykewicz
et al., 1986, Murray et al., 1986). As a consequence, the
immunological aspects of streptokinase treatment are of
great interest and their consideration forms part of this
thesis.
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The administration of high doses of streptokinase is
associated with a fall in blood pressure, the degree of
which is related to the rate of infusion. This response
limits the practical infusion rate of the drug. The
mechanism of this blood pressure fall is obscure, and the
haemodynamic responses to streptokinase and their possible
causes are discussed later in this thesis.
Despite the negative aspects discussed above, streptokinase
is effective and safe, as demonstrated in large scale
studies (GISSI, 1986), and relatively inexpensive. It is
the most commonly used thrombolytic agent in this
country.
Anistreplase
Anistreplase is an anisoylated plasminogen streptokinase
complex, in which the active serine site on plasminogen is
anisoylated with p-anisoic acid, and protects the molecule
from circulating plasma inhibitors, such as alpha2~
antiplasmin and alpha2-macroglobulin. The streptokinase-
plasminogen activator complex is still able to bind fibrin
at its lysine binding site. In plasma, anistreplase
undergoes deacylation by hydrolysis into the active moiety,
which is a potent plasminogen activator. The preferential
binding of the inactive complex by fibrin prior to
activation confers a degree of clot specificity by
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encouraging activation of the anistreplase complex at the
clot surface. However, doses in excess of 10 units are
associated with a systemic lytic state, due to release of
plasmin into the circulation (Ferres, 1987).
Dose findings studies with anistreplase have sought a
balance between efficacy in terms of a satisfactory
reperfusion rate and limited systemic fibrinolysis (Hillis
and Hornung, 1985). Dosing up to 15 units allowed
successful initial reperfusion, but with a high reocclusion
rate (Hillis et al., 1983). The currently recommended dose
of 30 units is effective in achieving coronary patency, but
is associated with a systemic lytic state reflected in a
fall in plasma fibrinogen of approximately 30% (Been et
al., 1986).
Although a dose-response relationship has been demonstrated
for intracoronary anistreplase in doses of 15-30mg (Jones
et al., 1984, Autrey, 1984, Kasper et al., 1984, Been et
al., 1984), there is less convincing evidence for a dose-
response relationship for intravenous administration
(Leizorovicz et al., 1987). Doses in excess of 30 units
have not been evaluated.
As anistreplase is a derivative of streptokinase, it can be
expected to suffer from the same limitations of
immunological and haemodynamic responses, which are also
discussed as part of the work of this thesis. Its major
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advantage over streptokinase lies in its ability to be
administered as a single intravenous injection over 5
minutes, in contrast with the 60 minute continuous
intravenous infusion recommended for streptokinase.
Tissue-plasminogen activators
These serine proteases were described as long ago as 1946
(Astrup and Permin), but their lack of availability in any
amount from human tissues limited interest until Collen et
al. reported the isolation and purification of tissue- type
plasminogen activator (t-PA) from a melanoma cell line in
1982. Subsequently, Pennica et al. (1983) cloned the gene
responsible for the synthesis of t-PA and expressed it in
E.coli, allowing the production of recombinant tissue-type
plasminogen activator (rt-PA) in sufficient quantity to
allow its evaluation and first use in man (van der Werf et
al., 1983).
The advantages of rt-PA as a thrombolytic agent are
several. Firstly being a human protein, it lacks
antigenicity, and although associated with a small fall in
blood pressure, is in general very well tolerated (Lew et
al., 1985). The compound has a very short half-life in the
circulation, of the order of 5 minutes (Garabedian et al.,
1986), allowing close manipulation of administration
regimens and brief alteration of haemostatic control.
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Rt-PA is also relatively clot selective, at least in small
doses. The mechanism of its clot specificity is the low
affinity of the compound for circulating plasminogen,
accompanied by a high affinity for fibrin, to which it
binds at specific sites in the kringle structures.
Plasminogen has a high affinity for this rt-PA-fibrin
complex and binds it avidly, and then is activated at the
clot surface to form plasmin.
The ability of rt-PA to lyse thrombi without initiating a
lytic state was first demonstrated by van der Werf and co¬
workers in 1984 at first in animals, and then in patients
(van der Werf et al., 1984), with the achievement of
coronary reperfusion in 6 of 7 patients without depleting
fibrinogen, plasminogen and alpha2~antiplasmin. However,
early studies were associated with a high incidence of
coronary reocclusion. Collen et al., (1984) achieved
coronary reperfusion in 75% of patients with an intravenous
infusion of 0.5-0.75mg/kg rt-PA, but 5 of a sub-group of 9
patients reperfused with intracoronary rt-PA suffered early
reocclusion. Gold et al. (1986) reported a reocclusion
rate of 45% in those patients with a persistent high grade
stenosis and falling plasma rt-PA concentrations. In
contrast, Verstraete et al., (1987) observed a reocclusion
rate of only 8% within 24 hours.
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Although the clot specificity of rt-PA was thought to be an
important asset of this compound at the time of its
development, doses of rt-PA necessary to provide
satisfactory coronary reperfusion rates in fact cause a
systemic lytic state. Rao et al., (1988) compared the
degree of systemic fibrinogenolysis induced by 1.5 MIU of
streptokinase infused over 1 hour to that following 80mg
rt-PA infused over 3 hours. Although rt-PA caused a lesser
effect, it did cause a 33% fall in fibrinogen at 5 hours
and 57% fall in plasminogen, confirming a significant
systemic lytic effect. Similarly Verstraete et al. (1985)
showed that fibrinogen fell by 48% following a dose of rt-
PA of 0.75 mg/kg. However current opinion now suggests
that a degree of systemic activation may be advantageous in
limiting early coronary reocclusion, and also reducing
plasma viscosity.
The original form of rt-PA developed was a two-chain
preparation (duteplase), but subsequently a single strand
species was developed (alteplase) which had a higher
specific activity (Garabedian et al., 1987, Collen, 1985)
and which was able to be produced in greater quantity.
The major advantage of rt-PA remains its lack of
antigenicity, although this must be balanced against its
expense relative to streptokinase and anistreplase. For
this reason, rt-PA is recommended as the drug of choice for
patients with significant levels of antibody to
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streptokinase, most probably following previous treatment
with streptokinase-containing thrombolytic agents. Exactly
how long the appropriate interval following treatment with
streptokinase or anistreplase remains to a large extent
unknown. The current recommendation is one year. In this
thesis, further data are presented relevant to the antibody
response to streptokinase and anistreplase, and the
possible influence of acquired resistance on these agents'
effects.
The manufacturer's recommended administration regimen is
100mg alteplase as a 3 hour decremental intravenous
infusion, but there remains the possibility of manipulating
both the total dose administered and the rate of
administration to optimise this drug's thrombolytic
efficacy. A large part of this thesis is concerned with
the assessment of novel administration regimens of
alteplase, with the assessment of the pharmacokinetic
properties of the drug administered as boluses.
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ASSESSMENT OF THROMBOLYTIC EFFICACY
A. CORONARY REPERFUSION
The original rationale of thrombolytic therapy is to
restore coronary artery patency by lysing the occlusive
thrombus, thus restoring the blood supply to the ischaemic
muscle beyond the occlusion, and so salvaging myocardium
under jeopardy.
Coronary Reperfusion can be assessed angiographically, in
recent times in accordance with the TIMI criteria (Williams
et al., 1986), and requires a pretreatment coronary
angiogram to exclude a sub-total occlusion as the cause of
the myocardial infarction (deWood et al., 1980). Many of
the early studies using intracoronary administration of
thrombolytic agent assessed reperfusion, but a pretreatment
angiogram necessarily delays thrombolytic therapy. Hence,
other studies have assessed coronary patency at a given
time point, conventionally 90 minutes after therapy. The
difference between these two measures is the incidence of
spontaneous reperfusion, as reported by deWood et al.
(1980), being approximately 15-20% at this time point.
The time element is of crucial importance in regard to the
assessment and comparison of thrombolytic agents/regimens
in achieving coronary patency. Without thrombolytic
therapy, occluded coronary arteries reperfuse spontaneously
in due course (deWood et al., 1980), and patency rates with
all thrombolytic agents increase with time following
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therapy. For example the coronary patency rates with 5
units of anistreplase and 1.5 MIU streptokinase assessed at
90 minutes are 55% and 53%, but assessed 24 hours after
therapy, patency increases to 81% and 87.5% (Hogg et al.,
1990) .
In addition the time from onset of myocardial infarction to
institution of thrombolytic therapy is critical, as the
longer the delay, the lower the reperfusion rate (Smalling
et al. , 1 982). For example, in the early assessment of
anistreplase in small patient numbers, an excellent
coronary reperfusion rate was achieved (Been et al. , 1985,
Kasper et al., 1986). When Timmis et al., (1987) studied
the same dose in similar numbers, by extending the
therapeutic time window from 3 to 6 hours, the reperfusion
rate dropped to 56%. When assessed in larger numbers in a
multicentre trial (Anderson et al., 1988), the reperfusion
rate with a 6 hour time window was 51%, a rate confirmed by
Hogg et al. (1990).
The next section and figures illustrate the efficacy of the
major thrombolytic agents with respect to restoring
coronary patency.
Streptokinase
The ability of streptokinase to achieve coronary
reperfusion/patency has been discussed in the earlier part
of this chapter, dealing with the historical basis of
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I
reperfusion therapy. In brief, intracoronary doses of
streptokinase are associated with reperfusion rates ranging
from 60 - 87% (Timmis 1982, Figure 1).
The use of intravenous streptokinase carries obvious
advantages in terms of ease of use, and more rapid
administration without the need for coronary angiography.
As mentioned above, the study by Alderman et al. (1984)
compared intracoronary and intravenous streptokinase, and
reperfusion, and demonstrated that intravenous
administration of streptokinase caused acceptable levels of
coronary reperfusion (62%). The advent of intravenous
therapy meant that the delay necessary for pretreatment
angiography was unacceptable, hence most of the studies of
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Code for Figure 1.




A Mathey, 1981 73% 2000 u/min, n=30
B Rentrop, 1981 76% 1000-2000 u/min,n=29
C Timmis, 1982 88% mean 211 u,n=84
D Cowley, 1983 87% 201,00 ± 74,000 u,n=23
E Anderson, 1983 79% mean 5000 u/min,n=24
F Gold, 1983 85% 2000-6000 u/min,n=40
G Khaja, 1983 60% 15,000 + 5000 u/min, n=20
H Leiboff, 1984 69% mean 240,000 u, n=22
I Alderman,1984 73% mean 343,000 u, n=11
J Kennedy, 1985 71 % 4000 u/min,max 350000,n=134
K Rentrop,1989 60% 240,000 u, n=67
L Kaspar, 1987 63% 250,000 U, n=16
M Anderson, 1988 60% 240,000 U, n=111
N Tennant, 1984 57% 240,000 U, n=35
0 Anderson, 1 983 (P)79% <300,000 u, n=50
P Simoons, 1986 (P)85% <250,000 u, n=533
P = Patency
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Reported rates for intravenous therapy range from 31-75%,
including those studies assessing coronary patency within 2
hours of therapy. The patency rates from these studies are
summarised in Figure 2. The studies assessed all use the
"standard" streptokinase dose of 1.5 MILJ, although the
duration of treatment has varied, and in some cases is
given in conjunction with other agents.
Anistreplase
Although early studies with intravenous anistreplase
suggested that it may be as effective as intracoronary
streptokinase in restoring coronary patency, this has not
been confirmed in subsequent studies. Figure 3 summarises
the available data. 30 U of anistreplase as a 5 minute
intravenous injection results in coronary patency rates of
46-83%, although the high patency rates of Kaspar et al.
(1986) must be interpreted with caution in view of the wide
confidence limits, and patency of the order of 50-70% seems
a reasonable interpretation.
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Figure 2. PATENCY RATES FOLLOWING INTRAVENOUS
STREPTOKINASE
CODE ON FOLLOWING PAGE
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Code for Figure 2.
CORONARY REPERFUSION RATES WITH INTRAVENOUS STREPTOKINASE
PATENCY
CODE STUDY RATE DOSE COMMENTS
A Ganz, 1984 96% .75 or 1.5 MIU, n=78,
non-invasive assessment,
late angios
B Spann, 1984 49% .85 or 1.5 MIU, n=43,
C ECSG, 1985 55% 1.5 MIU,n=62
D Stack, 1988 44% 1.5 MIU, n=216
E Grines, 1989 75% 1.5 MIU+50mg
rt-PA,n=40
F PRIMI, 1989 64% 1.5 MIU, n=203
G Hogg, 1990 53% 1.5 MIU, n=63
H Brochier, 1987 51% 1.5 MIU, n=58
I TIMI-1,1987 31 %(R) 1.5 MIU, n=159
R = Reperfusion
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Figure 3. PATENCY RATES FOLLOWING INTRAVENOUS
ANISTREPLASE
CODE ON FOLLOWING PAGE
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Code for Figure 3.
CORONARY PATENCY/RKPKRFUSION RATES WITH ANISTREPLASE
PATENCY/
CODE STUDY REPERFUSION DOSE COMMENTS
A Bonnier, 1988 46% 30 U, n=42
B Kaspar, 1987 83% 30 U, n=8
C Anderson, 1988 51% 30 U, n=115
D Brochier, 1987 70%(P) 30 U, n=58




There is a considerable literature available on the ability
of rt-PA to achieve or restore coronary patency in acute
myocardial infarction. The data are however difficult to
interpret for reasons discussed below.
Several confounding influences have led to difficulty in
the interpretation of the efficacy of alteplase in
restoring coronary patency. Early studies were performed
with double-chain r-tPA, or duteplase, whereas more recent
studies have used single-chain r-tPA, or alteplase, and it
is known that the specific activities of these two
preparations differ (Garabedian et al., 1987, Muller et
al., 1987). In addition, whereas some studies have
observed patency, others have observed reperfusion of an
artery occluded before treatment. The index artery may not
necessarily be completely occluded at time of presentation,
and also, spontaneous reperfusion of a previously occluded
artery may occur (deWood 1980), therefore patency and
reperfusion rates differ. In addition and most
importantly, widely varying doses and dosage schedules have
been used in different studies based on differing study
populations.
Verstraete and co-workers (1985) have demonstrated patency
rates of 61% at 75-90 minutes post-therapy using 0.75 mg/kg
of double-chain rt-PA over 90 minutes. The same group
using a 40mg infusion of double-chain rt-PA over 90
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minutes, achieved a coronary patency rate of 66% at 90
minutes (Verstraete et al., 1987). Topol and the TAMI
group (Topol et al., 1987, Topol et al., 1989a, 1989b) have
achieved a patency rate of 68% patency using 70 mg of
double-chain r-tPA over 90 minutes, and 79% using the high
dose of 1.5 mg/kg of alteplase over 4 hours, in
conjunction with a high dose of heparin. The TIMI group in
TIMI-1 (TIMI-1, 1985, Chesebro et al., 1987) used 80 mg of
double-chain rt-PA over 3 hours, finding a reperfusion rate
of 56%. Williams et al. (1986) using the same dose of 80
mg over 3 hours found a similar reperfusion rate of 68%.
A study by Neuhaus et al. (1989) suggested that accelerated
administration of rt-PA may increase coronary patency.
They studied a 100mg dose of alteplase over 2.5 hours,
given as a 15mg bolus, then 50mg over 30 minutes and 35 mg
over the next 90 minutes. They demonstrated a patency rate
of 74% (95%CL: 62-84%) at 60 minutes, increasing to 91%
(82-96%) at 90 minutes. More recently, a front-loaded
regimen of alteplase of 15mg bolus, 50mg over 30 minutes
and 35mg over 60 minutes has been studied in comparison
with 30 units of intravenous anistreplase, in the TAPS
study (von Essen et al., 1991). These results have
recently been presented in abstract form only. This regimen
achieved 73.4% coronary patency at 60 minutes, and 84.4%
patency at 90 minutes, maintained to 24 hours. These
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patency rates were significantly higher than that achieved
with anistreplase, although there was a higher reocclusion
rate with alteplase.
Published experience with bolus doses of alteplase is
limited. Verstraete et al. (1989) using single boluses of
alteplase, found that doses of 60 mg and 50 mg were
associated with reperfusion rates at 90 minutes of 32% and
45% respectively, although a maximum dose of 70 mg achieved
72% reperfusion. However, this study was extended to
include 60 patients, using the 70mg bolus dose (80mg in
patients weighing more than 90kg) (Tranchesi et al., 1991).
The reperfusion rate at 60 minutes was 55% (43-66%), and
48% (37-60%) at 90 minutes, suggesting that this regimen
was not ideal for clinical use.
Khan et al., (1990) have evaluated 4 boluses of 25mg over
60 minutes of the double-chain t-PA and demonstrated
recanalisation in 11 of 14 patients, and suggested that
this regimen achieves coronary patency more rapidly.
A small study by Smalling et al., (1990) using rapid
intravenous infusion of a weight-adjusted dose of
alteplase, and a median dose of 145mg, reported a 90 minute
patency rate of 84%, which was significantly higher than
the control group who received a conventional 3 hour
infusion of 100mg.
74
Some of the studies evaluating coronary reperfusion or
patency at 90 minutes are summarised in Figure 4. Overall
reported coronary patency rates at 90 minutes after therapy
have varied between 53% patency and 86% reperfusion.
B. PRESERVATION OF LEFT VENTRICULAR FUNCTION
A further aim of thrombolytic therapy is the reduction in
left ventricular necrosis, thereby preserving left
ventricular function. Several methods are available for
the assessment of left ventricular function. Left
ventriculography has been used, but because of its invasive
nature makes serial estimates of left ventricular function
difficult. Although echocardiography is non-invasive and
easily repeated, the quality of image obtained may preclude
accurate assessment of left ventricular volumes in a
proportion of individuals, and there may be considerable
inter-observer errors. Many studies have used radionuclide
angiography, which is non-invasive reproducible and yields



























§ H z o
CORONARYPATENCY/ ERFUSIONRATES WITHTISSUEPLA MINOG NACTIVATOR PATENCY/REPERFUSIONRATE(%)
100





















Code for Figure 4.
CORONARY REPKRFUSION/PATENCY RATES WITH rt-PA
PATENCY/
CODE STUDY REPERFUSION DOSE COMMENTS
A ECSG, 1984 86%
B Collen, 1984 75%
C ECSG, 1985 70%
D ECSG, 1985 61%
E Williams,1986 68%
F TIMI-1,1987 66%
G ECSG, 1987 66%
H Muller, 1987 71 %
I Verstraete,1987 66%
J Neuhaus, 1988 86%
K Armstrong, 1989 68%
L Grines, 1988 71 %
M Johns, 1988 76%
N GAUS, 1988 69%
0 Topol,TAMI-3,1989 79%
P TOPOL,TAMI, 68%
Q Verstraete, 1990 72%
R Smalling,1990 84%
S Khan, 1990 79%
T Tranchesi, 1990 72%
U Koster, 1990 53%
0.54-1.4 x106IU/30-60min,
































It is important when assessing left ventricular function in
the post infarct period to take into consideration several
factors. Firstly, it is well documented that left
ventricular ejection fraction in patients with acute
myocardial infarction shows spontaneous improvement even
when not treated with thrombolytic therapy (Dewhurst &
Muir, 1983, Schwarz et al., 1982). Schwarz and co-workers
showed the time course of the improvement to be two weeks
and correlated with the amount of residual flow to the
infarct zone, with the mean change in ejection fraction for
patients with residual flow being 6.9 ± 2.3% compared to
-2.2 ± 1.7% without (p<0.01). Clearly in the absence of
adequate controls this would make data on improvement in
left ventricular function difficult to interpret.
Secondly, it is probably necessary to consider not only
global ejection fraction, but to examine changes in
regional wall motion. Rogers et al. (1984) showed that in
those patients with no flow to the infarct zone, either
anterograde or via collaterals, there was a fall in global
ejection fraction over the two weeks following infarction,
which was due to a reduction in systolic contribution from
the non-infarct zone, most likely due to a non-sustained
initial hyperkinesis of the non-infarct zone. It might be
expected that this compensatory hyperkinesis may vary
between different individuals, and be modified by previous
myocardial infarction.
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Thirdly, in many of the studies assessing left ventricular
function after thrombolytic therapy, the ejection fraction
data is incomplete in up to 30%, possibly introducing a
systematic error. This is particularly likely, as those
patients in whom left ventricular function data is
incomplete, are more likely to be those who are
haemodynamically unstable, that is those with larger
infarcts, and/or a poorer response to therapy.
Early publications by Reduto et al. (1981) and Smalling et
al. (1982) suggested that thrombolytic therapy in acute
myocardial infarction could preserve left ventricular
function. These early studies were controlled but not
randomised, and the randomised studies of Anderson et al.
(1983) and Khaja et al. (1983) published conflicting
results. Ritchie et al., (1984) were unable to demonstrate
a benefit of intracoronary streptokinase on infarct size or
left ventricular function. However they were subsequently
able to show that intravenous streptokinase reduced infarct
size and preserved left ventricular ejection fraction
(Ritchie et al., 1988). The benefits in the intravenous
study were confined to those patients with anterior
infarction treated within 3 hours of onset of symptoms, and
they explained the discrepancy between their studies on the
basis that the time to treatment in the intravenous study
was on average one hour shorter.
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Overall, despite the limitations discussed above, benefit
in regard to left ventricular function has been
demonstrated for the available thrombolytic agents. Figure
5 illustrates the available data from controlled
trials of the difference in ejection fraction of those
patients receiving different forms of thrombolytic therapy.
In 11 of the 16 data sets, the 95% confidence limits fail
to cross the zero line, and it can be concluded that
thrombolytic therapy preserves myocardial function,

















Code for Figure 5.
NUMBER OF TIME OF
CODE STUDY PATIENTS TREATMENT EVALUATION
A Khaja, 1983 40 IC SK 1 hour
B Khaja, 1983 40 IC SK 2 days
C Ritchie, 1984 250 IC SK 8-9 wks
D Anderson, 1983 50 IC SK 10 days
E Serruys, 1986 533 IC SK 2 weeks
F Schroeder, 1 989 1741 IV SK 1 month
G White, 1987 219 IV SK 3 weeks
H Kennedy, 1988 368 IV SK 3 weeks
I Armstrong, 1989 118 IV duteplase 4 hours
J Armstrong, 1989 118 IV duteplase 9 days
K NHFAustr, 1988 1 44 IV duteplase 1 week
L van der Werf,1988 721 IV alteplase 10-22d
M O'Rourke, 1988 1 47 IV alteplase 3 weeks
N O'Rourke, 1988 1 47 IV alteplase 3 weeks
0 Bassand, 1989 231 IV anistreplase 2-7 d







In many respects, the acid test of the efficacy of
thrombolytic therapy is whether the prognosis of acute
myocardial infarction is altered in terms of improved
survival. There have now been several large mortality
studies performed which allow us to reliably answer this
question (Figure 6).
As has been already discussed, early small studies of
streptokinase in acute myocardial infarction showed variable
effects on mortality, and it was the metanalysis of the
combined results which first implied that there was a
consistent improvement in mortality.
The first major mortality study was GISSI, which randomly
assigned 11806 patients to either intravenous streptokinase
or standard therapy, assessing mortality after 3 weeks
(GISSI, 1986) then again at 12 months (GISSI, 1987). These
papers, irrevocably establishing the benefits of intravenous
streptokinase, showed an 18% relative reduction in mortality
at 21 days (an absolute reduction of 2.3% mortality,
p=0.0002, relative risk 0.81), which remained a 9% relative
reduction in mortality at 12 months (an absolute reduction



























Figure 6. CHANGE IN MORTALITY RELATIVE TO PLACEBO WITHIN
THREE MONTHS FOLLOWING THROMBOLYTIC THERAPY
CODE ON FOLLOWING PAGE
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Code for Figure 6.
CHANGE IN MORTALITY RELATIVE TO PLACEBO WITHIN THREE MONTHS
FOLLOWING THROMBOLYTIC THERAPY.
DIFFERENCE
CODE STUDY DRUG IN MORTALITY COMMENTS
A Western IC SK -7% n=250, <12h
Washington
B ICIN IC SK -6% n=533, <4h
C ISIS-2 IV SK -3% n=17187, <24h
D White IV SK -11% n=219, <6h
E ISAM IV SK -1% n=1741, <6h
F GISSI-1 IV SK -2% n=11806, <12h
G ECSG-4 IV D -3% n=721, <5h
H ASSET IV A -3% n=5011, <5h









The greater benefits of early therapy were also clearly
described. The relative risk of death following
streptokinase received within 3 hours of onset of symptoms
of myocardial infarction was 0.74, rising to 0.87 for 6-9
hours, and 1.19 for 9-12 hours. However, the benefits from
treatment beyond 6 hours were not clear, as the relative
risks for these delays were not significantly different
from unity. The relatively few patients who received
thrombolytic therapy within 1 hour of onset of symptoms had
an extraordinarily low relative risk of 0.49, with 95%
confidence intervals of 0.34-0.69. This pattern persisted
in the mortality improvement at 12 months, with the
relative risk of the subgroup of patients being treated
within 1 hour being 0.73, although the confidence intervals
were widened to embrace unity.
This study also established the safety of intravenous
streptokinase in this population, with the complication
rate in the streptokinase group being low, with an
incidence of stroke of 0.2%, which was comparable for the
two groups, of major bleeds of 0.3%, and of anaphylactoid
reactions of 0.1%. As this study was unblinded, it must be
considered that this was an over-estimate of the true
incidence.
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The second large scale study of intravenous streptokinase
was the Second International Study of Infarct Survival
(ISIS-2, 1987). This study was based on 17187 patients with
a clinical diagnosis of acute myocardial infarction who were
randomised to receive intravenous streptokinase, oral
aspirin, both or neither, in a placebo controlled design.
Mortality was assessed at 5 weeks, and there was a 25%
relative reduction in vascular deaths at this time point in
those receiving streptokinase (95% CL 18-32%, 9.2 vs 12.0%,
absolute reduction 2.8%, p<0.00001). In addition aspirin
alone conveyed considerable advantage, with a 23% relative
reduction in mortality compared to placebo (9.4 vs 11.8%,
absolute reduction 2.4%, p<0.00001). The combination of
streptokinase and placebo achieved an unparalleled reduction
in mortality of 42% (95% CL 34-50%, absolute reduction 4.8%,
13.2 vs 8.0% , p<0.00001), establishing the gold standard
for thrombolytic therapy in the future.
Again the beneficial influence of early treatment was
confirmed, with those treated within 4 hours of symptoms
gaining a reduction in odds ratio of vascular death of 35%,
compared to 16% and 21% for those receiving treatment within
the 5-12 and 13-24 hour windows respectively. The reduction
in odds ratio achieved statistical significance in the 5-12
hour group but not in those receiving therapy after 12
hours.
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Study of the adverse event profile in this large blinded,
placebo controlled trial was also rewarding. Hypotension
and bradycardia was considerably more common in the
streptokinase group (10.0 vs 2.0%), as were reported
allergic reactions (4.4 vs 0.9%) although most of these
events were minor and of little clinical significance.
There was a significant excess of bleeding events in the
streptokinase treated group, with a minor bleeding rate of
3.5 vs 1.0%, and a major bleeding rate of 0.5 vs 0.2%
(p<0.001). There was also a significant excess of
confirmed cerebral haemorrhage with streptokinase, although
with a total number of only 7 events (0.08% vs 0, p<0.02).
The overall stroke rate was comparable overall, reflecting
a diminution of late stroke rate in the streptokinase group
compared to placebo, presumably due to a lower incidence of
embolic events. The incidence of haemorrhagic events was
increased by the concomitant use of heparin, but not of
aspirin.
One interesting aspect of the ISIS-2 study was that it was
based on patients who were thought by their attending
physician to be suffering from acute myocardial infarction.
There were no rigid electrocardiographic entry criteria
indicative of myocardial infarction required. Nevertheless
56% of the patients randomised had ST elevation diagnostic
of acute myocardial infarction. However, 8% had
electrocardiographic (ECG) changes of ST depression only,
and a further 27% had abnormal ECGs but which were not
88
necessarily confirmatory of acute myocardial infarction.
Two percent had normal ECGs. Sub-group analysis suggested
that those patients with normal ECGs or ST depression did
not receive obvious benefit from thrombolytic therapy,
although this retrospective subgroup analysis must be
interpreted with caution.
That this improvement in mortality could be translated into
similar success with other thrombolytic agents was
demonstrated by the studies ASSET and AIMS.
The Anglo-Scandinavian Study of Early Thrombolysis (ASSET,
1988) was based on 5011 patients treated within 5 hours of
onset of symptoms with alteplase as a decremental
intravenous infusion of 100 mg over 3 hours, compared with
placebo. Concomitant therapy with heparin, as a 5000 IU
bolus, then an intravenous infusion of 1000 IU/hour was
given for 21 hours. Aspirin was not given. The results
showed a relative reduction in mortality at one month of
26% (95% CL 11-39%, 7.2 vs 9.8%). On this occasion, it
appeared that delay in treatment had no apparent
detrimental effect, in that groups treated before and after
3 hours of onset of symptoms had similar mortality at one
month. Again there were no strict ECG criteria for entry,
and 18% of patients had a normal ECG at presentation.
Overall 72.8% proved to have an in-hospital diagnosis of
myocardial infarction. The benefits on mortality were
maintained to 6 months (relative reduction 21%, 95% CL 8-
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32%, mortality 10.4 vs 13.1%), with a more pronounced
benefit for those with a confirmed diagnosis of myocardial
infarction (relative reduction 26%, 95% CL 14-37%, 12.6 vs
17.1%), and one year (relative reduction 12.6%, 13.2 vs
15.1%). (Wilcox et al., 1988, Wilcox et al., 1989, Wilcox
et al., 1990) .
The Anistreplase in Myocardial Infarction (AIMS, 1988)
study assessed the effect on mortality of 30 U of
anistreplase as a five minute intravenous bolus,
administered to 1258 patients in a randomised double-blind
placebo-controlled study within 6 hours of onset of
symptoms of acute myocardial infarction, confirmed by ST
segment elevation on the presentation ECG. In addition all
patients received heparin followed by warfarin for at least
3 months, and timolol in the absence of contraindications
(AIMS Trial Study Group, 1988 and 1990). Mortality at 30
days was reduced from 12.1 to 6.4% (relative reduction 47%,
95% CL 21-65%), and at one year follow-up the mortality was
11% in the anistreplase group and 18% in the placebo group
(relative reduction 43%, 95% CL 21-59%). Again this study
failed to show any differential benefit of treatment before
4 hours or between 4-6 hours.
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Following the clear-cut evidence from these placebo-
controlled large scale mortality studies, the benefits of
thrombolytic therapy were clearly established, and any
further placebo-controlled trials would be ethically
unjustified. There are however two further large scale
mortality studies which merit mention.
GISSI-2 (1990) assessed the effects of intravenous
streptokinase and 100 mg of alteplase as a 3 hour
decremental infusion of 100mg, each with or without
subcutaneous heparin, in a total of 20749 randomised
patients. All patients received B-adrenoceptor antagonists
unless contraindicated. In-hospital mortality in the two
groups was similar at 8.7%, alteplase and heparin 9.2%,
streptokinase 9.2%, and streptokinase and heparin 7.9%. The
conclusion was that there was no difference in hospital
mortality between the treatment strategies. Although there
has since been discussion regarding the most appropriate
concomitant regimen for heparin, it must be considered that
the conclusion drawn is valid, within the confines of the
study design (GISSI-2, 1990).
ISIS-3 has recently been published (ISIS-3, 1992). Patients
with suspected myocardial infarction were recruited, and
concomitant therapy was 162mg aspirin and subcutaneous
heparin 12500 IU bd, starting at 4 hours. The results
indicate that there was no material difference between
streptokinase, anistreplase and alteplase, as regards
mortality assessed at 5 weeks, with mortality rates of
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10.5%, 10.6% and 10.3% respectively. There was however a
significant difference in the rate of cerebral bleeds, being
0.3%, 0.6% and 0.7% respectively (p<0.001), and the overall
stroke rates were 1.1%, 1.4% and 1.5% (p<0.001). Thus in
this study population of patients with suspected myocardial
infarction, and receiving the standard treatment regimens of
the three thrombolytic agents available in this country, and
with the concomitant therapy described, there is no
difference between the agents with regard to efficacy, but
there is a lower incidence of stroke with streptokinase.
CONCLUSIONS
It is possible that the use of thrombolytic therapy in acute
myocardial infarction has been the most extensively
researched and assessed drug treatment in modern medicine.
It is also probably the single most important innovation in
the management of acute myocardial infarction, certainly
since the introduction of the coronary care unit in the
1960s.
The early studies of the benefits of intravenous
streptokinase were misleading, largely due to their small
numbers and lack of adequate randomisation, and almost led
to the discarding of this therapy. However, since the
pioneering metanalysis of Stampfer and Yusuf suggested the
possibility of a benefit concealed within these conflicting
studies, many well designed studies of the different
thrombolytic agents have been performed, and we can now
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confidently state that streptokinase, tissue-type
plasminogen activator, and anistreplase are all capable of
recanalising occluded coronary arteries, preserving left
ventricular function, and improving mortality if
administered early in the course of acute myocardial
infarction.
However, there remain many questions which cannot be
answered from the currently available data. For example,
which is the most efficacious agent. Most of the studies
have been performed using "standard" doses and
administration regimens of the thrombolytic agents. The
accepted standard dose of streptokinase has been 1.5 MIU
administered as a continuous intravenous infusion over 60
minutes. This dose is essentially empirical. Although 1.25
MIU has been shown to establish a lytic state in 97% of the
normal population (Verstraete et al., 1985), no adequate
dose findings studies have been performed, nor have the
pharmacokinetic properties or pharmacodynamic effects of
this infusion been fully assessed. For example, from first
principles a "front-loaded" regimen of streptokinase might
appear attractive, achieving an early high concentration of
agent, possibly maximising the chances of achieving early
reperfusion. Similarly, the dose finding studies of
anistreplase have been incomplete and doses of anistreplase
in excess of the standard 30 units have never been
administered to man. The studies involving tissue-type
plasminogen activator have been confused by using different
doses of different preparations of rt-PA which are known to
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have different specific activities. Although patency rates
have been shown to be dose-dependent, so also have the
complication rates, in particular of intracerebral
haemorrhage (TIMI-2, 1989). However, the manipulation of
doses and plasma concentrations of rt-PA remains relatively
unexplored.
The possibilities of combining different drugs in the
different regimens also remains an intriguing area.
Although some preliminary studies have been performed with
combinations of rt-PA and scupa, there remains much scope
for research in this area.
The latest of the large scale mortality studies have
confirmed the high efficacy and safety of the simple regimen
of streptokinase and aspirin. In the context of the high
cost of the other thrombolytic agents, it is also the most
cost-effective treatment. However, as has been discussed
above, the streptokinase-containing thrombolytic agents are
not without their problems. In particular, the role of
antibodies and acquired resistance to these agents remains
largely undefined. In the light of the increasing use of
the streptokinase-containing thrombolytic agents in clinical
practice in this country, the question of when is the "safe"
interval for readministration of streptokinase, and what are
the possible effects of antibodies to streptokinase on the
efficacy and safety of thrombolytic therapy, are probably
the two most important questions in contemporary cardiology.
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In this thesis, I have attempted to address some of these
questions. I have compared the pharmacokinetic properties
of the two streptokinase-containing thrombolytic agents,
streptokinase and anistreplase. I have studied the
influence of acquired resistance to streptokinase on the
thrombolytic efficacy of the streptokinase-containing
thrombolytic agents, observed the haemodynamic changes
following thrombolytic therapy, and related these changes
parameters both of streptokinase resistance and of fibrin-
and fibrinogenolysis. Finally, bearing in mind the
limitations of the streptokinase-containing thrombolytic
agents in certain circumstances, I have attempted to
evaluate novel regimens of rt-PA, given as intravenous
boluses, by observing their effects on coronary patency.
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CHAPTER THREE
COMPARISON OF THE PHARMACOKINETIC PROPERTIES OF




In view of the established advantage of the early
institution of thrombolytic therapy in acute myocardial
infarction in terms of improved clinical benefits of higher
coronary patency, left ventricular preservation and
decreased mortality, (GISSI, 1986, ISAM, 1986, ISIS II,
1987, AIMS, 1988), the ideal thrombolytic agent would have
the following pharmacological properties. It would be
easily and rapidly administered by the intravenous route,
and once given would achieve high early concentrations in
the circulation, giving an early peak of thrombolytic
activity, and have pharmacokinetic properties such that
thrombolytic activity was maintained for a long enough
period to prevent early coronary reocclusion. Currently
available agents and regimens are not ideal, but the study
of the pharmacokinetic properties of these agents will allow
the development of optimal administration regimens.
Streptokinase binds with plasminogen (or plasmin) in the
blood to form the complex streptokinase-glu-plasminogen
(-plasmin) which is an effective plasminogen activator
(Anderson et al., 1987). Anisoylated lys-plasminogen
streptokinase activator complex (APSAC, anistreplase) is a
pro-enzyme giving rise to the plasminogen activator complex
streptokinase-lys-plasminogen by deacylation within the
plasma. The activator complexes of the two agents are of
comparable potency in the activation of plasminogen.
Deacylation of anistreplase occurs with a half-life of 105
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minutes in vitro and is thought to be rate-limiting for the
removal of anistreplase from the circulation (Ferres et al.,
1987, Standring et al., 1987), and to be slower than the
elimination of streptokinase-plasminogen or streptokinase
(Fears, 1989).
Previous studies addressing the pharmacokinetic properties
of the streptokinase-containing thrombolytic agents are
relatively few in number (Been et al., 1986, Kohler et al.,
1987, Mentzer et al., 1986). The studies have used
different assay techniques for streptokinase, measuring
different species of lytic activity, largely dependent on
whether human or bovine plasminogen and fibrinogen were used
in the assay, and the concentrations in the assay media,
these technical differences making direct comparison
difficult. In addition, the timing and number of their
sampling time points were not specifically tailored to the
estimation of pharmacokinetic parameters, and compromise the
estimation of these parameters. Despite these limitations,
they have suggested that streptokinase is rapidly eliminated
and its concentration-time profile fit either a mono- or bi-
exponential pharmacokinetic model (Kohler et al., 1987,
Mentzer et al., 1986). Previous work in man has suggested
that anistreplase is eliminated from the circulation much
more slowly than streptokinase (Been et al., 1986, Kohler et
al., 1987). In the present study, the pharmacokinetic
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properties of these agents have been directly compared with
a protocol of sampling times tailored for this purpose,
using a functional bioassay, to allow definitive conclusions
to be drawn.
METHODS
Twenty-four consecutive patients (18 male, 6 female, age
range 48 to 72 years) with acute myocardial infarction, as
judged by strict ECG criteria of at least 2mm ST elevation
in two praecordial leads or at least 1 mm ST elevation in
two limb leads, presenting within 6 hours of onset of pain,
and without any of the standard contraindications to
thrombolytic therapy were treated with either a conventional
dose of 1.5 x 10^ I.U. of streptokinase infused over 60
minutes, or 30 U of anistreplase as a 5 minute continuous
intravenous injection. The study protocol is detailed in
Appendix III. The patient population was a sub-group of the
128 patients recruited in a comparative study of
streptokinase and anistreplase, and whose details are listed
in Appendix I.
Blood samples were obtained from an indwelling venous
catheter at frequent intervals up to 24 hours post dosing
(0,6,10,20,30,45,60,75,90 minutes, 2,4,6,9,12 and 24 hours),
and collected into 0.1 volume of 3.8% sodium citrate,
separated immediately at 4°C and the plasma stored at -70°C.
Total fibrinolytic activity was measured by a described
technique (Been et al., 1986, Nunn et al., 1987) and used a
functional bioassay of the plasma concentrations of the
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thrombolytic agents. The preparation of euglobulin
fractions has been reported in detail elsewhere (Standring
et al. , 1988) but, in brief, 50y.l plasma samples were
diluted into 910y.l 0.011% acetic acid and the resulting
precipitates solubilized in 1.5ml 0.05M sodium phosphate/
0.1M sodium chloride/0.01% Tveen 80 buffer, pH 7.4, to give
a 30 fold dilution of the original plasma. This dilution
factor was found, during preliminary validation studies on
the fibrin plate assay, to abolish the interference of
variable endogenous plasminogen and plasmin in the samples
(Nunn et al., 1987). Fibrinolytic activity was assayed by
the lysis of fibrin plates, prepared from human fibrinogen
(containing 2 pg plasminogen/mg fibrinogen), incubated at
37°C for at least 18 hours. The plates were stained with
bromophenol blue and lysis zones measured on an AMS image
analyser. Quadruplicate determinations were performed at
each time point and typical coefficients of variation ranged
from 0.44 to 2.6% (mean 1.6%, n=11) for anistreplase and
from 0.36 to 6,6% (mean 2.4%, n=10) for streptokinase. The
concentration of activator was calculated for each patient
employing the appropriate standards diluted into autologous
predosing plasma i.e. streptokinase for streptokinase
treated patients and anistreplase for anistreplase treated
patients. Standards were prepared in the patient's own
pretreatment plasma to allow for any interpatient
variability; the slopes of the standards ranged from 1.57 to
3.26 (mean 2.42) for streptokinase, and 1.78 to 3.07 (mean
2.47) for anistreplase. Both streptokinase and anistreplase
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standards gave linear responses with correlation
coefficients of 0.9946 (percentage coefficient of
variation, %CV 0.34) for streptokinase (n=12) and 0.9938
(%CV 0.21) for anistreplase (n=12).
Internal standards were also included in each assay, in
pretreatment, and 10 minutes to 2 hours post treatment
samples, and processed concurrently. The average recovery
for the entire group of 12 patients was 91% for
streptokinase and 94% for anistreplase. The limit of
reliable determination was 0.08 x 10~®M (3.91 IU/ml) for 10
streptokinase treated patients and 0.04 x 10~®M (1.95 IU/ml)
for the remaining two. For anistreplase the lower limit of
determination was 0.06 x 10~®M (7.81x10~^U/ml).
Plasma concentration of streptokinase- and anistreplase -
time data were fitted to a one-compartment or two-
compartment model by non-linear regression as appropriate to
each individual data set. Modelling was performed using a
computer program, MODFIT, which employs a modified
Danielson-Fletcher-Powell algorithm (Allen, 1989). The same
data sets were subjected to model-independent analysis,
calculating area under concentration-time curves from zero
to the last data point (AtJC^) using a linear trapezoidal
method. The area under the curve extrapolated from the last
data point to infinity was estimated using the last data
point and the rate constant of the terminal log-linear
phase, as determined by non-linear regression analysis of the
terminal phase. These data were used to calculate clearance
101
(CL) and volume of distribution (V), according to
established methods (Gibaldi and Perrier, 1982). The
terminal phase half-life (t 1/2^ was a^-so determined by
regression analysis and, in addition, the time to loss of
half the maximal fibrinolytic activity from the end of the
dosing period was calculated by linear regression analysis.
Instantaneous mean residence times (MRT), which compensate
for the differences in the duration of dosing between
streptokinase and anistreplase, were determined by moment
analysis (Riegelman and Collier, 1980).
Pharmacokinetic parameters for anistreplase and




Derived pharmacokinetic parameters are summarised in
Table 1 and mean concentration-time curves represented in
Figure 7. Concentration time curves following a 60 minute
infusion of 1.5 MIU of streptokinase were analysed by model-
independent methods only as the data could not be adequately
fitted to a compartmental model. The terminal phase rate
constant was determined using non-linear regression analysis
- 2 0
with a weighting concentration .
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Maximum plasma concentration (Cmax) occurred within 1.25
hours (tmax) of the start of the infusion of 1.5 MIU of
streptokinase over a 1 hour period (mean 0.9 hours).
Concentrations subsequently declined rapidly to less than
15% of Cmax in all subjects by 4 hours after start of
infusion, and in most subjects were below the limit of
reliable determination. The post peak decline in
concentration approximated to a mono-exponential fall
(maximum % CV of the regression lines was 26%) as determined
by MODFIT (Allen, 1989).
The volume of distribution of streptokinase was small,
approximating to that of plasma proteins, and this in
conjunction with a moderately rapid clearance defines a
relatively rapid terminal phase elimination constant and a
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Figure 7. PLASMA CONCENTRATIONS
FOLLOWING INTRAVENOUS
STREPTOKINASE OVER 60
OF STREPTOKINASE (MEAN + SD)





Anistreplase (n=12) SK (n=12)
MEAN (SD) MEAN (SD)
t
max <h> 0.154 (0.07) 0.9(0.21) **
Cmax (M x 10~8) 5.59 (2.22) 3.85 (1.18) +
Volume of Distribution (1)
Model-independent (V) 5.90 (1.91) 5.68 (2.29)NS
Computer-modelled (Vss) 5.25 (1.49)
Clearance (1/h)
Model-independent (CL) 3.87 (1.52) 7.08 (2.91) *
Computer-modelled (CL) 3.72 (1.35)
Terminal phase elimination half-life (h)
Model-independent t^/2 1.16 (0.38) 0.61 (0.24) **
Computer-modelled 1-15 (0.38)
Time to half maximal fibrinolytic activity (h)
1.12 (0.31) 0.48(0.14)**
Mean residence time (h)
1 .55 (0.48) 0.76 (0.31 ) **
+ P<0.05 * P<0.01 ** P<0.001
NS = Non significant
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b) ANISTREPLASE
The maximum total activity of anistreplase (Cmax) occurred
within 20 minutes (tmax) of the start of the 5 minute
intravenous injection of 30 units of anistreplase (mean 0.15
hours).
Activity fell to less than 15% of maximum by 4 hours. In 6
of 12 patients, an early rapid decline phase of the
concentration-time curve could be delineated, conforming to
a two-compartment model. In 5 subjects the data sets
conformed to a one-compartment model. In one subject,
neither model provided a satisfactory fit and these data
were analysed by model-independent methods only. The
derived parameters were similar regardless of which model
was most appropriate, and were comparable with parameters
derived from model-independent analysis.
Pharmacokinetic parameters are summarised in Table 1 and
mean total activity-time curves represented in Figure 8.
The volume of distribution of anistreplase and its
deacylated product is relatively small, consistent with
anistreplase and its metabolite being largely confined to
the systemic circulation. Clearance is modest and in
conjunction with a small volume of distribution allows a
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Figure 8. PLASMA CONCENTRATIONS OF ANISTREPLASE (MEAN + SD)
FOLLOWING INTRAVENOUS INJECTION OF 30 U OF
ANISTREPLASE OVER 5 MINUTES
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DISCUSSION
Coronary reperfusion rates are highest when thrombolytic
therapy is administered early in the course of myocardial
infarction (Lew et al., 1986, Kennedy et al., 1985,
Weinstein, 1982, Khalilullah et al., 1984), and is
associated with greatest clinical benefits (AIMS, 1988,
GISSI, 1986, ISIS II, 1987, Simoons et al., 1985 & 1986,
Anderson, 1984, ISAM, 1986). For earlier institution of
therapy, a suitable thrombolytic agent must be administered
in a simple regimen allowing easy administration in
difficult circumstances, and with the increasing interest in
the possibility of thrombolytic therapy at home, applicable
even outside the hospital environment. The ideal regimen
should therefore achieve a high early concentration, and
resulting fibrinolytic activity (short tmax and high Cmax).
A slow elimination phase, allowing maintenance of adequate
concentrations from a single "bolus" injection (long t-\/2,
low CL) for an appropriate period of time, would be expected
to minimise early coronary reocclusion.
Early recommendations for the use of streptokinase were for
a prolonged low dose infusion, but more recent usage in
myocardial infarction has adopted the now standard, but
essentially empirical dose of 1.5 MIU over 60 minutes. The
recommended dose of anistreplase was based on being
equivalent to 1-1.5 MIU of streptokinase. Following the
administration of streptokinase and anistreplase, both in
their standard treatment regimen for myocardial infarction,
anistreplase achieves a significantly earlier, high
1 08
concentration, with a peak plasma concentration of 5.59 x
— 8
10 M within 4.5 minutes of the end of its infusion period,
as would be predicted from its more rapid infusion.
In this study, it has been shown that both streptokinase and
anistreplase have a small volume of distribution,
approximately twice that of plasma volume and similar to the
volume of distribution of plasma proteins (Rowland & Tozer,
1980). This would be consistent with both agents behaving
as proteins with no specific carrier mechanism, being
largely confined to the systemic circulation.
The elimination phase half-life of streptokinase of 0.61
hours is very similar to previous estimates based on fibrin
plate lysis assay in acute myocardial infarction (Kohler
1987) and slightly longer than estimates based on other
functional assays of 0.3 hours (Martin 1982) and 0.38 hours
(Mentzer et al., 1986). These small differences may be
accounted for by variation in assay specificity and
pharmacokinetic analysis. Claims of a considerably longer
terminal phase, with a half-life of 1.38 hours (Grierson &
Bjornson, 1987, Fletcher et al., 1958) are based on
radioimmunoassay or amidolytic assay methods for
streptokinase. These methods do not differentiate between
active and inactive streptokinase fragments, or take account
of in vivo de-iodination. Similarly, the amidolytic assays
based on the lysis of chromogenic substrate do not evaluate
the fibrinolytic sites of the activator molecule, and also
109
therefore cannot differentiate active and inactive
streptokinase fragments, or fragments bound by circulating
inhibitors such as c^-antiplasmin, neither is it entirely
specific for streptokinase. Previous studies based on the
lysis of bovine fibrin are also problematic, in that this
assay is particularly sensitive to endogenous human
plasminogen. Some previous studies have been based on
inadequate sampling protocols, and because of these
methodological problems, these studies are not entirely
comparable.
In this study, both drugs have been assayed by the same
fibrinolytic bioassay based on human fibrin plate lysis. It
has been shown that administration of this dose of either
thrombolytic agent does not completely deplete circulating
plasminogen, therefore all the streptokinase present would
be in its fibrinolytically active complexed form. Dilution
of the euglobulin fractions thirty-fold eliminates the
influence of endogenous plasminogen on the assay procedure
(Fears et al., 1989). Therefore this assay method measures
the functional moiety and is relevant to the clinical
application of these drugs.
It has been shown that streptokinase and anistreplase have
similar small volumes of distribution, but that
streptokinase is effectively cleared from the circulation
twice as quickly as anistreplase, (7.08 vs 3.87 1/hours,
p<0.01). In vitro studies of deacylation of anistreplase in
human blood or plasma have shown a deacylation half-life of
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1.76 hours (Ferres 1987). The shorter half-life of
elimation of anistreplase activity (1.16 hours) would
therefore support the concept that the deacylation of
anistreplase is the rate-limiting step in its elimination.
Both streptokinase as a 60 minute infusion of 1.5 MIU
(Verstraete et al., 1985) and anistreplase as a 5 minute
injection of 30 U (Been et al., 1985, Hillis et al., 1987,
Ikram et al., 1986, Timmis et al., 1987) are well-tolerated
and effective in restoring coronary patency in acute
myocardial infarction. In this study, it has been confirmed
that anistreplase in this dosage schedule achieves higher
levels of total thrombolytic activity, which are attained




PRE-DOSING ANTIBODY LEVELS AND EFFICACY OF
STREPTOKINASE CONTAINING THROMBOLYTIC AGENTS
1 1 2
INTRODUCTION
The effectiveness of streptokinase and anistreplase in the
treatment of acute myocardial infarction has already been
discussed in detail. Their efficacy in achieving coronary
patency (Anderson et al., 1983, Kennedy et al., 1983, Been
et al., 1986), preserving left ventricular function (ISAM
Study Group, 1986, Bassand et al., 1989) and improving
mortality (GISSI, 1989, AIMS, 1988) has been well
demonstrated. The thrombolytic effects of both these agents
are mediated by the activation of plasminogen by a
streptokinase-activator complex, in the case of
streptokinase following the combining of streptokinase with
circulating plasmin(-ogen) (Anderson et al., 1987), and of
anistreplase following the rate-limiting hydrolysis of the
compound in the circulation liberating streptokinase-lys-
plasminogen (Ferres, 1987).
In some patients however, successful thrombolysis is not
achieved. It has been suggested that high levels of
resistance to streptokinase, probably acquired by previous
exposure to streptococci, can compromise the therapeutic
response to streptokinase (Hirsh et al., 1970, James, 1973).
To overcome this, the "standard" dose of 1.5 MIU of
streptokinase aims to achieve a lytic state in a high
proportion of the population. A dose of 1.25 MIU has been
shown to achieve a lytic state in 97% of the population
(Verstraete et al., 1966). However previous clinical
studies have not shown any relation between pretreatment
anti-SK IgG concentration and efficacy as assessed by
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reperfusion rate or time to reperfusion after intracoronary
streptokinase or intravenous anistreplase (Hoffmann et al.,
1988) .
This study extends previous studies by examining the
relationship between the streptokinase resistance titre
(SKRT), and the concentration of specific antibody to
streptokinase of the IgG class, and therapeutic response to
the streptokinase-containing thrombolytic agents,
streptokinase and anistreplase assessed by coronary
angiography. The streptokinase resistance titre is a
measure of the total inhibitory capacity of the patient's
plasma to streptokinase, and reflects not only the
contribution of anti-streptokinase antibodies, but in
addition the effects of circulating plasma inhibitors such
as a2-antiplasmin and macroglobulins, and is influenced by
changes in other plasma proteins such as fibrinogen and
plasminogen, which show large changes following thrombolytic
therapy. Unlike the streptokinase resistance titre, the
anti-SK IgG concentration is a direct measure of the immune
response reflecting previous exposure to streptococcal




The study group consisted of a cohort of 128 consecutive
patients the details of which are recorded in Appendix I.
The study protocol is included in Appendix IV. All patients
presented within 6 hours of onset of symptoms of myocardial
infarction, having had chest pain for at least 30 minutes,
and without any of the standard contraindications to
thrombolytic therapy (TIMI, 1985) or coronary angiography.
All patients had at least 1mm of ST elevation in two or more
limb leads, or at least 2mm ST elevation in two or more
praecordial leads. We excluded patients over the age of 70
years, those with a systolic blood pressure less than 95
mmHg, or those who had experienced a previous myocardial
infarction in the same anatomical distribution, or who had
previously received thrombolytic therapy. Following
discussion with the patient and attending relatives, written
informed consent was obtained.
The mean age (SD) of the patients was 55.6 (8.3) years, with
a range of 31-70 years. Mean time from onset of symptoms to
commencement of thrombolytic therapy was 204 (79) minutes.
There were 101 men and 27 women. Patients were treated with
either 1.5 MIU streptokinase (65 patients) as a continuous
intravenous infusion over 60 minutes, or 30 units of
anistreplase (63 patients) as a 5 minute intravenous
injection, in a double-blind, double-dummy study design.
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All patients received 2mg/hour isosorbide dinitrate as a
continuous intravenous infusion for at least 30 minutes
prior to the commencement of thrombolytic therapy, and 100mg
hydrocortisone and 1Omg chlorpheniramine intravenously
immediately before thrombolytic treatment.
Coronary angiography was performed from the femoral route by
Judkin's method, at 90 minutes and 24 (18-30) hours after
treatment, injecting the infarct related artery first as
indicated by the admission electrocardiogram. Coronary
perfusion was scored on the TIMI scale (TIMI, 1985 and
Appendix II), by an independent, experienced cardiologist,
blinded to the study protocol.
Venous blood samples were collected in all patients prior to
the administration of thrombolytic therapy. In 96 patients
(48 streptokinase, 48 anistreplase) streptokinase resistance
titres were measured. In 124 patients (60 streptokinase, 64
anistreplase) specific anti-streptokinase antibodies of the
immunoglobulin G (IgG) class were assayed, using a specific
micro-radioimmunoassay which has been described previously
(Moran et al., 1985).
The data for each treatment group were analysed separately,
then jointly using non-parametric descriptive statistics and
tests of location, complying with the conventional level of
significance (p<0.05). Linear regression analysis was
performed on normally transformed data. Normality was
confirmed using the Shapiro-Wilks test.
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RESULTS
In the study population neither SKRT nor anti-SK IgG
concentrations were normally distributed, with marked
skewing towards higher values. However, log-j g of the anti-
SK IgG concentrations, and the fourth root of the
streptokinase resistance titres were normally distributed.
Comparing the two treatment groups, it was found that the
group treated with anistreplase had significantly higher
SKRT than the streptokinase group (median 50 vs 20 IU.SK.ml
, p<0.05, Fig 9). No significant difference was found
between the two groups for anti-SK IgG concentrations.
Regression analysis of the distribution of anti-SK IgG
concentration revealed a weak but statistically significant
negative correlation between log-jg-IgG values and age
(Figures 10 & 11). The regression equation was:
Log-|g(IgG) = 0.953 - 0.01 66 (age)
p=0.02, R-sq = 7.3%.
There was a similar relationship between 4V(streptokinase
resistance titre) and age. The regression equation was:
4V(SKRT) = 3-34 - 0.014 (age)
p=0.41, R-sq = 4.3%.
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BASELINE MEDIAN SK RESISTANCE TITRE
IN SK AND ANISTREPLASE TREATMENT GROUPS
SKRT (IU.SK/ml)
HII STREPTOKINASE BBS ANISTREPLASE
BASELINE MEDIAN IgG CONCENTRATION




Figure 9. BASELINE STREPTOKINASE RESISTANCE TITRE FOR THE
STREPTOKINASE AND ANISTREPLASE TREATED PATIENT GROUPS
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Figure 11. SCATTER DIAGRAM OF DISTRIBUTION OF
STREPTOKINASE RESISTANCE TITRE (FOURTH ROOT
TRANSFORMED) AGAINST AGE
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Details of the coronary patency rates in the treatment groups
have been previously published (Hogg et al., 1990). In
summary, the streptokinase group achieved a patency rate of
53% at 90 minutes and 87.5% at 24 hours, and the
anistreplase group a patency of 55% and 81% respectively.
There were no significant differences between the patency
rates of the two treatment groups at either time point.
There were no significant differences in the streptokinase
resistance titres or anti-SK IgG concentrations for the
streptokinase or anistreplase treated groups analysed
separately with regard to coronary patency at either 90
minutes or 24 hours. Considering the patients in both
treatment groups together, there was a significant
difference in streptokinase resistance titre between those
patients with TIMI grades 0&1 versus TIMI grades 2&3 at 24
hours (median 100 vs 50 SK IU ml-^, p=0.015). In addition,
there were non-significant trends towards a higher
streptokinase resistance titre in those patients with an
occluded index coronary artery at 90 minutes (TIMI grade 0
or 1 , vs grade 2 or 3, median 50 vs 20 SK IU ml-^,p=0.089,
Table 2) and towards a higher anti-SK IgG concentration in
these groups with TIMI grades 0&1 at both 90 minutes and 24
hours, (1.53 vs 0.925, p=0.050, and 1.65 vs 1.04 pg SK
binding ml~^,p=0.075, Table 3).
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Figures 12 & 13 show streptokinase resistance titres and
anti-SK IgG concentrations of the combined groups related
angiographic patency scores at 90 minutes and 24 hours.
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Table 2
Median SKRT values (SK ID al-1) according to TIMI grading
(all patients)
Tine of angiogram 90 minutes 24 hours
TIMI 0&1 50(n=41) 100(n=13)
TIMI 2&3 20(n=47) 50(n=75)
p value 0.089 0.015
Table 3
Median anti-SK IgG levels yg SK binding ml~^ according to
TIMI grading (all patients)
Time of angiogram 90 minutes 24 hours
TIMI 0&1 1 .53(n=52) 1.65(n=18)
TIMI 2&3 0.925(n=62) 1.040(n=95)
p value 0.050 0.075
1 23
Figure 12. MEDIAN STREPTOKINASE RESISTANCE TITRES RELATED
TO CORONARY PATENCY GRADES, FOR BOTH STREPTOKINASE
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Figure 13. MEDIAN ANTI-SK IgG CONCENTRATION RELATED TO
CORONARY PATENCY GRADES, FOR BOTH STREPTOKINASE




The exact prevalence of antibodies to streptococcal protein
and resistance to streptokinase among the community remains
to a large extent undefined. It has previously been
suggested (Hirsh et al., 1970, James, 1973) that high levels
of resistance to streptokinase may negate the efficacy of
streptokinase administered to establish a lytic state for
the treatment of disorders such as myocardial infarction.
With the increasing administration, and possible repeat
administration, of thrombolytic therapy for this indication,
it is important to define the relevance of resistance to
streptokinase-containing thrombolytic agents.
The most commonly prescribed thrombolytic agent in the
United Kingdom is streptokinase, and therapeutic
administration of this agent and anistreplase (see Chapter
6) is known to stimulate the development of antibodies to
the streptokinase moiety (Jalihal and Morris, 1990).
However, the extent, time course and relevance of this
response remains undefined, and is further studied in
Chapter 6.
In this study, the influence of IgG anti-streptokinase
antibody and the functionally based assay of streptokinase
resistance titres on the ability of streptokinase-containing
thrombolytic agents to achieve coronary patency following
acute myocardial infarction has been studied. The
streptokinase resistance titre is a well-established
functional assay used to assess in vivo global resistance to
1 26
streptokinase. The specific anti-streptokinase IgG assay is
relatively new, and the exact relevance of this antibody to
the mechanism of acquired resistance to streptokinase
remains to be established. It is suggested that it is a
reliable marker of previous exposure to streptococcal
protein.
These data demonstrate that there is a wide range of SKRT
and anti-SK IgG concentrations among the population
presenting with acute myocardial infarction. The
distribution of these markers is markedly skewed, with the
majority of the relevant population having a low resistance
to streptokinase. We have also shown that resistance to
streptokinase and anti-SK IgG concentration decrease with
age.
Within the range of these measured parameters, streptokinase
resistance titre has a small, but demonstrable, influence on
the efficacy of the streptokinase-containing thrombolytic
agents, streptokinase and anistreplase. There is a
significantly higher streptokinase resistance titre among
those patients with TIMI grades 0&1 at 24 hours, and trends
toward higher streptokinase resistance titres among the
comparable group for TIMI grades at 90 minutes. There were
also trends towards higher anti-SK IgG in these groups. The
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differences are relatively minor and consistent with some
previous studies which have suggested that the efficacy of
these agents are not substantially influenced by resistance
to streptokinase (Rothbard, 1985, Hoffmann, 1988).
These differences were only apparent when the two treatment
groups were analysed together. Although these two
thrombolytic agents are distinct pharmacological compounds,
their thrombolytic effects are both mediated by an extremely
similar streptokinase-plasminogen activator complex. There
are theoretical reasons why the two agents might be affected
differently by humorally mediated resistance. The
streptokinase molecule in anistreplase is already bound to
lys-plasminogen, and therefore may be less susceptible to
interference by circulating antibodies directed at this
binding site. The obscuration of the catalytically-active
centre in the administered inactive form of anistreplase may
diminish the potency of antibodies directed at the active
centre of the streptokinase moiety, and the higher affinity
of the anistreplase for fibrin relative to that of
streptokinase, may make it less effectively bound by
competing antibodies. Nevertheless, the presence of non¬
significant trends in the two smaller treatment groups which
when combined achieve conventional statistical significance
is highly suggestive of a Type II error attributable to the
relatively small numbers in some of the sub-groups.
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In the range measured in the population prior to receiving
thrombolytic therapy for acute myocardial infarction, the
streptokinase resistance titre and anti-SK IgG
concentrations as gauges of previous exposure to
streptococcal protein, have a small, but significant,
negative influence on the efficacy of the thrombolytic
agents streptokinase and anistreplase as judged by their
ability to achieve coronary patency. It remains important
to document the influence of higher levels of resistance
which are found following previous therapy with
streptokinase, and the time course of these immunological
reactions. Such studies may allow the development of
flexible dosing regimens of thrombolytic agents aimed at
saturating the patient's resistance to streptokinase,
allowing the establishment of a lytic state. In this
context, the role of high antibody levels in the mechanism
of blood pressure changes and allergic reactions to
streptokinase requires elucidation, and this question forms
the basis of the next chapter in this thesis.
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CHAPTER FIVE
HYPOTENSIVE RESPONSES FOLLOWING THROMBOLYTIC THERAPY WITH




Streptokinase has been in clinical use for many years
(Fletcher et al., 1959), and its propensity for causing
systemic hypotension has been long documented (Ganz et al.,
1984, Alderman et al., 1984). The mechanism of this fall
in blood pressure has not been elucidated. Several
possible mechanisms have been suggested, including an
immune-mediated "allergic" response, possibly due to IgE
class antibodies (Dykewicz et al., 1988); plasmin
activation by streptokinase, with resulting activation of
the bradykinin-kallikrein or complement systems (Green et
al., 1984); direct vasodilatation due to streptokinase
itself; reduction in blood viscosity (Lew et al., 1985); or
activation of endothelium-dependent systems such as the
endothelium derived relaxing factor, EDRF or prostaglandin
systems.
In this study the incidence, time course and magnitude of
hypotensive episodes following treatment with the
streptokinase-containing thrombolytic agents, streptokinase
and anistreplase, have been documented. An association
between hypotension and prior exposure to streptococcal
antigen, as measured by streptokinase resistance titre and
anti-SK IgG concentration, was sought. In addition, the
relationship to plasmin activation, as measured by changes
in plasma fibrinogen and the release of fragments of




The same study population as for the previous chapter were
used. Patient details are summarised in Table 4, and
individual demographic data recorded in Appendix I. The
mean (± SD) time from onset of symptoms to commencement of
thrombolytic therapy was 204 (± 79) minutes. There were
101 men and 27 women, with a mean age of 55.6 years.
Patients were treated with either 1.5 MIU streptokinase (63
patients) as a continuous intravenous infusion over 60
minutes, or 30 units of anistreplase (65 patients) as a 5
minute intravenous injection, in a double-blind, double-
dummy design.
All patients received 2mg/hour isosorbide dinitrate as a
continuous intravenous infusion for at least 30 minutes
prior to the commencement of thrombolytic therapy, and
prophylactic treatment with 1Omg chlorpheniramine and 100mg
hydrocortisone intravenously. Patients were allowed other
drugs, including opioid analgesics as clinically indicated.
Those patients with a history of prior exposure to
streptokinase-containing thrombolytic agents, a previous
myocardial infarction in the same anatomical distribution
or a baseline systolic blood pressure of less than 95 mmHg
were excluded. The study protocol is included in Appendix
III.
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Venous blood samples were taken, prior to the
administration of thrombolytic therapy. Streptokinase
resistance titres were measured in 96 patients (48
streptokinase, 48 anistreplase). In 124 patients
(60 streptokinase, 64 anistreplase), specific anti-
streptokinase antibodies of the immunoglobulin G (IgG)
class were assayed, as has been described in the preceding
chapter (Moran et al., 1985).
Venous blood samples were also taken from 78 patients at 0,
6, 10, 15, 30, 45, 60, 90 minutes, 2,4,6,9,12 hours, 1, 2,
3, 4, and 5 days after thrombolytic therapy and
subsequently assayed for plasma fibrinogen (Clauss assay),
B-S 15-42 peptide (RIA, IMCO), D-dimer (ELISA, AGEN) and
plasma viscosity corrected for haematocrit (Coulter-
Harkness capillary viscometer, at 37°c). From these
profiles, individual areas under the concentration-time
curve (AUC) were calculated over the first 90 minutes for
B-8 15-42, the falls in fibrinogen from baseline and
corrected plasma viscosity, and over 5 days for D-dimer in






55.6 ± 8.3 years
31 - 70
204 ± 79 minutes
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Details of study patient populatxon





Mean time to therapy ( ± SD)
Blood pressure was monitored at 2 minute intervals by a
semi-automatic sphygmomanometer cuff (Sentron) and
permanent hard copies stored. The blood pressure was
observed for at least 10 minutes prior to the start of
thrombolytic therapy, on a stable dose of intravenous
nitrates, and the final recording taken as the baseline
recording. A hypotensive response was arbitrarily defined
as a fall in systolic blood pressure of at least 20mmHg
lasting for at least three cycles of the automatic cuff (6
minutes), and were classified as early (within 30 minutes
of start of thrombolytic therapy), late (30 - 90 minutes)
or both (ie: persistent).
STATISTICAL METHODS
Differences in frequency of hypotensive episodes between
the agents were compared by the Chi-squared test. The AUCs
of change in fibrinogen, B-B 15-42 plasma viscosity and d-
Dimer for the different groups, according to presence or
absence of hypotensive episodes were compared using the
non-parametric Kruskal-Wallis and Chi-squared tests on
independent samples. Blood pressure changes were
calculated as changes from the stable baseline value, and
changes from baseline expressed as mean and 95% confidence
limits. The conventional level of significance was
adopted. For clarity of presentation, means and standard




As has been discussed previously, neither streptokinase
resistance titre nor anti-SK IgG concentrations were
normally distributed, with marked skewing toward a few high
values.
52 patients had a myocardial infarction affecting the
anterior distribution, 21 (40.4%) of whom suffered a
hypotensive response; of these 17 were early, 7 late and 3
both. 73 patients had an inferior myocardial infarction,
and 34 suffered a hypotensive response (45.5%); of these,
29 were early, 14 late and 9 both. Those patients in whom
the hypotensive episodes were attributable to a primary
cardiac arrhythmia (7 patients) were excluded. There were
no significant differences between the site of infarction
and frequency of hypotension following thrombolytic therapy
(Table 5 and Figure 14).
There was no significant difference in baseline blood
pressures between the two treatment groups. The mean
baseline systolic blood pressure was 131.1 ± 23.1 mmHg, and
the mean diastolic blood pressure 80.5 ± 13.5 mmHg.
Following thrombolytic therapy there was a fall in both
systolic and diastolic blood pressure. The amplitude and
duration of the blood pressure changes were identical for
streptokinase and anistreplase (Figures 15-18). The
maximum mean fall in systolic blood pressure was 16.9
(95%CL 12.2 to 24.54, range -105 to +20) mmHg, and the
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Table 5.
Hypotensive episodes in relation to site of infarct and
thrombolytic agent.
Also Figure 14.
Early Late Total Both lib Fall
Anterior 17 7 21 3 31 NS
Inferior 29 14 34 9 39 NS
SK 20 9 23 6 40 NS
Anistreplase 26 13 33 6 32 NS
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maximum mean fall in diastolic blood pressure was 13.7
(95%CL 10.3 to 17.1, range -70 to +10) mmHg. The fall in
both mean systolic and diastolic blood pressure commenced
at 4 minutes after therapy, and had resolved by 34 minutes.
Following anistreplase, there was a minor trend for the
diastolic blood pressure to remain below baseline.
In the patients, the hypotension was in general well-
tolerated, and in many was asymptomatic. In all patients,
blood pressure was restored to acceptable levels by
adoption of the Trendelenburg position and/or temporary
discontinuation of the isosorbide dinitrate infusion, with
only one patient requiring inotropic support at this time.
23 (37%) of the 63 patients treated with streptokinase had
a hypotensive response, 20 occurring early, 9 late and 6
both early and late (Figure 14). Of the 65 patients
treated with anistreplase, 33 (51%) had a hypotensive
response, 26 early, 13 late and 6 both. There was a trend
towards a higher frequency of hypotensive episodes in the
anistreplase group, which did not reach statistical
significance. There was no difference in the severity of
hypotensive episodes between the two treatment groups, with
only one requiring specific intervention. The
streptokinase resistance titres and anti-SK IgG
concentrations for the groups of blood pressure response
were similar. The mean streptokinase resistance titre of
those patients without a hypotensive response treated with
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INCIDENCE (%) OF HYPOTENSIVE EPISODES
ACCORDING TO SITE OF INFARCT
I i i i i
EARLY LATE TOTAL BOTH NO FALL
INCIDENCE (%) OF HYPOTENSIVE EPISODES
ACCORDING TO THROMBOLYTIC AGENT
Figure 14. HYPOTENSIVE EPISODES (PERCENTAGE OF TOTAL)
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Figure 16. CHANGES IN DIASTOLIC BLOOD PRESSURE (MEAN, 95%
CONFIDENCE LIMITS) FOLLOWING SK 1.5 MIU/60 MINUTES
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Figure 17. CHANGES IN SYSTOLIC BLOOD PRESSURE (MEAN, 95%
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Figure 18. CHANGES IN DIASTOLIC BLOOD PRESSURE (MEAN, 95%
CONFIDENCE LIMITS) FOLLOWING ANISTREPLASE 30 U/5
MINUTES
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streptokinase was 47.2 ± 45.2 compared to 39.2 ± 29.2 SK
IU.ml-1 for all patients with a hypotensive response.
Similarly for those patients treated with anistreplase, the
streptokinase resistance titres were 59.2 ± 47.6 vs 75.9 ±
86.4 SK IU.ml-^. None of the differences were
statistically significant, using non-parametric tests of
location. The anti-SK IgG concentrations for the
comparable groups were 2.12 ± 1.95 vs 1.19 ± 1.10 for the
streptokinase-treated group, and 1.45 ± 1.38 vs 1.98 ± 2.45
jj.g SK binding.ml-^ . None of the differences in anti-SK IgG
were statistically significant. (Table 6 and Figure 19).
The areas under the concentration-time curves (AUCs) for
B-fl 15-42, D-dimer and the fall in fibrinogen and corrected
plasma viscosity showed a moderate variance. The AUCs for
all the parameters, for all the groups of blood pressure
response were similar, with no significant differences
identified. (Table 7 and Figure 20).
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Table 6
Hypotensive episodes in relation to streptokinase




Early Late Total Both No Fall
Streptokinase
Mean 37.6 58.0 39.2 75.0 47.2 NS
SD 29.2 40.2 31.0 35.4 45.2
Anistreplase
Mean 84.7 48.9 75.9 20 59.2 NS
SD 100.9 39.8 86.4 - 47.6
Anti-SK IgG
(jag SK binding ml )
Streptokinase
Mean 1.09 1.13 1.19 0.77 2.12 NS
SD 1.12 0.78 1.10 0.59 1.95
Anistreplase
Mean 2.03 1.41 1.98 0.95 1.45 NS
SD 2.65 1.26 2.45 0.86 1.38
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Table 7.
Hypotensive episodes in relation to area under time-
concentration curves of D-dimer (0-5 days), B-B 15-42 and
fall in fibrinogen (0-90 minutes) (mean ± SD).
Also figure 20.
D-dimer B-B 15-42 Fibrinogen
No fall 50019 (37084) 477 (239) 2.27 (1.04)
Early 53021 (37208) 482 (194) 2.20 (0.97)
Late 45338 (25381) 441 (164) 1 .79 (1.08)
Both 45403 (30153) 452 (176) 1 .96 (1.24)
p value NS NS NS
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HYPOTENSIVE EPISODES RELATED













Figure 19. HYPOTENSIVE EPISODES IN RELATION TO PRETREATMENT
STREPTOKINASE RESISTANCE TITRES AND ANTI-SK
IgG CONCENTRATIONS
HYPOTENSIVE EPISODES RELATED
TO MEAN IgG CONCENTRATIONS
IgG CONC (uG SK BINDING/ml)
"iT~
■■streptokinase emi anistreplase
EARLY LATE TOTAL BOTH NO FALL
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b-B 15-42d-DIMER
NO FALLEARLY LATE BOTHBOTH NO FALLEARLY LATE
FIBRINOGEN FALL
f.hr/1
EARLY LATE BOTH NO FALL
Figure 20. HYPOTENSIVE EPSIODES IN RELATION TO AREA UNDER
TIME-CONCENTRATION CURVES OF D-DIMER (0-5 DAYS),




Although the fall in blood pressure following thrombolytic
therapy has been previously reported, this is the most
detailed study examining the frequency, time of onset and
duration of blood pressure response following streptokinase
and anistreplase, using preset definitions of hypotension.
In clinical experience, these falls in blood pressure are
short-lived, often asymptomatic and rarely require
therapeutic measures beyond the adoption of a head down
position and the temporary discontinuation of co¬
administered vasodilator therapy, such as intravenous
nitrates. Previous studies have reported similar findings.
Valentine et al., (1985) commented on a 17% incidence of
hypotension related to intravenous streptokinase infusion.
In the GISSI-1 study (1986) there was a reported incidence
of only 3% of 11806 patients, probably an underestimate
reflecting the imprecision of the definition of
hypotension, perhaps insufficiency of measurement, and the
paucity of associated clinical events.
This study confirms the incidence of this side-effect as 23
of 63 (37%) patients following streptokinase, and 33 of 65
(51%) following anistreplase, in a population of patients
with baseline systolic blood pressure exceeding 95 mmHg.
The difference between the two agents is not statistically
significant. The power of this study to detect the
apparent difference in frequency of hypotensive response
between the two agents, assuming a 5% chance of a Type I
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error, is 62.7%, therefore a Type II error cannot be
excluded. If such a difference is real, a study to
demonstrate this difference with 90% power would require in
excess of 500 patients.
Most of the hypotensive responses observed occurred within
the first 30 minutes of therapy (46 of 55 hypotensive
responses), be the treatment either a 5 minute intravenous
bolus of anistreplase, or a 60 minute continuous
intravenous infusion of streptokinase, and in most cases
was short-lived, with only 12 of these cases showing
hypotension persisting beyond 30 minutes after thrombolytic
therapy.
We have also shown that the propensity for a hypotensive
response is equally distributed between anterior and
inferior infarcts. There are arguments for either site of
myocardial infarct to be more prone to hypotension.
Anterior infarcts are associated with a greater degree of
left ventricular dysfunction, and they would therefore be
more susceptible to hypotension, as has been described by
Lew et al. (1985). However, one suggested mechanism for
hypotension in this context is the Bezold-Jarisch vagal
reflex, which is usually associated temporally with
coronary reperfusion in inferior wall myocardial infarction
(Wei et al., 1983, Koren et al., 1986), making inferior
myocardial infarctions more prone to hypotension. In this
study, 21 of 52 (40%) anterior myocardial infarcts had a
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hypotensive response to thrombolytic therapy compared to 34
of 73 (46%) inferior infarcts (NS), not substantiating any
difference between the two groups.
The degree of blood pressure fall in this study using
conventional doses of streptokinase and anistreplase are
less than those shown by Lew et al. (1985) who demonstrated
a mean fall in systolic and diastolic blood pressure of 35
and 20 mmHg respectively, following a very rapid infusion
of streptokinase of 750,000 IU over 7-78 minutes (mean 30
minutes), with systolic blood pressure falling below 90
mmHg in 38% of their patients. The comparable incidence
for our patients was 33% for streptokinase, and 55% for
anistreplase (NS, power 0.69, assuming Type I rate of
0.05). They too found the period of hypotension to be
brief, lasting 9 ± 6 minutes, and the incidence equally
distributed between anterior and inferior myocardial
infarcts. The magnitude of the hypotensive response is
related to the rate of administration of streptokinase.
White et al., (1987) noted the systolic blood pressure to
fall below 80 mmHg in 9% of their patients receiving 1.5
MIU of streptokinase over only 30 minutes.
The streptokinase resistance titre is a well established
functional parameter of global resistance to lysis of
fibrin by streptokinase, and its level in man reflects
previous exposure to streptococcal protein, probably in the
form of previous streptococcal infections (Flute, 1973).
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Streptokinase resistance titres in this study population
were in general low, but with a marked skewing towards a
few, very high titres. The anti-SK IgG concentrations
measured are specific circulating antibodies of the IgG
class raised against streptokinase, and can similarly be
expected to reflect exposure to streptococci. In this
study, no association has been demonstrated between these
markers measured pretreatment, and the incidence of
hypotensive responses to the streptokinase-containing
thrombolytic agents. This would imply that these
antibodies in these low concentrations are not directly
implicated in an immunological mechanism responsible for
the hypotensive responses observed. As markers of previous
exposure to streptococcal protein and an associated immune
response, these antibodies reflect other immunological
mediators. The absence of an association suggests that the
hypotensive response is not directly influenced by these
immunological factors, at least in the low concentrations
observed. It is difficult to extrapolate these results to
the considerably higher streptokinase resistance titres
seen up to one year following therapy with the
streptokinase-containing thrombolytic agents (Jalihal et
al., 1990), but the risks of retreatment may be less than
has been suggested.
B-G 15-42 is a peptide degradation fragment of
fibrin(ogen), and is a measure of plasmin activity due to
plasminogen activation by the streptokinase-plasminogen
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activator complex. D-dimer is a breakdown product of
cross-linked fibrin, a measure of clot lysis. The systemic
effects of the two thrombolytic agents are estimated by
changes in circulating fibrinogen and plasma viscosity.
It has previously been demonstrated that the release curves
of B-fl 15-42 and D-dimer, and effects on plasma fibrinogen
are identical in both timing and magnitude with both the
streptokinase-containing thrombolytic agents (Douglas et
al., 1988), and it is therefore justifiable to analyse data
from both treatment groups. The time course of the release
profiles of the two peptides, the reduction in plasma
viscosity and circulating fibrinogen are very different.
In this study, the changes in B-B 15-42, plasma viscosity
and fibrinogen were calculated over the first 90 minutes,
the period most relevant to the blood pressure changes.
The D-dimer release has been measured over the period of 0-
5 days in view of the persistence of this peptide in the
circulation.
In this study no relation between these parameters of
fibrin- and fibrinogen-olysis and the incidence of
hypotensive response has been shown. The fibrinogen
changes in particular have a large variance, and while it
is not possible to entirely exclude a weak association, it
is unlikely that any relation of clinical significance
exists.
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Previous workers (Lew et al., 1985) have discussed the
possibility that the hypotensive response following
streptokinase may be due to a reduction in peripheral
vascular resistance reflecting reduced plasma viscosity
caused by the fall in plasma fibrinogen. The present study
excludes this hypothesis by demonstrating a lack of
association between the fall in fibrinogen and corrected
plasma viscosity and the blood pressure response.
It has also been suggested that fibrin degradation products
can activate the prostaglandin-prostacyclin system causing
vasodilatation and hypotension (Andersson, 1983). We were
unable to show such a relationship between blood pressure
and the fibrin product D-dimer, nor changes in fibrinogen.
Similarly, it has been suggested that serious allergic-type
reactions may be mediated by activation of the complement
pathway, by complement lysis mediated by plasmin in response
to plasminogen activators eg: rt-PA (Bennett et al., 1987).
Again if this were the mechanism involved, it would be
anticipated that there would be demonstrable differences in
other parameters of plasmin activity.
The exact mechanism of the hypotension observed following
the administration of streptokinase-containing thrombolytic
agents remains unexplained. Other possible explanations
include a direct negative inotropic or vasodilator effect
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of the thrombolytic agents, an effect on the baroreceptors,
endothelium mediated vasodilatation (for example due to
endothelium derived relaxing factor) or neurohumoural
mediation perhaps by atrial natriuretic peptide.
In this study, the hypotensive response to these agents is
common, short-lived and generally well-tolerated.
Nevertheless this side effect limits the rate of
administration of the streptokinase-containing thrombolytic
agents. It is therefore important to identify the
mechanism of this response, possibly allowing the
development of pharmacological means of modulating the
blood pressure response to these agents.
1 55
CHAPTER SIX





The previous chapters have discussed the influence of
pretreatment resistance to streptokinase on the efficacy of
the streptokinase-containing thrombolytic agents,
streptokinase and anistreplase, as judged by their ability
to achieve coronary patency and their influence on
hypotension following the administration of these agents.
These studies did not demonstrate an obvious effect, but
suggested that those patients with higher levels of
resistance, reflected in high streptokinase resistance
titre or anti-SK IgG concentration, have a poorer outcome
in terms of grades of reperfusion.
As has been discussed above, the pretreatment resistance in
the population was in general low, as would be expected in
a population not previously exposed to streptokinase, and
those with high levels were few in number. Previous
studies have demonstrated that those patients with very
high resistance to streptokinase, probably acquired by
recent streptococcal infection, have a poor lytic response
to streptokinase (Hirsh et al., 1970, James, 1973). With
the increasing use of thrombolytic therapy for indications
such as acute myocardial infarction, the major importance
of acquired resistance to the streptokinase-containing
thrombolytic agents lies in the area of those patients who
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are re-exposed to these agents. In particular it is
important to define the safe time period for retreatment
with streptokinase, with regard to both efficacy and
freedom from adverse events.
It was the purpose of this study to define the time course
of induction and decline of resistance to streptokinase.
It has already been shown that the streptokinase resistance
titre reaches a peak value at two weeks following therapy,
and is returning towards pretreatment levels by six months
(Fletcher et al., 1959, Fostering et al., 1978, Massel et
al., 1989, Jalihal and Morris, 1990).
In this study, the observation period was extended and
includes observations on both the induction of specific
antibodies as the anti-SK IgG concentration, in addition to
the streptokinase resistance titre, a global reflection of
both antibody-mediated resistance and the influence of
components such as a2-antiplasmin, and proteins such as
fibrinogen and plasminogen. The fibrinolytic response to
streptokinase and anistreplase, in the time period




128 consecutive eligible patients (101 male, 27 female, age
range 31-70 years) were recruited, being the entire study
population of the anistreplase / streptokinase comparative
study, the details of which have already been recorded
(Appendix I). All patients presented with acute myocardial
infarction, and without contraindications to thrombolytic
therapy, and received either a conventional dose of 1.5 MIU
streptokinase infused intravenously over 60 minutes, or 30
U of anistreplase as a 5 minute continuous intravenous
injection, in a double-blind double-dummy design. Patients
with prior exposure to streptokinase-containing
thrombolytic agents were excluded (Appendix IV).
Blood samples were collected from each patient prior to
dosing and serially at 2 and 4 weeks, 3, 6, and 12 months.
In a subgroup of 40, blood samples were taken daily for the
first 14 days to determine the early rise in resistance
following thrombolytic therapy. After one year, following
interim analysis of the results, 67 of these patients were
sampled on one further occasion, which was distributed over
the period of 12 to 30 months following therapy.
Streptokinase resistance titre and specific anti-SK IgG
concentrations were measured in individual plasma samples
using methods which have already been described.
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Clot lysis assay
The clot assay described measures the release of soluble
fibrin degradation products from radio-labelled plasma
I TC
clots incubated in autologous plasma. [ JI]-fibrinogen
(3pCi, 33pg/1 Opl) was mixed with pooled citrated human
plasma giving a final concentration of 6 pCi/ml plasma.
This mixture was kept on ice until immediately prior to use
when calcium chloride and bovine thrombin were added to
give final concentrations of 23mM and 0.43U/ml
respectively, and aliquots dispensed into 0.5 ml
microtubes. The microtubes were incubated at 37°c for 10
minutes then kept on ice for a further 20 minutes. The
resulting clots were dislodged with a 200 pi jet of human
serum albumin (1% HSA) in phosphate buffered saline, pH 7.3
and transferred to a flat bottomed tube using a wide bore
pipette. The HSA buffer was replaced by autologous plasma
(300pl) and incubated in a water bath at 37®c.
The thrombolytic agents streptokinase and anistreplase were
diluted into 0.05M sodium phosphate/0.1M sodium
chloride/0.01% Tween 80 buffer pH 7.4 prior to use, and an
aliquot of 30pl added to the plasma phase surrounding the
clot and mixed. Aliquots of 20 pi were removed at time
intervals from 0.5 to 4 hours, and gamma-counted along with
the remaining plasma containing the clot. A control lysis
study using buffer alone was performed to calculate
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spontaneous clot lysis. Thus clot lysis due to different
concentrations of plasminogen activator over a range of
incubation times was calculated and the spontaneous lysis
subtracted. These assays were performed in quadruplicate.
DATA ANALYSIS
The data is markedly skewed toward the higher results, and
for this reason a variety of stratagems have been used for
the display of the data. The baseline pretreatment data
can be transformed to a normal distribution by log-^ q
transformation for the anti-SK IgG concentration and the
calculation of the fourth root for streptokinase resistance
titre. Thus a proportion of each data set at each time
point greater than one or two standard deviations above the
mean can be calculated. In addition, the medians and means
of the transformed data have been displayed, along with the
proportion at each time point outwith the pretreatment
range.
RESULTS
The pretreatment streptokinase resistance titre was
measured in 97 patients, and a mean of 56 patients were
studied at each time point to 12 months giving a follow-up
rate of 57%. After the 12 month initial follow-up period,
67 patients attended for repeat measurement (68%), divided
into three time points. The pretreatment anti-SK IgG
concentration was measured in 125 patients, and a mean of
67 patients were available for follow-up specimens to 12
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months (53%). The 67 patients in whom anti-SK IgG
concentrations were measured in the period from 18-30
months represented 54% of the original population. Not all
of the original cohort was available for follow-up over
this period, due to death or disability.
Streptokinase Resistance Titre
The time course of the streptokinase resistance titre was
similar in both the streptokinase and anistreplase
treatment groups (Figure 21). Pretreatment titres were
exceeded by 5 days after dosing, and achieved peak values
of 40-fold of median at 14 days after treatment. After 12
months, each patient was sampled on one more occasion, over
the period of 12-30 months following therapy. The values
were collated into groups at 18, 24 and 30 months, with
different patients appearing at each time point.
Although the rate of rise in streptokinase resistance titre
and time course of its fall were identical between the two
treatment groups, there was a fortuitous higher
pretreatment streptokinase resistance titre in the group
allocated to anistreplase (median 50 vs 20 IU/ml, p<0.05).
(Figure 9, Chapter 4).
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Figure 21. DEVELOPMENT OF STREPTOKINASE RESISTANCE TITRE
FOLLOWING 1.5 MIU STREPTOKINASE AND 30 U ANISTREPLASE
SKRT (IU.SK/ml)
STREPTOKINASE B3 ANISTREPLASE
0 .25 .5 1 2 3 6 12 13 24 30
TIME AFTER THERAPY (MONTHS)
DEVELOPMENT OF IgG ACCORDING TO
THROMBOLYTIC AGENT
IgG CONCENTRATION (IU.SK BINDING/ml)
0 .25 .5 1 2 3 6 12 18 24 30
TIME AFTER THERAPY (MONTHS)
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Peak titres were attained 2 weeks after dosing (Figure 22),
and started to decline by 3-6 months, however the elevation
in individual pretreatment levels remained marked in those
patients with a complete data set (Figure 23). For the
whole population studied, 72% of the values had returned to
within the pretreatment range by 6 months, and all were
within the pretreatment range by eighteen months (Figure
24). However, only 49% of values were within two standard
deviations of the pretreatment population at 12 months, and
only 58% in the subgroup studied at 24 months (Figure 25).
The decline in streptokinase resistance titre in the period
from 12 to at least 24 months after treatment was very
slow.
Using the median streptokinase resistance titre for each
sampled group at each time point, and an estimated volume
of distribution of plasma proteins of 6 1, it is possible
to calculate the theoretical dose of streptokinase which
would be neutralised by this degree of resistance. The
results are displayed in Figure 26. Similar approaches
have been used by other authors (Jalihal and Morris, 1990).
Using this model, all of the standard dose of streptokinase
is neutralised by the circulating resistance for at least
12 months, and approximately 50% of the dose remains
inhibited to 30 months.
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Figure 22. EARLY RISE IN STREPTOKINASE RESISTANCE TITRE
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Figure 24. PROPORTION OF VALUES OF STREPTOKINASE RESISTANCE
TITRE EXCEEDING THE PRETREATMENT RANGE OVER
30 MONTHS FOLLOWING TREATMENT
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Figure 25. PROPORTION OF VALUES OF STREPTOKINASE RESISTANCE
TITRE EXCEEDING PRETREATMENT MEAN PLUS 1 OR 2
STANDARD DEVIATIONS OVER 30 MONTHS FOLLOWING
TREATMENT
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THEORETICALD SEOFSKNEUT ALISED WITHTIMEAFTERHERAPY
MIUSTREPTOKINASE 0 .25512362840 TIMEAFTERHERAPY(MONTHS)
Anti-SK IgG Concentrations
There were no differences in either the pretreatment anti-
SK IgG concentrations, or the time course of changes in
anti-SK IgG concentration between the two treatment groups.
Following thrombolytic treatment there was a fall in anti-
SK IgG concentration, attributable to antibody
sequestration as antigen-antibody complexes, as has been
described previously (Hoffmann et al., 1988).
Subsequently, values returned to baseline within 5 days
(Figure 21).
Peak values in anti-SK IgG concentration were achieved 14
days after therapy, with a peak level of 150-fold
pretreatment level. The subsequent decline in antibody
concentration was slow (Figure 28), with 48% of individual
anti-SK IgG values returning to within the pretreatment
range by 12 months after dosing, and 89% at 30 months
(Figure 29). Only 39% of the population had returned to
within two standard deviations of the pretreatment
distribution at one year, and 50% at two years (Figure 30).
At the latter time point there remained a nine-fold rise in
median anti-SK IgG concentration relative to baseline.
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Figure 27. EARLY RISE IN ANTI-SK IgG CONCENTRATIONS OVER






















Figure 29. PROPORTION OF VALUES OF ANTI-SK IgG CONCENTRATION






























Figure 30. PROPORTION OF VALUES OF ANTI-SK IgG CONCENTRATION
EXCEEDING PRETREATMENT MEAN PLUS 1 OR 2 STANDARD
DEVIATION OVER 30 MONTHS FOLLOWING TREATMENT
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Clot Lysis Assay on Pooled Plas*a Samples
It is difficult to extrapolate from the anti-SK IgG
concentrations and streptokinase resistance titres to their
possible functional (neutralising) effects, especially in
view of the fact that the only relationship discussed in
previous chapters is based on low levels of circulating
resistance, in a population not previously exposed to
streptokinase. The purpose of the pooled clot lysis assay
was therefore to further investigate possible effects of
the two measures of streptokinase resistance on the
thrombolytic response. The limited sample volume available
from individual patients necessitated pooling aliquots of
plasma at each sampling point from pretreatment to 30
months, with samples from patients treated with
anistreplase or streptokinase being pooled separately.
Fibrinogen, plasminogen, c^-antiplasmin, and c^-
macroglobulin were measured in each pool, and there were no
major differences in these proteins between the
pretreatment pool and any of the pools for the time points
to 30 months (Table 8). Differences in fibrinolytic
responses to the two thrombolytic agents can therefore be
ascribed to changes in antibody.
The concentration-effect curves for the period of 0-30
months are shown in Figures 31 & 32. The fibrinolytic
1 75



















































































































































































Figure 31. CONCENTRATION-EFFECT CURVES OF IN VITRO LYSIS
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response measured up to 5 days was unchanged, but the
pooled results from 7 days to 6 months showed near complete
inhibition of fibrinolysis in vivo. There was some
recovery in response observed at 18-30 months, for example
approximately 25% of the fibrinolytic response was present
at 12 months, increasing to 75% at 30 months.
However, these pooled results reflect the arithmetic mean
of antibody concentrations and resistance within the
samples. In order to reduce the bias due to the influence
of the relatively few very high values within the
population, I constructed a model relating streptokinase
resistance titre and anti-SK IgG concentration to the
proportion of lysis achieved within the assay at 90 minutes
and 4 hours. It is possible to derive the following linear
regression equations:
% Lysis at 90 minutes = 108 - 17.3 x ^VSKRT
R2 = 77% p<0.0001
% Lysis at 4 hours = 134 - 20.7 x ^VSKRT
R2 = 88% p<0.0001
% Lysis at 90 minutes =
92.6 - 44.0 x log-j q( IgG concentration)
R2 = 87% p<0.0001
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% Lysis at 4 hours =
116 - 52.8 x log^QdgG concentration)
R2 = 95% p<0.0001
Using these relationships, it is possible to titrate the
more representative median values of anti-SK IgG
concentration and streptokinase resistance titre for the
time points studied and predict the proportion of in vitro
lysis which would be achieved for these time points. As can
be seen (Figure 33) it would appear that in vitro
fibrinolysis is very rapidly inhibited, and remains less
than 50% of baseline until 12 months. Following this there
is recovery of in vitro lysis, but baseline lysis is not
achieved within the 30 months of the study period.
As has been mentioned above, the time points after 12 months
consisted of fewer patients with each pool comprising a mean
of 22 patients compared to a mean of 56 for streptokinase
resistance titre and 67 for anti-SK IgG patients for the
time points up to 12 months. It cannot be excluded that the
relatively small numbers of patients available may have














~i 1 1 1 r
.25 .50 1.0 2 3 6 12 18
MONTHS AFTER TREATMENT
Figure 33. TIME COURSE OF IN VITRO CLOT LYSIS AT
90 MINUTES AND 4 HOURS CALCULATED FROM THE
MEDIAN STREPTOKINASE RESISTANCE TITRE AND




In the light of increasing use of thrombolytic therapy for
acute myocardial infarction, there is an increasingly
urgent need to establish a safe interval for repeat
administration of streptokinase-containing thrombolytic
agents. The data presented here show that high levels of
neutralising antibody and streptokinase resistance are
rapidly induced following treatment with streptokinase and
anistreplase, and that the response to these two agents is
identical.
Previous studies have demonstrated similar rises and time
course in streptokinase resistance titre, with return of
the titre towards baseline at 6-12 months (Fletcher et al.,
1959, Kostering et al., 1978, Massel et al., 1989, Jalihal
and Morris, 1990). Based on these studies, estimates of a
recommended time to the possibility of re-dosing with
streptokinase have varied from 3 to more than 6 months.
Data published recently by Elliott (1991) suggest that the
resistance to streptokinase may persist for at least 4
years before showing significant decline from the value of
12 months. Our streptokinase resistance titre data suggest
that a large proportion of a standard repeat dose at 6
months would still be neutralised, and possibly a
significant proportion of a similar dose at 12 months.
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The induction of specific antibodies to streptokinase of
the IgG class broadly parallells the induction of
streptokinase resistance titre. The induction of anti-SK
IgG over the first two months is similar to results
published for an enzyme-linked immunosorbent assay (ELISA)
method of analysis of anti-SK IgG (Davies et al., 1990).
However, the induction of IgG antibodies appears to be more
rapid when measured by ELISA than in this study or in other
studies using the same microradioimmunoassay method
(Hoffmann et al., 1988).
Although high levels of anti-SK IgG constitute a major
contribution to streptokinase resistance, the initial fall
in anti-SK IgG concentration in the first 4 days after
treatment with streptokinase or anistreplase is not
accompanied by a concomitant fall in streptokinase
resistance titre. This could be explained by changes in
the fibrinolytic assay reflecting changes in fibrinogen,
plasminogen and o^-antiplasmin in the early phase of
myocardial infarction treated with thrombolytic therapy.
In addition, the difference in pretreatment streptokinase
resistance titre between the two treatment groups despite
similar anti-SK IgG concentration, and the poor correlation
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between changes in anti-SK IgG and streptokinase resistance
titre after 3 months must reflect the contributions of
other inhibitors, or antibodies of other immunoglobulin
classes.
As well as the question of efficacy with repeat dosing with
streptokinase-containing thrombolytic agents, there is the
important concern regarding whether high concentrations of
anti-SK IgG and other classes of antibodies are a risk
factor for allergic-type reactions. Anti-SK IgG antibodies
have occasionally been implicated in adverse events
following streptokinase therapy (Davies et al., 1990). In
the large mortality studies of streptokinase (ISIS-2, 1988,
GISSI, 1986) and anistreplase (AIMS, 1990), the incidence
of severe allergic-type reactions was very low. Those few
patients in the current study who showed an allergic-type
response, were not obviously associated with different
anti-SK IgG concentration or streptokinase resistance titre
than those who did not (Hogg et al., 1990), and a
correlation between anti-SK IgG concentration or
streptokinase resistance titre and hypotensive responses
has not been demonstrated as has been discussed in Chapter
6. However, in these studies, the levels of resistance was
in a non-exposed population, and it is difficult to
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extrapolate these results to the situation of patients
being retreated with streptokinase-containing thrombolytic
agents in the presence of higher, or possibly considerably
higher, levels of resistance.
Interpretation of the pooled clot lysis data is complicated
by several factors. Firstly, although as has been
discussed, the distribution of anti-SK IgG concentration
within the population was markedly skewed towards the
higher values, by performing the assay on pooled samples an
arithmetic mean is necessarily constructed, which would
overestimate the influence of the higher values. To
diminish these effects, the median streptokinase resistance
titres, in conjunction with a linear regression model
relating the SKRT to the degree of inhibition of in vitro
lysis after 90 minutes and 4 hours of incubation, have been
used to calculate the median degree of inhibition of in
vitro lysis predicted for each time point.
In addition, IgG antibodies are polyclonal, and it is
possible that mixing of samples in pools may lead to
synergy between different populations of antibodies. This
particular in vitro assay may also exaggerate the influence
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of antibody, as other work using a human fibrin plate
technique suggests that anti-SK IgG may have less
inhibitory effect than observed here (Hoffmann et al.,
1988, Fears et al., 1987).
It is also difficult to translate in vitro fibrinolysis
into in vivo efficacy as judged by coronary patency. In
particular, 1.5 MIU of streptokinase infused intravenously
over 60 minutes achieves a maximum plasma concentration of
— R
streptokinase of 3.85 M x 10 , and is associated with a
coronary patency rate of 53% at 90 minutes and 87.5% at 24
hours (Hogg et al., 1990) and a reduction in mortality of
18% (GISSI, 1986). However, a similar concentration of
streptokinase in vitro would achieve less than 50% lysis of
fibrin. Similar conclusions can be drawn from a standard
dose of 30 units of anistreplase, which achieves a peak
— R
plasma concentration of 5.59 M x 10 .
Possible explanations for the underestimation of the
potential clot lysis by the in vitro system is the
relatively large mass of fibrin produced in vivo relative
to plasminogen activator present, and the lack of any
potential contribution of pulsatile flow and local vascular
dynamics in vitro.
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Nevertheless, these results indicate that relative to the
unexposed pretreatment state, the degree of lysis achieved
following exposure to streptokinase-containing antibodies
and streptokinase resistance titre is substantially
diminished up to at least 12 months, with some recovery
thereafter but with little further recovery up to 30 months.
The relatively greater inhibition of early in vitro
fibrinolysis would suggest a delaying effect on the
initiation of fibrinolysis. In the absence of further data
to clarify the situation or the interpretation of the
pooled clot lysis data, it has to be tentatively concluded
that the efficacy of retreatment with a standard dose of
streptokinase or anistreplase would be substantially
compromised at these time points.
However, unless high anti-SK IgG concentration and
streptokinase resistance titres are shown in due course to
be a risk factor for serious allergic reactions, it may be
possible to devise alternative dosing schedules for
retreatment with streptokinase-containing thrombolytic
agents, possibly with a "front-loaded" regimen, perhaps
guided by pretreatment streptokinase resistance titres,
with a view to saturating circulating resistance.
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Clearly the most appropriate study would be to perform an
efficacy/patency study on patients who have previously been
treated with streptokinase. However this study would be
particularly difficult to perform because of ethical
concerns regarding efficacy and safety, and also because of
the difficulty in recruiting sufficient numbers of suitable
patients.
It must be considered that streptokinase and anistreplase
administered more than five days, and at least up to 12
months, after prior streptokinase-containing thrombolytic
agents may not be effective, and may have an increased risk
of allergic-type reactions. Further studies are reguired
to delineate this latter risk. At the present time, if
retreatment with thrombolytic agents is required during
this time period, the recommended course of action would be
to use a thrombolytic agent, which would not be influenced
by resistance to streptokinase, such as rt-PA.
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CHAPTER SEVEN
THE EFFICACY AND PHARMACOKINETICS OF TWO 35 MG BOLUSES OF
ALTEPLASE IN ACUTE MYOCARDIAL INFARCTION
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INTRODUCTION
The profile of the ideal thrombolytic drug has been
mentioned already, with regard to its desired
pharmacokinetic properties. It should be easily and
rapidly administered by the intravenous route, and should
effectively and rapidly restore coronary patency without
adverse side-effects. The ease of administration of the
agent becomes increasingly important with the stress laid
on immediate therapy on arrival in hospital and the
possibility of initiation of therapy in the community.
Rt-PA has been shown to be an efficacious agent in
restoring coronary patency (TIMI-1, 1985, Chesebro et al.,
1987, Williams et al., 1986, Collen et al., 1984,
Verstraete et al., 1985a, Verstraete et al., 1985b) and
achieves a higher patency than a conventional dose of
intravenous streptokinase (TIMI-1, 1985, Chesebro et al.,
1987). At present, the recommended dosage regimen for
alteplase is a 10 mg bolus, followed by an involved
decremental infusion of 90 mg over 3 hours. This regimen
was based on the apparent short half-life of alteplase in
the circulation (Tanswell et al. , 1989), but clearly this
regimen is cumbersome to apply urgently.
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This study was performed to assess the efficacy of two
boluses of 35 mg alteplase administered intravenously
thirty minutes apart, in achieving coronary patency
assessed by angiography, and to observe the pharmacokinetic
corollaries of this regimen.
PATIENTS AND METHODS
Thirty-three consecutive patients were admitted to Stobhill
Coronary Care Unit and recruited into the study. Patients
were eligible for inclusion if they presented with chest
pain of at least 30 minutes duration, could be treated
within 6 hours of symptom onset and had
electrocardiographic evidence of acute myocardial
infarction (ST elevation >1 mm in 2 or more limb leads or
>2 mm in 2 or more praecordial leads). Patients were
excluded if they were over 75 years of age, had a previous
infarct in the same anatomical distribution, or had any of
the recognised contraindications to thrombolytic therapy
(TIMI-1, 1985) or coronary angiography. The study protocol
was approved by the local Research & Ethical committee and
is included in Appendix III.
The base-line characteristics of the patients recruited are
summarised in Table 9 and detailed in Appendix I. Of the
33 patients recruited, 23 were male and 10 female, their
mean age was 56 ± 11 years, with a range of 40 to 74 years.
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TABLE 9
DETAILS OF STUDY PATIENT POPULATION










Mean time to therapy
Mean time to first
angiographic injection
Mean weight
Dose of alteplase administered











208 ± 75 minutes
49.4 ± 13.3 minutes
73.2 ± 12.8 kg
70 mg
0.984 ± 0.173 mg/kg
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The mean time from onset of symptoms to the administration
of the first bolus was 208 ± 75 min. The mean weight of
the patients was 73.2 ± 12.8 kg, deriving a mean dose of
alteplase administered of 0.984 ± 0.173 mg/kg.
Following written informed consent, and discussion with
accompanying relatives, the patients received 35 mg
alteplase intravenously over 30 seconds, which was repeated
30 minutes later. All patients received 150 mg aspirin
orally immediately on entry to the study and daily
thereafter. All patients received an intravenous infusion
of glyceryl trinitrate starting at 0.25 mg/hour unless
there was a specific contraindication.
Coronary angiography was performed in the Coronary Care
Unit using an Image Intensifier (Siremobil 2N/2H) linked to
a video tape recorder (JVC CR8200E). Details of this
system have been previously described (Hillis et al. ,
1986). The Seldinger percutaneous approach was used and a
femoral sheath left in situ. The coronary angiogram was
commenced immediately after the second bolus of alteplase
(30 minutes), and the infarct related coronary artery, as
indicated by the admission ECG was visualised as soon as
possible after 30 minutes, with serial selective injections
at 60 and 90 minutes. The degree of perfusion was scored
according to the TIMI scale (Appendix II) on the first
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angiographic run of each series, and reviewed by an
independent experienced cardiologist, a score of 0-1 taken
to indicate non-patency and 2-3 patency (TIMI-1, 1985).
If the artery was occluded at 90 minutes, the study
protocol allowed an option for additional therapy to be
given to the total dose of 100 mg alteplase, as recommended
by the product license. The other coronary arteries were
visualised in standard angiographic projections. The
femoral sheath was left in situ and coronary angiography
repeated at 24 ± 8 hours following treatment, to assess
patency and reocclusion.
Intravenous heparin infusion was commenced in all patients
3-4 hours after onset of therapy, and the dose titrated
against the thrombin time to a therapeutic ratio of two to
three to one. No bolus of heparin was given at initiation
of alteplase therapy. In all cases, heparin was
discontinued for a short period at the time of the second
angiogram to allow removal of the femoral sheath.
Venous blood samples were collected via an indwelling
venous catheter from the first 24 patients pretreatment,
then 10,20,30,40,50,60 minutes, 2,4,8,12,24 hours after the
first bolus of alteplase, into sodium citrate, centrifuged
immediately at 0°c, separated and frozen at -40°c.





Coronary angiography was commenced at 30 minutes after the
administration of the first bolus of alteplase, and the
infarct related artery was first visualised at a mean time
of 49.4 ± 13.3 minutes (Table 10). The artery was
visualised within 55 minutes in 26 of 30 (86%) patients.
In three patients an acute angiogram was not obtained, one
because of haemodynamic instability, one because the
patient died before 90 minutes, and one because it was not
possible to inject the right coronary artery.
In three subjects, although the entry criteria were
satisfied, serial ECG changes of acute myocardial
infarction did not occur and cardiac enzymes were normal.
In one of these subjects the right coronary artery could
not be visualised, and is not included in the angiographic
data. In all other patients angiography was obtained
within 90 minutes of start of therapy and the results
presented are patency rates of all patients in whom
coronary visualisation was achieved at each time point.
At the first injection of the infarct-related artery (49.4
± 13.3 minutes) 23 of 30 (77%, 95% confidence limits 61 to
92%) arteries were patent. At 90 minutes, this had




































Two subjects received a further intracoronary dose of 30 mg
alteplase following the 90 minute angiogram. In one, there
was intermittent reperfusion of the index artery during the
period of angiographic observation. In the other,
following left main coronary artery occlusion there was
penetration only (Grade 1) of the circumflex artery at 90
minutes. In both patients, the arteries were patent at the
24 hour angiogram.
One subject did not undergo 24 hour angiogram because of
haematoma formation following splitting of the femoral
sheath. At 24 hours, 24 of 29 arteries (83%, confidence
limits 69 to 97%) were patent. Seven patients improved
their angiographic appearance by at least one grade, 3
gaining reperfusion. However 5 deteriorated at least one
grade with 3 arteries reoccluding (3 of 29, 10%, 95%
confidence limits 0 to 22%).
ADVERSE EVENTS
The only adverse events documented in this study group were
bleeding complications. Five patients developed
significant haematomata related to the site of arterial
access for coronary angiography. Two patients suffered
minor coffee ground haematemesis and one other bled from
the gums. No patient required blood transfusion or
specific intervention, and there were no sequelae.
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One patient died during the study. This patient was known
to have severe triple vessel disease and a previous
myocardial infarction. Shortly following admission and
treatment, he developed cardiogenic shock and died despite
inotropic support.
PLASMA t-PA CONCENTRATIONS
Mean pretreatment plasma t-PA concentration was 20.1 ± 4.3
ng/ml, significantly higher than the laboratory normal (3.6
± 1.3 ng/ml, MacGregor et al., 1990). Mean concentration
rose to 4435.8 ± 2117.8 ng/ml within ten minutes of the
first bolus of alteplase, falling to 425.8 ± 288.3 ng/ml
prior to the second bolus, rising again to a peak of 4233.3
± 2217.5 ng/ml within 10 minutes of the second bolus
(Figure 34). Mean concentrations then fell rapidly to
approximately twice the pretreatment values at 4 hours
(40.6 ± 28.6 ng/ml). After this time period, the t-PA
concentrations were low, variable and approximately at
physiological levels.
These low variable t-PA concentrations introduced
considerable random variation in the pharmacokinetic
fitting, therefore the data fitted were the baseline-
subtracted concentrations confined to the four hour period
after the administration of alteplase. This approach has
been adopted by previous authors (Tanswell et al., 1989,
Seifried et al., 1989).
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Figure 34. MEAN PLASMA t-PA CONCENTRATIONS FOLLOWING TWO
INTRAVENOUS BOLUSES OF 35MG ALTEPLASE SEPARATED
BY 30 MINUTES
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The individual declines in t-PA concentration were fitted
to one, two- and three-compartment pharmacokinetic models,
but a satisfactory fit was obtained only with the one-
compartment model. Pharmacokinetic parameters derived from
this model were: volume of distribution 3.11 ± 1.89 1
(CV:35.6 ± 26.7%); clearance 21.3 ± 9.3 1/h (CV: 14.1 ±
11.7%) and half-life 5.9 ±1.7 min. The coefficients of
variation (CV) expressed are means and standard deviations
of the coefficients of variation of the individual fitted
data and express the quality of fit of the model (Table
11). Using this model, the plasma t-PA concentrations were
estimated at two minutes after the beginning of the
intravenous boluses of alteplase, as a measure of the peak
concentrations achieved using this administration regimen.
The peak concentration was 12389 ± 8580 ng/ml two minutes
after the first bolus and 10811 ± 6802 ng/ml after the
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These results show that alteplase administered
intravenously as two boluses of 35 mg separated by 30
minutes is effective in restoring coronary artery patency
in acute myocardial infarction. To allow comparison with
other patency studies, the primary end point of efficacy
was patency at 90 minutes following therapy, but in
addition the angiograms at earlier time points allow an
assessment of the time to reperfusion. At the time of
first injection, at a mean of 49 minutes post-therapy, 77%
of the patients had patent index coronary arteries,
improving to 87% within 90 minutes, showing that patency is
achieved rapidly and effectively.
Direct comparison of this study with previous published
studies using tissue-type tissue plasminogen activator (r-
tPA) is difficult because of several confounding factors.
Other studies have used differing administration regimens
of widely varying doses of two different preparations of
rt-PA, each with different specific activities (Garabedian
et al., 1987, Muller et al., 1987). In addition, whereas
some studies have observed patency, others have observed
reperfusion, with a difference due to spontaneous
reperfusion and sub-total coronary occlusion at
presentation (deWood et al., 1980).
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Verstraete and co-workers (Verstraete et al., 1985) have
demonstrated patency rates of 61% at 75-90 minutes post-
therapy using 0.75 mg/kg of double-chain rt-PA over 90
minutes. The same group using a 40mg infusion of double-
chain rt-PA over 90 minutes, achieved a coronary patency
rate of 66% at 90 minutes (Verstraete et al., 1987). Topol
and the TAMI group (Topol et al., 1987a, 1987b, 1989) have
achieved a patency rate of 68% patency using 70 mg of rt-PA
over 90 minutes, and 79% using the high dose of 1.5 mg/kg
of alteplase over 4 hours, in conjunction with a high dose
of heparin. The TIMI group in TIMI-1 (TIMI-1, 1985,
Chesebro, 1987) used 80 mg of double-chain rt-PA over 3
hours, finding a reperfusion rate of 56%. Williams et al.
(1986) using the same dose of 80 mg over 3 hours found a
similar reperfusion rate of 68%.
Published experience with bolus doses of alteplase is
limited. Verstraete et al. (1989) using single boluses of
alteplase, found that doses of 60 mg and 50 mg were
associated with reperfusion rates at 90 minutes of 32% and
45% respectively, although a maximum dose of 70 mg achieved
72% reperfusion. However, these results could not be
supported when repeated in larger numbers by the same
authors (Tranchesi et al., 1991). Using the 70mg bolus
dose, they found reperfusion rates of 32 and 45% at 60 and
90 minutes.
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Khan et al., (1990) have evaluated 4 boluses of 25mg over
60 minutes of the double-chain t-PA and demonstrated
recanalisation in 11 of 14 patients, and suggested that
this regimen achieves coronary patency more rapidly. In
this study, 70mg divided into two boluses, also achieves a
high patency rate, and would be expected to be associated
with fewer bleeding complications (TIMI-2, 1989).
A small study by Smalling et al. (1990) using rapid
intravenous infusions of a weight-adjusted dose of
alteplase, and a median dose of 145mg, reported a 90 minute
patency rate of 84%, which was significantly higher than
the control group who received a conventional 3 hour
infusion of 100mg. The studies performed by Neuhaus and
his group (Neuhaus et al., 1989, von Essen et al., 1991)
looked at accelerated "front-loaded" intravenous infusion
regimens of 100mg of alteplase over 150 and 90 minutes, and
observed 90 minute patency rates of 91% and 84.4%. These
results suggest that rapid administration of the
thrombolytic agent achieves higher patency, and that it is
the peak concentration of agent achieved which is
important, an inference supported by the data in this
study.
It is of note that the higher patency rates in the
literature were achieved with higher weight adjusted doses
of rt-PA, although the need for weight adjusted doses with
alteplase has recently been questioned. In the recently
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reported TAPS study, an accelerated front-loaded
administration regimen of 100mg alteplase over 90 minutes,
given with an initial 1Omg bolus, there was little evidence
to support higher patency in the lighter patients who
received a higher weight-related dose. However, there was
evidence that these patients achieved a more complete
degree of reperfusion.
In the present study, the total of 70mg alteplase
represents a mean dose of 0.98 mg/kg. This contrasts with
1.5 mg/kg administered by Topol et al. (1989) and the fixed
dose of 150 mg used in the TIMI II study (1989) or 100 mg
used in the Australian National Heart Foundation Study
(1988), recommended by the manufacturers (Actilyse data
Sheet, 1989), and now in regular use. Despite the lower
dose used, the patency rate of 87% at 90 minutes compares
favourably with the published data.
Pharmacokinetic analysis of the plasma t-PA concentration-
time profile following this bolus administration regimen of
alteplase shows that very high, short-lived concentrations
of t-PA are achieved shortly after injection of the drug.
The concentration of t-PA achieved at 10 minutes of 4435.8
± 2117.8 ng/ml is 34% higher than the peak concentration
attained by Seifried et al., (1989) with 100mg of single
chain rt-PA delivered as a 1Omg bolus and 90 minute
decremental infusion. We measured t-PA concentrations in
excess of 2,300 ng/ml in all the patients, and predicted
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concentrations at two minutes following the boluses of
alteplase in excess of 10,000 ng/ml. As would be expected,
the time period when t-PA concentration is in excess of
1000 ng/ml is shorter with bolus administration than with
prolonged infusion.
Despite the short duration of high plasma t-PA
concentrations, the reocclusion rate to 24 hours of 3 of 29
patients (10%) is comparable to previous experience
(Verstraete et al., 1987).
The pretreatment t-PA concentrations were elevated, but 4-8
hours following alteplase, levels fell to physiological
values. After 4 hours in all patients, t-PA levels were
low and variable, making fitting to pharmacokinetic models
difficult. To eradicate this variable, the data were
fitted for the first 4 hours only, using baseline-
subtracted values. Despite the frequent blood samples,
multiple phases of elimination could not be defined, unlike
in previous papers. The data fitted the chosen model
satisfactorily, as reflected in the low standard deviations
of each individually fitted parameter. These individual
standard deviations have been expressed as coefficients of
variation (CV) of their respective estimated parameter and
the CV's expressed as the mean. Thus the mean CV of the
estimate of mean clearance was 14% and that of the estimate
of mean volume of distribution 36%, indicative of a
reliable estimate of the mean parameters. Previous studies
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have not published details of the quality of fit of their
models, and therefore it is difficult to know the degree of
reliance that can be placed on their estimations (Tanswell
et al., 1989, Seifried et al., 1989).
The findings in this study confirm the rapid clearance of
t-PA from the circulation with half-life of 5.9 ± 1.7
minutes, and modest inter-patient variability, closely
correlating with previous reports in patients, although
somewhat slower than findings in normal volunteers with a
lower total dose, possibly reflecting diminished cardiac
output and hepatic blood flow in these patients with
myocardial infarction. The estimate of volume of
distribution of 3.1 ± 1.9 1 is very similar to previous
estimates in both patients and volunteers.
Some workers have found a dose-related rise in bleeding
complications, in particular intracranial bleeding (TIMI-2,
1989). In this study, using a relatively small dose of
alteplase, bleeding complications were observed in 8 of 33
(24%), with 5 of these being related to arterial access for
coronary angiography, leaving 3 minor gastrointestinal
bleeding episodes (9%). No patients required transfusion
or specific intervention. These results are similar to
previously published data (TIMI-1, 1984, Collen et al.,
1984, Verstraete et al., 1985), but the small numbers in
this study do not allow firm conclusions to be drawn.
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The data in this chapter show that alteplase administered
as two intravenous boluses of 35 mg, 30 minutes apart,
reliably produces very high concentrations of t-PA in the
plasma, which is rapidly cleared from the circulation, and
allows a high coronary patency rate in acute myocardial
infarction. The total dose administered was less than that
used in many studies reporting high patency, yet
reocclusion rates were similar to those reported
previously. The greater simplicity of administration and
higher efficacy of this regimen may allow alteplase therapy
to be safely initiated earlier in the course of acute




LOW DOSE BOLUS ALTEPLASE IN ACUTE MYOCARDIAL INFARCTION.
209
INTRODUCTION
Previous studies have demonstrated that high doses of rt-
PA, while associated with higher coronary patency than low
dose regimens, are also associated with higher complication
rates, in particular of intracranial haemorrhage (TIMI II,
1989). In addition, the high cost of some of the available
thrombolytic agents makes the expense of therapy a
significant consideration in the selection of the agent and
dose used. Thus any administration regimen of thrombolytic
agents is a compromise between efficacy, safety and cost.
Following the demonstration of the very high coronary
patency achieved by a bolus dose regimen of two 35mg
alteplase separated by 30 minutes, it was logical to assess
the efficacy of a slightly smaller dose of alteplase to
discern if this regimen would be associated with similar
high efficacy, using less drug, possibly with further
advantages with regard to safety, and less expense. The
efficacy of three intravenous 20mg boluses of alteplase in
achieving coronary patency was assessed in this study.
PATIENTS AND METHODS
Twenty-one consecutive patients (13 male, 8 female, age
range 40-72, mean 59 years) were recruited, using the same
entry criteria as discussed in the previous chapter. The
study protocol is included in Appendix III.
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Following written, informed consent and discussion with
accompanying relatives, the patients received 20 mg
alteplase by the intravenous route over 30 seconds. This
was repeated 20 and 40 minutes later. As in the previous
study, all patients received 150 mg aspirin orally on
admission and daily thereafter, and glyceryl trinitrate
0.25 mg/hour by continuous intravenous infusion.
The details of the methods and timing of coronary
angiography were exactly as described in the previous
chapter. All angiograms were successfully performed within
90 minutes of the start of therapy. The degree of
perfusion was scored according to the TIMI grading
(Chesebro et al., 1987, Appendix II).
If the infarct related artery was occluded at 90 minutes
following therapy, "rescue" dosing of a further 40 mg was
administered by the intracoronary route, to a total dose of
100mg. This allowed clarification that patency of the
infarct related arteries was achievable even if not
reperfused by initial therapy. To attempt to reopen
arteries which had suffered early reocclusion, which was
frequent in the early part of the study, it was decided
that all patients should receive a further 40 mg following
the 90 minute angiogram, by the intracoronary route over 20
minutes if the artery was occluded, or by the intravenous
route over 60 minutes if the artery was patent at 90
minutes. Details of therapy administered are included in
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Table 12. Overall, 13 of 21 patients received further
alteplase after 90 minutes. Intravenous heparin infusion
was commenced in all patients 3-4 hours after the start of
therapy, and the infusion rate adjusted to maintain a
thrombin time ratio of 2-3 to one. The heparin was
discontinued for a short period prior to the second
angiogram to allow removal of the femoral sheath.
In all patients blood was drawn from an in-dwelling venous
catheter prior to treatment, then 10,20,30,40,50,60,90
minutes, 2,4,6,9,12 and 24 hours after administration of
the first bolus of alteplase and plasma t-PA concentration
measured using the same preparation and assay techniques as
in the previous chapter (MacGregor et al., 1987).
RESULTS
The characteristics of the patients recruited are
summarised in Table 13 and detailed in Appendix I. 13 of
the 21 patients recruited were male. The mean age of the
population was 59.0 ± 10.2 years, ranging from 40-75 years.
The mean time from onset of chest pain to initiation of
therapy was 177 ± 90 minutes.
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TABLE 12




injection First 60 90 24
NAME IRA Rx (mins) injection mins mins hoi
DC RCA A 41 0 0 2 2
WG LAD A 52 2 2 2 2
JS RCA A 46 0 2 2 3
MH RCA A 53 2 2 2 3
WG LAD A 60 3 3 3 3
CS RCA A 60 2 2 3 3
JT LAD A 50 3 3 3 3
WM RCA A 55 2 2 2 0
MMF RCA B 60 2 2 0 0
AF LAD B 25 0 2 0 2
VC LAD B 43 0 1 0 3
TG LAD B 50 3 3 0 3
MM RCA B 50 2 2 2 3
JOD LAD B 60 0 0 0 2
JJ RCA B 49 0 2 1 0
JMK LAD B 47 2 3 1 2
MB RCA B 55 1 2 0 3
JJ' RCA C 60 3 3 3 ND
RG C ND
WMK RCA D 41 0 0 0 0
AH RCA E 60 2 2 2 3
Treatment Code (Rx)
CODE TREATMENT
A 20mg x 3 intravenous
B 20mg x 3 intravenous +40mg intracoronary at 90mins
C 20mg x 3 intravenous +40mg intravenous at 90mins
D 20mg x 3 intravenous +20mg intracoronary at 90mins
E 20mg x 3 intravenous +40mg intravenous at 120mins
IRA = infarct related artery
ND = not done
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TABLE 13
DETAILS OF STUDY PATIENT POPULATION









Mean time to therapy (SD)










177 ± 90 mins
51 ± 9 mins
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angiographic patency
Coronary angiography was commenced at 30 minutes after the
first bolus of alteplase. In 20 of 21 patients, the
infarct-related artery was injected within 60 minutes of
the administration of the first bolus, at a mean time of
51±9 minutes. One patient in whom the right coronary
artery was not injected, was excluded from analysis.
At the first injection of the coronary artery (51 minutes
after onset of therapy), 12 of 20 coronary arteries were
patent (60%, 95% confidence interval 37 to 83%). This
patency rate increased to 16 of 20 arteries (80%, 95%
confidence interval 61 to 97%) at 60 minutes, but then fell
to 11 of 20 (55%, 95% confidence interval 32 to 78%, Table
14) at 90 minutes. In the time interval between the first
coronary injection and the 90 minute injection, 7 arteries
decreased their TIMI score by at least one grade, and 6 of
these reoccluded. Thus the reocclusion rate to 90 minutes
was 6 of 20 arteries (30%, 95% confidence limit 9 to 51%).
Twelve of the 20 patients undergoing coronary angiography
received further doses of alteplase, 11 of these receiving
a further 40 mg, to a total dose of 100mg, as currently
recommended (Actilyse Data Sheet, 1989). Nineteen of the
twenty patients had a patent coronary artery at the end of
the procedure, and these arteries must therefore be















INJECTION 60 90 24
(51 ± 9 MNS) MNS MNS HOURS
7 3 7 4
1 1 2 0
8 11 7 5
4 5 4 10
12 of 16 of 11 of 15 of
20(60%) 20(80%) 20(55%) 19(79%
37-83% 61-97% 32-78% 59-98%
At repeat angiography at 24 hours, the coronary patency
rate was 15 of 19 arteries (79%, 95% confidence limit 59 to
98%). One further patient did not undergo repeat
angiography because of haematoma formation in relation to
the femoral arterial sheath. Following rescue therapy, 4
of 19 arteries reoccluded before the 24 hour angiogram
(21%, CL 2-40%), while one patient reperfused late.
t-PA CONCENTRATIONS
The pretreatment t-PA concentrations in the study
population were elevated (12.2±4.3 ng/ml) compared to the
normal range (3.6 ± 1.3 ng/ml) as reported previously
(Booth et al., 1990). Ten minutes following each of the
three intravenous boluses of 20 mg alteplase, the mean
plasma t-PA concentration rose to 1849-2138 ng/ml, falling
to 523-731 ng/ml prior to the next bolus (Figure 35).
Following the 90 minute sample, different dosing schedules
were used on clinical judgment (Table 12).
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Figure 35. MEAN PLASMA t-PA CONCENTRATIONS FOLLOWING THREE!
INTRAVENOUS BOLUSES OF 20 MG ALTEPLASE EACH
SEPARATED BY 20 MINUTES
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adverse everts
Four patients developed bleeding complications. Three of
these were groin haematomata related to femoral artery
puncture. One of these events occurred 36 hours after
thrombolytic therapy, when the patient was excessively
anticoagulated with heparin. One patient bled from an
antecubital fossa venous cut-down site for insertion of
Swan-Ganz catheter for haemodynamic monitoring. In none of
the patients were specific measures or blood transfusion
required, and none developed long term sequelae. No
patients developed "spontaneous" bleeding in this series.
Of the first six patients given additional intracoronary
alteplase after the 90 minute angiogram, at a rate of 40mg
in 40 mis volume over approximately 8-10 minutes, three of
these experienced ventricular fibrillation necessitating DC
cardioversion, which was successful in all cases. The rate
of subsequent intracoronary infusion of alteplase was
reduced to 40 mg over 20 minutes.
DISCUSSION
This study demonstrates that three 20mg boluses of alteplase
over 60 minutes although effective at restoring coronary
patency in 80% of arteries, is associated with a high
reocclusion rate. Although the confidence limits are wide
reflecting the relatively small study sample, this would
suggest that this administration regimen is unsuitable for
clinical use. However, further dosing with intracoronary
alteplase to a total dose of 100mg, is able to restore
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patency. The treatment regimen after the 90 minute
angiogram varied between the patients according to clinical
requirements, and it is therefore difficult to draw any
conclusions.
High t-PA concentrations were achieved, but with the known
short half-life of t-PA in the circulation, the high
concentrations are predictably short-lived. The
concentrations measured ten minutes following each bolus
were 1849-2138 ng/ml, which is comparable to the steady-
state concentration of approximately 2210 ng/ml found during
the first infusion phase of 50 mg over 1 hour in the
recommended decremental infusion regimen (Seifried et al.,
1989). It can be concluded therefore that although the peak
plasma levels achieved are high enough to achieve initial
reperfusion, a longer duration of effect is required to
allow more complete lysis of thrombus and prevention of
reocclusion.
There is evidence that coronary patency following rt-PA is
related to the weight-adjusted dose received (Smalling et
al., 1990, von Essen et al., 1991, Topol et al., 1987). The
mean (SD) initial dose of alteplase received in this study
was 0.842 (0.144) mg/kg, which is less than that used in the
studies quoted. In this study, the patients received
different doses of alteplase after 90 minutes, and it is
valid only to compare the t-PA concentrations and
pharmacokinetics up to this point. Within these
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limitations, and in the small numbers available, there was
no significant relationship between AUCgQ or peak t-PA
concentration and coronary patency at the time points up to
90 minutes.
Previous studies with t-PA have shown various reocclusion
rates, although few have assessed reocclusion at such an
early time point. Early studies with t-PA on relatively
small study populations found reocclusion rates of 20% and
45%, (Williams et al., 1986, Gold et al., 1986) the former
using a three hour infusion of 80 mg of duteplase and
repeating coronary angiography at an interval of 1-16 days,
and the latter 0.4-0.75 mg/kg of rt-PA over 60-120 minutes,
with reocclusion occurring despite heparin, in those with
high grade residual stenoses, when the plasma concentration
of t-PA fell below 700 ng/ml. Verstraete et al., (1987)
gave 40 mg duteplase over 90 minutes, in a study
specifically designed to examine reocclusion rates.
Following initial angiography at 75-90 minutes, their
patients were randomised to receive either a further 30mg of
rt-PA or placebo over 6 hours, repeating angiography at 6-24
hours, and again prior to discharge. They found that
reocclusion up to 6-24 hours was similar in both groups,
namely 5 and 6%. The reocclusion rate at 1-4 weeks was 12%,
showing no benefit of continued rt-PA infusion. A similar
study using alteplase concluded that a continuing infusion
of rt-PA over 4 hours prevented coronary reocclusion (Johns
et al., 1988).
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In this study, no initial bolus of heparin was given, but it
was introduced by continuous intravenous infusion 2-3 hours
after initial presentation, the rate of which was adjusted
to maintain a strict state of anti-coagulation.
There has been much recent correspondence concerning the
role of heparin as adjunctive therapy to rt-PA (White,
1990). Experimental studies have suggested the need for
early administration of heparin at the time of initiation of
thrombolytic therapy with rt-PA (Cercek et al., 1986). This
finding is partially corroborated by clinical evidence, in
that studies using a bolus dose of heparin coincident with
the introduction of thrombolytic therapy were associated
with a more favourable outcome (Chesebro et al., 1987, and
TIMI II, 1989). However, bolus administration of heparin at
the time of thrombolytic therapy did not improve coronary
patency at 90 minutes with 1.5 mg/kg rt-PA infused over 3
hours, nor diminish reocclusion over the period of
observation (Topol et al., 1989). Analysis of the role of
heparin after the institution of thrombolytic therapy in the
same study protocol as that used in GISSI-2 (International
Study Group, 1990) did not reveal any benefit of introducing
subcutaneous heparin 12 hours after thrombolytic treatment.
Some studies however have implied that early heparin may
have a role in maintaining coronary patency. Ross et al.,
(1990) showed more beneficial effects of early heparin
compared to a low dose of aspirin, with improved patency 18
hours after treatment with 100mg rt-PA, (82% vs 52%), and
similarly, Bleich et al. (1989) showed a 71% patency at a
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mean of 55-59 hours with heparin in addition to 1OOmg of rt-
PA over 3 hours, as opposed to 44% without. The recently
reported European Cooperative Study Group study (de Bono et
al., 1992) suggested that early heparin had a beneficial
role in the maintenance of patency measured at 48-120 hours
after therapy with 100 mg alteplase by infusion, with the
relative risk of an occluded vessel with heparin being 0.66
(95% confidence limits 0.47 to 0.93).
Rapold et al., (1989) have demonstrated that heparin can
prevent the rise in Fibrinopeptide A after thrombolytic
therapy, reflecting the suppression of on-going thrombotic
activity. The role of thrombin in this phenomenon may be
central, at least in part mediated by thrombin activation of
platelets, which is prevented by heparin (Greenbaum et al.,
1982) but not by aspirin (Chesebro et al., 1990).
Nevertheless, heparin administration does not appear to be
absolutely essential for the maintenance of coronary patency
following rt-PA in myocardial infarction. In the study
reported in Chapter 7, two 35mg boluses of alteplase
achieved a 90 minute coronary patency of 87%, with a
reocclusion rate of 10% when coronary angiograms were
repeated at 24 hours, when heparin was used in an identical
fashion as in the present study.
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It may be that less complete restoration of coronary patency
with greater amounts of residual intraluminal thrombus after
thrombolytic therapy, may predispose to propagation of
thrombus and hence reocclusion. This suggestion is
supported by previous studies which have suggested that the
more severe the residual lesion, the greater the likelihood
of reocclusion (Grines et al., 1988, Harrison et al., 1984,
Gold et al., 1986, Williams et al., 1986). It is of note
that in the patients in this study, 8 of the 12 patent
arteries at first angiographic visualisation, 11 of 16 at 60
minutes, and 7 of 11 at 90 minutes, were TIMI grade 2. Thus
a larger proportion of arteries had a less complete degree
of reperfusion, probably indicating more residual
intraluminal thrombus, acting as a persistent stimulus to
thrombus formation and platelet activation leading to
reocclusion.
Heparin administration in patients receiving thrombolytic
therapy is associated with excess minor bleeding (GISSI-2,
1990), but so also are higher doses of t-PA (TIMI-2, 1989).
Thus it would appear that the benefits of maintaining an
anti-coagulated state following thrombolytic therapy of
myocardial infarction, must be balanced against the risk of
haemorrhagic complications. In this study, bleeding
complications were relatively few, albeit in a small study
group, and as has been found previously (Simoons et al.,
1988), were largely related to invasive procedures. Of the
four events in the series, at least one of them can be
confidently attributed to over-anticoagulation with heparin,
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emphasising the importance of close monitoring of
anticoagulant therapy. None of the bleeding events were
serious nor required specific intervention. Overall, this
bleeding rate has to be contrasted with the high transfusion
rates found in some thrombolytic studies (Simoons et al.,
1985), although clearly firm conclusions cannot be drawn
from such a small study.
Although the coronary patency rate at 90 minutes following
therapy is disappointing, patency was effectively restored
in 95% of patients at the end of the procedure, following
administration of a further 40mg intracoronary alteplase,
without local interventional procedures, confirming the
efficacy of alteplase given by this route. The high
incidence of ventricular fibrillation in the first patients
receiving intracoronary alteplase, is most likely
attributable to the physical properties of the agent and
medium, and was not observed when a slower infusion rate was
used.
Although three intravenous doses of 20mg of alteplase
achieves plasma t-PA concentrations at least as high as
conventional infusion doses, and achieves high initial
coronary patency, the high concentrations are short-lived
and there is an unacceptably high early reocclusion rate.
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Further "rescue" doses of 40mg by the intracoronary route
restores patency, and following this and in the presence of
heparin, the reocclusion rate to 24 hours was low. In view
of the high early patency, it may be appropriate to re¬
evaluate this regimen in conjunction with heparin initiated





"The termination of angina pectoris is remarkable. For if
no accident intervene, but the disease go on to its height,
the patients all suddenly fall down and perish almost
immediately"
- Heberden (1710-1801)
"Fashions in therapy may have some justification; fashions
in diagnosis have none."
- Herrick and Tyson
"Some griefs are med'cinable."
- William Shakespeare, Cymbeline
The introduction of thrombolytic therapy in the treatment of
acute myocardial infarction is probably the single most
important development in the management of ischaemic heart
disease in recent times. Although initial assessment
suggested that the benefits of therapy were small, and its
application limited by the practicability of intracoronary
administration, studies comparing intravenous and
intracoronary streptokinase, and then large scale studies
assessing intravenous administration proved beyond doubt
that thrombolysis in acute myocardial infarction could be
widely applied and give considerable clinical benefits.
Although the principle of thrombolytic therapy in acute
myocardial infarction is established, there remain many
questions to be answered. These include which is the safest
and most effective agent; when can dosing with
streptokinase-containing thrombolytic agents be safely and
reliably repeated; do different thrombolytic agents have
specific indications and roles; and what is the optimal dose
and administration regimen of the thrombolytic agents. The
work in this thesis addresses these questions.
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Streptokinase is the thrombolytic agent which has been
available the longest time. The current standard
recommended dose of streptokinase in acute myocardial
infarction is 1.5 MIU as a continuous intravenous infusion
over 60 minutes. This dosage regimen is empirical, and
although this dose has been shown to achieve a lytic state
in a large proportion of a normal population (Verstraete et
al., 1966) there have been no studies adequately assessing
the dose-response relationship of intravenous streptokinase.
In practice, the rate of infusion of streptokinase is
limited by haemodynamic responses, in particular systemic
hypotension, yet details of the relationship between dose
and blood pressure and the mechanism of these changes have
never been fully investigated.
Time to treatment: Pharmacokinetic considerations and early
treatment
As has been discussed above, the benefits of thrombolytic
therapy for acute myocardial infarction are greater if the
agent can be given earlier in the course of the infarct.
Therefore attempts must be made to facilitate early
referral, assessment and treatment of suitable patients.
If the priority of treatment with a thrombolytic agent is to
restore coronary patency, then the ideal thrombolytic agent
would be easily administered, preferably as an intravenous
bolus, without significant adverse effects. The ideal agent
should rapidly achieve a high plasma concentration, and a
high fibrinolytic activity, thereby maximising the
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concentration gradient at the thrombus interface, and
initiating early clot lysis. It would be desirable for the
fibrinolytic effect to persist for a period of time to
minimise early coronary reocclusion.
In chapter three, the pharmacokinetic properties of the two
streptokinase-containing thrombolytic agents, streptokinase
and anistreplase, have been compared. The higher and
earlier peak plasma concentrations achieved (large Cmax and
short tmax), and the longer half-life available with a bolus
of 30 U of anistreplase, have been demonstrated, compared to
a 60 minute continuous intravenous of 1.5 MIU of
streptokinase. Therefore, in this context, anistreplase has
pharmacokinetic advantages over streptokinase, at least when
both agents are administered in their recommended standard
dosage regimen.
Limitations of the streptokinase-containing thrombolytic
agents: the role of acquired resistance and haemodynamic
responses
Both streptokinase and anistreplase contain streptokinase
which is derived from streptococcal protein. This exogenous
protein both stimulates an immune response and reacts with
circulating antibodies. However, understanding of the
relevance of antibodies and acquired resistance to these
agents is limited. Previous studies have testified to the
loss of efficacy of streptokinase when administered to
patients with high levels of circulating resistance (Hirsh
et al., 1970, James, 1973), following antecedent
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streptococcal infections, but these reports have been based
on few patients with unusually high levels of resistance,
and the relevance of lower levels of resistance has not been
fully explored.
In chapter four, the relationships between both the
streptokinase resistance titre and anti-SK IgG
concentrations, and efficacy, assessed as angiographic
coronary patency at 90 minutes and 24 hours after therapy
with streptokinase and anistreplase, have been studied. The
results must be interpreted in the context of the study
population which had not been previously exposed to
streptokinase, and therefore had generally low circulating
resistance to streptokinase. While these factors did not
grossly affect the ability of either of the thrombolytic
agents to restore coronary patency, there were consistent
trends for those patients with high levels of resistance to
have a poorer result. When the results from the two agents
were considered together, there was a significant difference
in the streptokinase resistance titres between those
patients with patent and occluded arteries, implying a small
but possibly important role for streptokinase resistance
titre in modifying the efficacy of the streptokinase-
containing thrombolytic agents.
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Hypotension following the administration of the
streptokinase-containing thrombolytic agents is also a
limitation to their use in acute myocardial infarction, in a
population who may be susceptible to hypotension. In the
fifth chapter, blood pressure changes following
streptokinase and anistreplase have been documented in
detail. Although there are significant falls in blood
pressure, these falls are short-lived and well-tolerated in
the great majority of patients.
The mechanisms of these blood pressure changes have not been
elucidated. In this study an association was sought between
hypotensive episodes and the markers of prior exposure to
streptococcal antigen, the streptokinase resistance titre
and anti-SK IgG concentrations; and also the release curves
of D-dimer, B-B 15-42, and the fall in fibrinogen, as
markers of thrombin activity; and corrected plasma
viscosity. No relationship between any of these parameters
was confirmed, refuting their implication in the hypotensive
mechanism. Further research is reguired to establish this
mechanism.
With the widespread use of streptokinase in the treatment of
acute myocardial infarction, the question of the safe time
interval for the readministration of the streptokinase-
containing thrombolytic agents is going to be of increasing
importance. The amplitude and duration of the antibody
response following therapy is of central importance in this
regard, and an area of particular current interest. The
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data in this thesis show that median streptokinase
resistance titre rises to a peak of a 40-fold rise at 14
days after therapy, with only 58% of the population
returning to within two standard deviations of the
pretreatment population within two years, and suggest that
the further decline in the titres after this time is very
slow. Calculations based on these data indicate that all of
the standard dose of streptokinase would be neutralised at
12 months, and approximately 50% at 30 months. Similar
results are presented for median anti-SK IgG concentration,
which reaches a peak of a 150-fold at 14 days, with 39% of
the population returning within two standard deviations at
one year, and 50% at two years, at which point the median
anti-SK IgG concentration was still nine-fold the
pretreatment concentration.
Attempts to translate these concentration data and
resistance titres to functional clot lysis were made using
an in vitro clot lysis assay. Unfortunately, the necessity
of using pooled plasma samples for this assay led to an
unavoidable biasing of the pools towards the relatively few
high antibody/resistance values. Although care must be
taken in the interpretation of these studies and
extrapolating to the in vivo situation, it would appear that
there was near complete inhibition of lysis over the time
period from 7 days to 9 months following thrombolytic
treatment. Even at 12 months, only 25% of the baseline
lytic activity was seen, increasing to 75% at 30 months. In
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order to compensate for the bias mentioned above, the data
have been examined using regression analysis techniques
relating the streptokinase resistance titre and anti-SK IgG
concentration to in vitro lytic activity, and the results
used to construct a model of inhibition of in vitro lysis
with time following thrombolytic therapy based on the median
values of the population. Using this technique, it still
appears that in vitro lysis remains less than 50% of
baseline at 12 months, thereafter recovering partially.
The question of retreatment with streptokinase-containing
thrombolytic agents depends on two pivotal questions.
Firstly, will the induced immunological responses block the
effect of the thrombolytic agent administered for the second
time, and secondly will they influence the side effect
profile, adversely affecting the risk:benefit ratio of these
agents?
The data in this thesis relating to the former question are
limited. Firstly there are the difficulties I have
discussed in relation to the interpretation of the in vitro
clot lysis, and secondly, in the population studied in
Chapter Four, the pretreatment resistance is much lower than
the values recorded following thrombolytic therapy, as would
be expected in a previously unexposed population.
Nevertheless, a negative effect can be demonstrated even
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within this small distribution, and it must be considered
that it is very likely that acquired resistance will affect
the efficacy of standard doses of the streptokinase-
containing thrombolytic agents.
The blood pressure changes following administration of
streptokinase and anistreplase in acute myocardial
infarction are short-lived and well-tolerated. In the same
previously unexposed population, no relationship can be
found between the likelihood of the occurrence of
significant hypotension and the immunological markers,
streptokinase resistance titre and anti-SK IgG
concentration. Again it must be stressed that the
pretreatment levels of resistance are low and it is
difficult to extrapolate to the much higher levels found
post-treatment, but the data in this thesis suggest that the
hypotension observed is not obviously related to
immunological factors. However, there are documented
relatively rare anaphylactoid reactions, and it seems likely
that at least some of these are related to antibody levels.
Further clinical data is required relevant to this topic
before hard conclusions can be drawn.
If the incidence of side effects is truly not related to
acquired resistance to streptokinase, it may be possible to
overcome the diminished efficacy by developing a front-
loaded infusion regimen of streptokinase, such that the
rapid infusion phase would be designed to saturate
circulating resistance, possibly with the required dose
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calculated from the patients' pretreatment streptokinase
resistance titre, allowing the latter part of the infusion
to be effective. Similarly, a larger dose of anistreplase as
an intravenous injection may achieve the same end. However
the limiting factor to such an approach is likely to be
hypotension following the more rapid infusion of
streptokinase. This argument stresses the need for further
basic research to identify the mechanism of the blood
pressure changes with streptokinase-containing thrombolytic
agents, with the ultimate aim of developing pharmacological
approaches to modifying this reaction.
In the meantime, repeat administration of streptokinase
within a short time scale cannot be advised. It is
currently recommended that streptokinase should not be
readministered from 5 days to 6 months following prior
treatment (Kabikinase data sheet, 1991), or possibly as long
as 12 months (Streptase data sheet, 1991). The
manufacturers of anistreplase also recommend a dosage
interval of 5 days to 12 months (Eminase data sheet, 1991).
Jalihal and Morris monitored streptokinase resistance titres
for 36 weeks following streptokinase, and recommended that
streptokinase should not be readministered for 8 months, and
probably one year. The data in this thesis would suggest
that there is persistence of increased streptokinase
resistance titres and anti-SK IgG concentrations for
considerably longer than this, and if this represents a
contraindication to repeat therapy, then the recommended
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interval should be at least two years. Recent studies by
Elliott et al. (1991) have suggested that the antibody
concentrations plateau following this and there is little
further decline over a four year period.
In the light of present knowledge, it is recommended that if
repeat thrombolytic therapy is indicated within these time
points, that a non-allergenic drug such as rt-PA should be
used.
Rt-PA bolus dosing
There has been much research into the use and efficacy of
rt-PA, both alteplase and duteplase, although the
interpretation of these studies has been confused by
differences in dosage regimens, preparations of rt-PA,
methods of assessment and study populations. The currently
recommended dose of alteplase is 100mg administered
intravenously as a 1Omg bolus followed by 50 mg over 1 hour,
then 40mg over 2 hours. This regimen is relatively
cumbersome to use and obviously requires the availability of
equipment such as an infusion pump. The last chapters of
this thesis address the use of alteplase in acute myocardial
infarction administered as two different intravenous bolus
regimens, assessing efficacy by coronary patency assessed
angiographically, and studying the pharmacokinetics of these
regimens.
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The use of two 35mg boluses of alteplase 30 minutes apart
achieved extremely high plasma concentrations of t-PA of
4435.8 ± 2117.8 ng/ml within ten minutes of the first bolus
of alteplase, falling to 425.8 ± 288.3 ng/ml prior to the
second bolus, rising again to a peak of 4233.3 ± 2217.5
ng/ml within 10 minutes of the second bolus. The coronary
patency at 90 minutes associated with this regimen was also
very high, being 26 of 30 (87%, 95% confidence limits 74 to
99%) arteries, comparable to the best published results.
The coronary reocclusion rate to 24 hours was relatively
low, being 3 of 29 (10%, 95% confidence limits 0 to 22%)
arteries, even although heparin was not introduced until 2-3
hours after therapy. In the small numbers involved in this
pilot study, this regimen is most promising both in terms of
efficacy and convenience of administration, and therefore
ease and rapidity of use. This dose is worthy of further
evaluation in a larger scale study.
In view of the high patency achieved with the total dose of
70mg alteplase, the last study assessed the efficacy of a
total dose of 60mg, given as three intravenous boluses of
20mg each separated in time by 20 minutes. Although very
high plasma t-PA concentrations were again achieved, with
peaks of 1849-2138 ng/ml, the patency results were
disappointing. A high coronary patency of 16 of 20 arteries
(80%, 95% confidence interval 61 to 97%) was produced at 60
minutes, but early reocclusion caused the overall patency
rate to fall to 11 of 20 (55%, 95% confidence interval 32 to
78%) at 90 minutes. High coronary patency was however
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restored following "rescue" therapy, indicating that a high
proportion of the arteries were able to be reperfused.
Again this study was performed without heparin introduced at
the initiation of thrombolytic therapy, and it would be
interesting to repeat the study in the presence of heparin.
The current study provides a model for reocclusion in the
context of acute myocardial infarction, but the low 90
minute patency rate in the admittedly small numbers studied
must suggest that this regimen is unlikely to become widely
used in clinical practice.
Future developments
There is no doubt that thrombolytic therapy has
revolutionised the modern management of acute myocardial
infarction, and that it will continue to have a continued
important role in the future. All the available plasminogen
activators have been unequivocally demonstrated to restore
coronary patency, preserve left ventricular function, and
reduce mortality.
Although this class of drugs has arguably been more
extensively researched than any other innovation in modern
medicine, the development of these drugs remains incomplete.
Many of the recommended administration regimens for these
drugs have been formulated empirically, and may not be
optimal. Further assessment of the pharmacokinetic and
pharmacodynamic properties of these drugs will allow a more
logical and critical approach to administration regimens.
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To date, the standard approach to recommended drug doses is
to provide a dose suitable for all patients. It is likely
that this is an over-simplification, and it may be necessary
to develop pharmacokinetic models allowing the tailoring of
thrombolytic regimens to an individual patient, in order to
maximise efficacy, ease, and therefore speed, of
administration and minimise side effects.
One other major outstanding question with regard to the
current and future use of thrombolytic therapy is when is it
safe to repeat therapy with the streptokinase-containing
thrombolytic agents? To provide clues to this answer,
further basic mechanistic research is required into the
haemodynamic changes following streptokinase and
anistreplase, and the possible development of antagonists to
these pathways; and further pursuit of the immune responses
to streptokinase and their clinical relevance. It may be
possible to identify those patients prone to the development
of higher and more persistent resistance, and to develop a
rapid bedside test of streptokinase resistance allowing the
tailoring of thrombolytic therapy regimens to the individual
patient, in order to overcome circulating resistance.
The story of thrombolytic therapy in acute myocardial
infarction has been a long and fascinating one, dating from
the first administration of streptokinase in the 1950s to
the recent development of new and exciting agents. Despite
initial skepticism and discouraging results, it is now
accepted as a standard part of modern coronary care.
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There can be little doubt that in the short period of its
widespread use, thrombolytic therapy has beneficially
influenced the prognosis of the most important cause of
death in our era. Nevertheless, there remain limitations
its use, and further work in this fascinating area will
continue to refine this weapon, allowing more widespread,
safer application and greater clinical benefits.
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PATIENTS INCLUDED IN STREPTOKINASE/ANISTREPLASE COMPARISON
TIME TIMI GRADE AT
kTIENT SEX AGE IRA TO Rx 90MIN 24HR DRUG SKRT Ig<
JM M 68 RCA 156 1 1 1 _ "| 4
JMcG M 66 RCA 250 2 2 1 -1 1 .48
DC M 50 RCA 1 38 2 -1 1 -1 1 .8
JC M 51 LAD 270 2 2 1 -1 1 .27
NMcD F 57 RCA 222 1 2 2 -1 0.8
WN M 42 RCA 112 2 2 2 -1 1 . 46
JO'C M 42 RCA 313 1 2 2 -1 0.51
WS M 55 -1 105 -1 -1 1 -1 0.8
JH M 61 LAD 120 1 1 2 -1 1 .6
CMcN M 59 RCA 180 2 1 1 -1 0.3
TR M 67 RCA 210 1 2 1 -1 0.21
PW M 49 RCA 155 2 2 2 -1 -1
EMcN M 60 LAD 76 1 -1 1 -1 -1
IA F 64 LAD 210 1 1 2 -1 4.1
TMcQ M 64 LAD 240 2 2 2 -1 1 .06
WW M 55 RCA 260 2 2 2 -1 0.6
RM M 59 LAD 130 0 3 1 -1 5.3
BR M 49 LAD 200 2 2 2 -1 0.91
MH F 52 -1 260 -1 -1 2 -1 0.94
JF M 45 LAD 150 1 2 1 -1 1 .43
SA M 47 LAD 335 2 2 2 -1 0.83
TG M 45 RCA 185 1 2 1 -1 4.3
RMcC M 42 RCA 278 2 2 2 -1 0.93
PK M 44 RCA 71 2 2 1 -1 0.42
DU M 49 Cx 295 2 2 2 -1 0.3
JH M 45 RCA 155 2 2 1 -1 6.8
WC M 55 RCA 350 1 1 2 -1 2
RR M 55 RCA 315 2 2 2 -1 3.9
KA M 59 LAD 280 0 2 1 -1 1 .04
MK F 52 LAD 200 2 2 2 -1 0.2
GMcM F 58 RCA 160 1 -1 2 50 2.57
NG F 58 RCA 235 2 2 1 20 0.18
WT M 61 LAD 270 2 2 1 20 2.32
DD M 50 LAD 125 2 2 1 20 3.61
AB M 48 LAD 180 1 1 1 20 1 . 57
WMcL M 58 RCA 150 1 -1 2 50 0.54
AP M 68 RCA 330 2 2 1 20 0. 49
WM M 53 LAD 175 1 -1 2 20 0.4
CM M 55 RCA 165 1 3 2 100 3.2
EH F 68 RCA 195 1 -1 1 100 4.74
JC M 65 LAD 295 1 2 2 20 0.83
WD M 52 RCA 360 2 2 1 20 1 .84
JA F 52 RCA 375 1 1 1 100 1 .87
SB F 66 RCA 90 2 2 2 50 1 .6
FC M 44 LAD 235 2 2 2 50 0.76
JL M 70 LAD 270 2 2 2 50 0.78
GC M 47 LAD 195 1 2 1 50 4.34
RMcD M 67 RCA 105 2 2 1 50 1 .22
MH F 64 Cx 320 -1 2 2 20 0.4
RE M 60 RCA 1 35 -1 -1 2 50 1.16
PL M 58 LAD 180 0 1 2 100 2.13
JD M 43 RCA 190 3 3 1 50 1.17
262
JF M 68 LAD 340 0 -1 2 50 0.66
NMcL F 59 RCA 150 0 3 2 50 0.36
RD M 40 RCA 210 1 2 1 1 00 5.45
JH M 54 -1 1 40 -1 -1 1 20 0.55
PM M 59 LAD 80 1 2 1 20 1 .73
JG M 48 LAD 365 3 3 1 20 0.39
AF M 44 RCA 215 1 2 1 20 1 .86
SW F 65 Cx 305 0 3 1 20 0.98
AW F 68 LAD 357 1 2 1 50 0.07
MMcG M 53 RCA 165 -1 0 2 50 1 .7
AO 1 N F 58 Cx 1 65 3 3 2 20 2.59
EMcG M 57 RCA 300 0 2 1 50 0.44
JB M 67 LAD 275 3 3 2 20 1 .72
WL M 61 LAD 21 5 3 2 1 5 0.27
JS M 53 LAD 175 1 2 2 20 1 .9
JE M 40 LAD 185 0 2 2 50 4.54
JC M 31 Cx 260 2 2 2 20 2.35
AM M 56 -1 380 -1 -1 1 20 0.8
JM M 62 LAD 21 0 1 2 2 50 5.1
WMcC M 59 RCA 95 2 2 2 50 0.76
DC M 46 LAD 55 2 2 2 50 1.17
JS M 57 LAD 300 2 2 1 50 0.24
DMcC F 59 LAD 180 2 2 2 100 0.36
WMcL M 64 LAD 330 2 2 2 50 0.22
CA F 65 RCA 230 2 2 1 100 0.92
ED M 55 LAD 235 2 2 1 1 00 3.48
FH M 54 RCA 270 1 2 2 1 00 1 .46
WA M 47 RCA 245 2 2 1 1 00 1 .04
DP M 56 Cx 195 1 2 1 20 72
WMcI M 51 RCA 175 2 2 1 20 2.1
JO M 59 LAD 330 1 2 1 20 0.013
NMcN M 61 Cx 220 1 2 2 1 00 0.6
CG F 60 RCA 90 1 2 2 200 3.24
WS M 50 RCA 55 2 1 2 50 0.99
GH M 67 LAD 250 1 2 1 20 0.5
RN M 56 LAD 275 1 1 2 200 0.14
JB M 55 LAD 1 65 2 2 2 100 1.13
GT M 67 LAD 175 2 2 1 100 0.51
GR M 51 Cx 1 20 2 2 2 20 0.17
RS M 58 -1 135 -1 -1 2 -1 -1
JN M 64 RCA 1 55 2 2 1 20 0.23
WD M 54 RCA 85 1 1 1 20 1 .49
JH M 55 LAD 215 2 2 1 5 0.3
JA F 57 LAD 180 1 2 1 1 00 2.7
MD F 59 LAD 220 2 2 2 20 0. 56
NU M 42 LAD 1 40 1 1 1 100 1 . 04
RK M 41 LAD 185 -1 2 1 1 00 2.81
TM M 46 LAD 80 2 2 1 20 0.68
MM F 62 LAD 230 2 2 2 20 0.8
JL M 62 LAD 320 1 2 2 50 1 .03
EH M 45 RCA 170 2 2 2 1 00 1 .57
HH M 59 Cx 95 2 2 2 20 0.14
JW M 56 RCA 135 1 1 2 50 1.14
EC F 52 RCA 125 -1 0 2 400 12.6
TS M 54 LAD 135 2 2 1 20 1 .35
JMcG M 42 RCA 130 3 3 2 200 7.011
AB F 47 RCA 270 0 2 1 50 5.1
263
MT F 55 RCA 1 42 3 3 1 50 2.67
MS F 55 LAD 185 0 2 1 20 2.39
RH M 55 RCA 1 25 2 3 1 20 0.54
PM M 52 Cx 215 3 3 1 20 0.59
AR M 64 RCA 55 3 3 2 20 0.82
JJ F 70 -1 350 -1 -1 1 5 0.32
PR M 61 -1 210 -1 -1 2 20 0.46
DMcG M 43 Cx 1 40 0 0 2 100 2.88
JS M 61 Cx 210 0 0 2 20 0.79
PC M 51 LAD 1 60 1 2 2 20 0.56
TJ M 41 LAD 290 0 0 1 200 3.79
TM M 63 RCA 285 2 3 2 100 2.75
CM F 41 RCA 185 0 3 2 50 3.69
GMcD M 65 LAD 250 3 3 1 20 1 .07
CC F 66 RCA 165 2 2 2 100 4.13
DC M 65 LAD 170 2 3 1 5 0.63
RK M 69 LAD 90 3 3 1 1 00 5.98
HT M 67 LAD 1 50 1 2 1 20 0.05
RH M 57 LAD 1 70 3 3 2 20 0.78
LAD = Left anterior descending coronary artery
RCA = Right coronary artery
Cx = circumflex coronary artery
TimeRx = time from onset of pain to treatment
Drug code: 1 = Streptokinase
2 = Anistreplase
-1 = missing data
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PATIENTS INCLUDED IN ANISTREPLASE/STREPTOKINASE
PHARMACOKINETIC STUDY
PATIENT SEX AGE DRUG
JM M 68 Streptokinase
JMcG M 66 Streptokinase
DC M 50 Streptokinase
JC M 51 Streptokinase
NMcD F 57 Anistreplase
WN M 42 Anistreplase
JO'C M 42 Anistreplase
WS M 55 Streptokinase
JH M 61 Anistreplase
CMcN M 59 Streptokinase
TR M 67 Streptokinase
PW M 49 Anistreplase
EMcN M 60 Streptokinase
IA F 64 Anistreplase
TMcQ M 64 Anistreplase
WW M 55 Anistreplase
RM M 59 Streptokinase
BR M 49 Anistreplase
MH F 52 Anistreplase
JF M 45 Streptokinase
SA M 47 Anistreplase
TG M 45 Streptokinase
RMcC M 42 Anistreplase
PK M 44 Streptokinase
265
PATIENTS INCLUDED IN 2x35mg BOLUS ALTEPLASE STUDY
TIME ——TIMI GRADES AT
TO 1st 1st 45 60 90 24
PATIENT SEX AGE IRA Rx INJECTION MINUTES HR
CB F 68 RCA 220 55 0 -1 0 0 0
JMcI M 40 LAD 340 38 0 0 0 0 0
DS F 74 LAD 250 51 1 -1 2 2 2
EL F 69 RCA 255 41 2 2 2 2 3
KS M 52 LAD 1 70 46 2 -1 2 2 2
MG F 48 LAD 370 35 2 2 2 2 3
JD F 57 LAD 185 37 2 2 2 2 3
JL M 53 RCA 165 60 2 -1 2 2 2
RMcM M 66 LAD 232 47 2 -1 2 2 3
DG M 68 RCA 48 41 2 2 2 2 2
HMcB F 58 RCA 187 50 2 -1 2 2 2
JG M 40 LAD 180 41 2 2 2 2 2
AC M 70 LAD 330 53 2 -1 0 3 3
MS M 62 RCA 355 47 2 -1 2 2 3
GS M 55 RCA 260 35 2 2 2 2 2
JC M 72 LAD 1 35 42 2 2 2 2 2
AO 1 H M 45 Cx 1 40 45 3 2 2 2 3
IL M 52 LAD 143 63 3 -1 -1 3 2
AW M 40 LAD 238 44 3 3 3 3 3
RMcB M 43 RCA 75 40 3 3 3 3 3
TP M 59 Cx 180 90 3 -1 -1 2 3
RN M 30 RCA 95 47 1 -1 2 2 2
AB M 52 RCA 185 47 2 -1 2 2 3
DD M 69 LAD 240 36 2 2 2 2 1
RN M 47 RCA 200 51 0 -1 2 2 1
MMcL F 64 -1 270 -1 -1 -1 -1 -1 -1
JD M 68 RCA 240 50 3 -1 3 3 3
GB M 45 RCA 1 40 47 2 -1 2 2 1
JM M 62 LMCA 185 60 0 -1 0 1 3
AH M 51 -1 255 -1 -1 -1 -1 •1 -1
JD F 46 RCA 247 55 3 -1 3 3 3
IB F 59 RCA 213 45 0 0 1 1 3
BMcC F 43 RCA 165 90 3 -1 -1 3 3
IRA = infarct related artery
LAD = Left anterior descending coronary artery
RCA = Right coronary artery
Cx = circumflex coronary artery
-1 = missing data
266
PATIENTS INCLUDED IN 3x2Oag ALTEPLASE STUDY
TIME TIMI GRADES AT—
TO 1st 1st 60 90 24
PATIENT SEX AGE IRA Rx Rx INJECTION MINUTES HR
DC M 59 RCA A 1 35 41 0 0 2 2
WG M 52 LAD A 110 52 2 2 2 2
MMCF F 67 RCA B 280 60 2 2 0 0
WMK M 68 RCA D 85 41 0 0 0 0
JS M 69 RCA A 235 46 0 2 2 3
AF F 60 LAD B 195 25 0 2 0 2
VC M 52 LAD B 85 43 0 1 0 3
TG M 53 LAD B 60 50 3 3 0 3
MM F 53 RCA B 200 50 2 2 2 3
MH F 69 RCA A 275 53 2 2 2 3
RG M 40 -1 C 195 -1 -1 -1 -1 -1
WG M 52 LAD A 1 1 0 60 3 3 3 3
CS M 66 RCA A 1 1 5 60 2 2 2 3
JT M 71 LAD A 350 50 3 3 3 3
JOD M 41 LAD B 65 60 0 0 0 2
JJ F 51 RCA B 325 49 0 2 1 0
JMK M 42 LAD B 185 47 2 3 1 2
WM M 62 RCA A 1 20 55 2 2 2 0
MB M 59 RCA B 1 28 55 1 2 0 3
JJ' F 71 RCA C 340 60 3 3 3 -1
AH F 72 RCA E 1 50 60 2 2 2 2
Treatment Code (Rx)
CODE TREATMENT
A 20Dag x 3 intravenous
B 20mg x 3 intravenous +40mg intracoronary at 90ains
C 2Qmg x 3 intravenous +40®g intravenous at 90mins
D 20mg x 3 intravenous +20mg intracoronary at 90mins
E 20mg x 3 intravenous +40mg intravenous at 120mins
IRA = infarct related artery
LAD = Left anterior descending coronary artery
RCA = Right coronary artery
-1 = missing data
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APPENDIX II
DEFINITION OF TIMI SCORES
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DEFINITION OF TIM SCORES
(Williams et al. , 1986)
GRADE 0 NO REPERFUSION: There is no antegrade flow
beyond the point of occlusion.
GRADE 1 PENETRATION WITH MINIMAL PERFUSION: The
contrast material passes beyond the area of
obstruction, but "hangs up" and fails to opacify
the entire coronary bed distal to the
obstruction for duration of the cine run.
GRADE 2 PARTIAL PERFUSION: The contrast material passes
across the obstruction and opacifies the
coronary bed distal to the obstruction.
However, the rate of entry into the vessel
distal to the obstruction or its rate of
clearance from the distal bed (or both) are
perceptibly slower than its entry or clearance
from comparable areas not perfused by the
previously occluded vessel, e.g. the opposite
coronary artery or the coronary bed proximal to
the obstruction.
GRADE 3 COMPLETE PERFUSION: Antegrade flow into the bed
distal to the obstruction occurs as promptly as
antegrade flow into the bed proximal to the
obstruction, and clearance of contrast material
from the involved bed is as rapid as clearance






ANISTREPLASK IN THE TREATMENT
OF ACUTE MYOCARDIAL INFARCTION.
1 . STUDY OBJECTIVES
1.1. To measure and compare angiographically documented
coronary artery patency at 90 minutes following
intravenous APSAC 30 Units or intravenous
streptokinase 1.5 million units.
1.2. To compare reocclusion rates at 24 hours after
dosing.
1.3. To compare the safety of the different compounds
with special reference to effects on blood pressure
in the first 90 minutes after dosing.
1.4. To document the immunological changes following
administration of the streptokinase-containing
thrombolytic agents, measuring streptokinase
resistance titre and anti-SK IgG concentrations
prior to therapy and over the following 12 months.
1.5. To investigate the role of pretreatment
streptokinase resistance titre and anti-SK IgG
concentration in the efficacy of and haemodynamic
responses to the streptokinase-containing
thrombolytic agents.
271
1.6. To seek a relationship between markers of fibrin-
and fibrinogen-olysis, and plasma viscosity and
haemodynamic changes.




APSAC is the active site p-anisoylated derivative of
the primary (human) lys-plasminogen- streptokinase
complex prepared by immediate acylation of the
serine residue in the active centre of that complex
as it is formed. The molecular weight is close to
131,000 Daltons.
APSAC is formulated in a mixture of clinical grade
human albumin, D-mannitol and L-lysine. It is
presented in vials, each containing 30 Units APSAC
as a sterile, white lyophilized powder.
2.2. Storage
APSAC 30U vials have a shelf-life of 2 years when
stored at or below 5°C.
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2.3. Streptokinase
Streptokinase is presented as a freeze-dried powder
in vials containing 600,000 units of streptokinase.
Streptokinase is stable for at least 3 years when
stored at room temperature (<25°C). Solutions
prepared for infusion but left over or not used
should be discarded.
3 . STUDY DESIGN
A double blind, randomised, angiographically
controlled study of intravenous APSAC or intravenous
streptokinase in acute myocardial infarction with
stratification according to infarct site.
3.1. Number of patients
A minimum of 80 patients will complete the study.
3.2. Patient Entry
Patients with clinical evidence of acute myocardial
infarction who satisfy the inclusion/exclusion
criteria will be eligible for randomisation.
3.3. Stratification and Randomisation
Patients will be stratified according to the site of
infarction. Each stratum has been separately pre-
randomised to receive APSAC 30 Units intravenous or
streptokinase 1.5 million Units intravenous
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3.4. Coronary Angiography
Angiography will be performed at 90 minutes and at
24 hours after dosing.
3.5. Blood pressure and heart rate Monitoring
Blood pressure and heart rate will be monitored
immediately before drug and continuously throughout
the 90 minutes post-treatment period. Blood
pressure and heart rate will be recorded on the case
report forms every 2 minutes until the end of the 90
minute angiogram.
The blood pressure will be observed for at least 10
minutes prior to the start of thrombolytic therapy,
on a stable dose of intravenous nitrates (2 mg/hr of
isosorbide dinitrate), and the final recording taken
as the baseline recording. A hypotensive response
is arbitrarily defined as a fall in systolic blood
pressure of at least 20mmHg lasting for at least
three cycles of the automatic cuff (6 minutes), and
will be classified as early (within 30 minutes of
start of thrombolytic therapy), late (30 - 90
minutes) or both.
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3.6. Primary Data End Points
3.6.1. Angiographically documented patency
(occlusion/perfusion grade 2,3) or occlusion
(occlusion/perfusion grade 0.1) of the presumed
infarct related vessel at 90 minutes after dosing.
3.6.2. Angiographically documented reocclusion
(occlusion/perfusion grade 0,1) or sustained patency
(occlusion/perfusion grade 2,3) at 24 hours after
dosing in those who had patent infarct related
vessels at 90 minutes.
3.7. Blood sampling
3.7.1. Venous blood samples will be collected prior to
thrombolytic therapy then at 6, 10, 15, 30, 45, 60,
90 minutes, 2,4,6,9,12 hours, 1, 2, 3, 4, and 5 days
after thrombolytic therapy and subsequently assayed
for plasma fibrinogen, B-B 15-42 peptide, D-dimer
and plasma viscosity corrected for haematocrit.
3.7.2. Venous blood samples will be collected prior to
therapy and then 2 and 4 weeks, 3, 6, and 12 months
and the streptokinase resistance titre and anti-SK
IgG concentrations measured. In the first 40
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patients, samples will be taken daily for the first
14 days to document the early rise in antibody
titres.
3.7.3. In twenty-four (12 streptokinase, 12 APSAC) patients
an intensive blood sampling protocol will be
undertaken for pharmacokinetic studies. Venous
blood samples will be taken at 0, 6, 10, 20, 30, 45,
60, 75, 90 minutes, 2, 4, 6, 9, 12 and 24 hours and
frozen immediately for subsequent analysis of total
fibrinolytic activity.
4. PATIENTS AND METHODS
All patients with suspected acute myocardial
infarction who satisfy the inclusion/exclusion
criteria will be admitted.
5. INCLUSION CRITERIA
Patients admitted to hospital;
5.1. Aged 70 years or under.
5.2. With chest pain or other symptoms of acute
myocardial infarction of at least 30 minutes
duration who can be treated within 6 hours of
symptom onset.
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5.3. With ECG evidence of ST segment elevation of at
least 0.1mV in two or more standard leads and/or
0.2mV in two or more praecordial leads.
5.4. In whom appropriate consent is obtained for
participation in the study.
6. EXCLUSION CRITERIA
6.1. Patients with systolic blood pressure below 95 mmHg.
6.2. Patients on anticoagulant therapy.
6.3. Patients with a known history of haemorrhagic
diatheses or significant recent bleeding from
another site.
6.4. Patients with documented or suspected active peptic
ulceration with 1 year.
6.5. Patients with a history of cerebrovascular accident.
6.6. Patients who have had surgery, major trauma or head












Patients who have received streptokinase or APSAC
therapy within the previous 6 months.
Patients with severe hypertension, blood pressure
above 200/120 mmHg.
Patients who have received prolonged chest
compression prior to randomisation.
Pregnant females or those in whom pregnancy cannot
be ruled out. Females who are menstruating or who
are of child bearing potential.
Patients with diabetic proliferative retinopathy.
Patients in whom coronary angiography is contra-
indicated .
Patients who have had coronary angioplasty within 1
month of presentation or those with a history of
CABG or prosthetic valve insertion.
Any condition requiring immediate surgical
intervention.
Any clinical suspicion of dissecting aneurysm.
Transmural myocardial infarction within 3 months.
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6.17. Patients with serious or life-threatening disease
unrelated to the circulatory system.
7. STRATIFICATION AND RANDOMISATION
Patients will be stratified according to the site of
infarction on the admission ECG. Those with
anterior or lateral infarction will be assigned to
group A and inferior or posterior infarction to
group I. Each of the 2 groups (A and I) has a
separate randomisation sequence for 30 Units APSAC
or 1.5 million units of streptokinase. Consecutive
numbers starting from 1 will be used within each
group.
Two identification, self-adhesive labels will be
detached from study drug pack, one to be placed in
the record form and the other attached to a postcard
which should be posted within 12 hours of patient
entry. The label identifies the precise batch of
study drug.
The double blind nature of the study will be ensured
by a "double dummy" technique. Patients will
receive "placebo APSAC" and "active streptokinase"
or "active APSAC" and "placebo streptokinase".
8. TREATMENT
The treatment regimen will be as follows:
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The vial labelled APSAC will be dissolved in 5 mis
of water for injection or physiological saline to be
administered intravenously over 5 minutes. To
minimise foaming, the solution must be gently
swirled AND NOT SHAKEN.
Two and one half of the three ampoules marked
streptokinase will be dissolved in 500ml of 5%
Dextrose to be infused over 60 minutes.
Injection and infusion will begin at the same time.
Solutions must be administered immediately after
reconstitution.
9. CORONARY ANGIOGRAPHY
9.1. Coronary angiography will be via a brachial or
femoral artery approach. At least three views (LCA)
or two views (RCA) of the infarct related vessel
will be taken during each procedure. One of these
will be the optimal view for maximising the percent
residual stenosis.
9.2. An angiogram will be performed at 90 minutes from
the start of dosing. The catheter will then be
withdrawn, but the sheath will be left in place for
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up to 48 hours.
Perfusion is defined as a grade 2 or 3
(occlusion/perfusion grade) at 90 minutes. Patients
with grade 0-1 occlusion at 90 minutes will not
require further angiographic study and will be given
the benefit of the best available treatment at the
discretion of the attending physician. They will be
recorded as "persistent occlusions" for the purpose
of the analysis.
9.3. Only patients with patency (occlusion/perfusion
grade 2-3) at 90 minutes will be required to undergo
coronary angiography at 24 hours after dosing, but
patients with non-patent arteries at 90 minutes may
undergo further angiography at the discretion of the
physician in charge.
10. BLOOD PRESSURE MONITORING
Arterial pressure and heart rate will be recorded
immediately before and continuously for 90 minutes
after dosing. Copies of all tracings will be
reported in the relevant section of the case record
form prior to their being placed in the inside
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cover.
1 1 . HEPARIN ADMINISTRATION
Based on the result of the 90 minute post treatment
angiogram, patients with Grade 0-1 occlusion may be
given heparin and/or other therapy at the discretion
of the attending physician. Patients with Grade 2-3
perfusion should receive heparin in a dose of 1 000-
1500 units per hour from between 4 and 6 hours after
APSAC therapy or when the thrombin time has
decreased to less than twice the control value.
Heparin treatment will be continued for 24 hours and
further anticoagulation is at the physicians
discretion.
1 2. ECG RECORDINGS
All patients will have single lead continuous ECG
rhythm recordings for the first 24 hours of the
study. Rhythm disturbances will be reported in the
appropriate section of the case report form.
Five 12 lead ECG's are required, these include one
on admission, at 2, 4, 16, 18 and 24 hours. If the
patients clinical condition changes substantially










Any symptoms thought to be associated with the
procedure, the treatment or the disease will be
noted.
Heart rate and blood pressure will be measured
before dosing and continually for the first 90
minutes after dosing. There will be further non¬
invasive measurements at 6, 12 and 24 hours after
dosing or more frequently if indicated by a change
in the patient's condition.
Temperature will be monitored at 6, 12 and 24 hours
after dosing. Measurements will be taken more
frequently if indicated by changes in the patient's
condition.
LABORATORY OBSERVATIONS
Blood samples will be drawn to determine Hepatitis B
status, cardiac enzyme concentrations, clinical
chemistry, haematology.
Hepatitis B status
A blood sample will be taken before dosing and
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tested for HBsAg.
14.2. Cardiac Enzymes Concentrations
Blood samples must be taken before dosing, at 90
minutes and 24 hours after dosing for the estimation
of CPK and routine cardiac enzymes.
14.3. Clinical Chemistry and Haematology
Blood samples will be taken before dosing, at 90
minutes and 24 hours after dosing for a routine
screen.
14.4. Urinalysis
A urine sample will be collected at 24 hours after
dosing for the estimation of pH, blood, ketones,
protein and bilirubin by means of "Dipstix".
15. PRECAUTIONS
15.1. Ancillary medications
No anti-platelet medication for 24 hours after
thrombolytic therapy.
Additional drugs, such as analgesics,
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antiarrhythmics etc., should be administered in
accordance with normal hospital practice. All
patients will receive a continuous infusion of
intravenous nitrates.
15.2. Dealing with excessive production of plasmin
For the treatment of severe uncontrolled bleeding,
it is suggested that the following steps be taken:
a) discontinue thrombolytic agent
b) application of local pressure where possible
c) reversal of the lytic state: Administer
TRANEXAMIC ACID in a standard dose of 500 mg
intravenously over 2 minutes (other agents may
be used). A further 500 mg tranexamic acid may
be administered if the bleeding is not
controlled after the replacement of clotting
factors.
d) replace clotting factors with cryoprecipitate,
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fresh frozen plasma, or whole blood,
e) replace blood loss.
16. STATISTICAL CONSIDERATION
The major efficacy variables in this protocol will
be patency at 90 minutes and reocclusion after
patency.
The main objectives of this study are the
measurements of patency and reocclusion after APSAC
and streptokinase and the effect of these agents on
blood pressure. Results will be compared using
relevant statistical procedures.
Information regarding adverse reactions and abnormal
laboratory tests will be presented in the form of
listings and tabulations.
1 7. DRUG ACCOUNTABILITY
17.1 On-site Storage and Distribution
All investigational drug supplies will be stored in
a refrigerator, maintained at 5°C at the study site.
Shelf life for APSAC is 2 years. Access to the
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study medication must be limited to the principal
investigator and other authorised members of his
staff.
During periodic monitoring by Beecham staff, the
drug supplies and case records will be reviewed for
accuracy and completeness.
18. INFORMED CONSENT AND PATIENT PRIVACY
It is the investigator's responsibility that each
subject or subject's legal representative signs an
informed consent statement prior to participation in
this study. Copies of the consent form with the
patient's initials will be retained by the
investigator.
The patients will be informed of their rights to
privacy but will be made aware that study data will
be submitted to Beecham and to drug regulatory
authorities for review and evaluation. They will
also be informed that both Beecham and the
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regulatory authorities have the right to inspect the
patient's medical records to verify the accuracy and
completeness of the study records and results.
19. REPORTING OF ADVERSE EVENTS
The date, time of onset, duration and severity of
any adverse reaction will be recorded. In the event
of a persistent severe adverse event, e.g.
hemiplegia resulting from CVA, the outcome should be
determined at intervals up to 1 year.
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A PILOT STUDY OF BOLUS TPA IN PATIENTS WITH ACUTE
MYOCARDIAL INFARCTION
INTRODUCTION
Thrombolytic therapy is now established as standard therapy
for the treatment of acute myocardial infarction. Tissue
plasminogen activator has been under clinical study since
the early 1980's and is now available for routine clinical
use. Until the present time, rt-PA has been used given as
a complicated decremental infusion regime. The rationale
behind this was that the half-life of the single chain
preparation of rt-PA (Actilyse) is about 5 minutes. Recent
clinical studies including observations by our own group
have indicated that the pharmacodynamic effects of rt-PA
exist for longer than the pharmacokinetic effects, i.e.
continued thrombolysis may occur up to 7 hours after
dosing. This has been suggested by animal studies, and has
recently been confirmed clinically. In animal studies,
Cercek (1987) and Eisert (1987) have suggested that bolus
t-PA increased the rate of lysis by a factor of two-fold or
more within the first 15 minutes after injection in a dose-
dependent manner. Clinical studies have also been
performed using bolus dosing of rt-PA in patients with
acute myocardial infarction (Eisert et al., 1988). Initial
bolus dosing has been used with 15-30 mg being given, with
follow on dosage schedules up to 100-150 mg. Initial
clinical experience with bolus dosing suggests that
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reperfusion is seen earlier, and that the minimal luminal
stenosis left after thrombolysis is lower in such groups.
The aim of the present study is to determine an efficacious
and safe bolus regimen of rt-PA to be administered in
patients admitted with acute myocardial infarction.
OBJECTIVES
1. To assess the effect of two boluses of rt-PA on the
patency of coronary vessels at 30, 60 and 90 minutes in
patients with acute myocardial infarction by invasive
and non invasive methods.
2. To assess the pharmacodynamic profile of rt-PA when
given as a bolus.
3. To assess the effects of bolus rt-PA on blood rheology.
STUDY DESIGN
This study has an open dose-ranging design to evaluate
bolus rt-PA. Initially 20 patients will be treated with
two boluses, the initial bolus being 35 mg rt-PA. This
would be repeated at 30 minutes, giving a total dose of 70
mg. Following the first 20 patient's treatment, the
results will be analysed, and a further 20 patients will be
treated at a further dosing level of 50 mg, repeated after
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30 minutes. This dose increment will be dependent on the
results obtained. The maximum total dose of rt-PA used in
this study will be 100 mg, as is the recommended dose
schedule at present used in clinical practice.
STUDY POPULATION
Inclusion Criteria
(i) Patients with acute myocardial infarction defined as:
a) Cardiac pain at rest lasting from thirty minutes
up to six hours.
b) ECG changes at presentation consistent with a
diagnosis of acute myocardial infarction.
Normally this will include ST segment elevation of
at least 2 mm in two praecordial leads or ST
segment elevation of 1 mm in two inferior leads.
However, patients with ECG diagnosis of posterior
myocardial infarction and right ventricular
myocardial infarction will also be included.
(ii) Males and females.
(iii) Age 18 to 75 inclusive.
(iv) Patients who have no contra-indications to
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angiography.
(v) Patients able to give informed consent to
participate.
(vi) Patients with no history or ECG changes of previous
myocardial infarction in same distribution.
(vii) Patients weighing over 67 kg.
Exclusion Criteria
(i) Patients with ECG abnormalities that make it
impossible to diagnose acute myocardial infarction.
This will include patients with left bundle branch
block and other severe conduction defect
abnormalities.
(ii) Patients with any contra-indications to thrombolytic
therapy:
Any bleeding diathesis
Major trauma or surgery within three months
Puncture of a non-compressible vessel within 10 days
Any major haemorrhage
Any patient on Warfarin or Coumarin anticoagulants
Any previous cerebrovascular accident including TIA
Any previous history of peptic ulceration
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Any proliferative retinopathy
Women who are pregnant, lactating or menstruating
History of severe poorly controlled hypertension
Any additional contraindication that is felt by the
clinician to be relevant at that time to bolus rt-PA
therapy.
METHODS
The patients will be assessed pre-study within the Coronary
Care Unit of Stobhill General Hospital. Thrombolytic
therapy has been administered as standard therapy since
1982, and this study will be conducted within the Unit
using standard monitoring facilities and general nursing
medical care as appropriate. Written informed consent will
be obtained from patients, both for administration of
thrombolytic therapy, and also permission for performance
of coronary arteriography. Where appropriate, and when
available, the protocol and procedure will be discussed
with any accompanying relatives.
The first bolus dose of rt-PA will be given as soon as
possible following diagnosis. In addition, all patients
will receive 150 mg of aspirin orally on admission.
Analgesia will be given as per standard practice, and at no
stage will any routine antiarrhythmic, inotropic nor
vasodilator therapy be witheld. A second bolus dose of rt-
PA will be given 30 minutes after the first bolus. At 3
hours following dosing, a bolus of heparin 5,000 units and
293
an infusion of 1,000 units per hour will then be commenced
with the rate of infusion being controlled using standard
coagulation screens. The second bolus of therapy will not
be administered if there are any new contra-indications such
as the occurrence of bleeding, cerebrovascular accident or
if any surgical intervention is required.
Coronary arteriography will be performed 30 minutes after
the infusion of rt-PA. An angiogram of the culprit vessel,
as judged by the admission ECG, will be performed, and a
second bolus dose will be administered thereafter. An
arterial sheath will be left in situ, and the coronary
arteriogram continued with further angiograms performed at
45, 60 and 90 minutes. The arterial sheath will be left in
situ, and coronary angiography will be repeated at 24
hours.
At all times the performance of coronary angiography will
be undertaken if the patient's clinical condition is
stable, and the investigation appropriate. Any form of
medical or intervention therapy can be performed at any
time at the discretion of the Consultant Cardiologist
managing the patient's overall condition.
Standard twelve lead ECGs will be performed at 0 time, time
2 hours, 4 hours, 8 hours, 12 hours and 24 hours following
dosing. Serial cardiac enzymes will be performed,
including CPK, AST, ALT and LDH at 4, 12 and 24 hours
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following admission to confirm diagnosis of acute
myocardial infarction. Routine haematology and biochemistry
will be performed as required for patient management, and a
coagulation status will be performed to allow
anticoagulation.
PHARMACOKINETIC ASSESSMENT
Serial blood samples will be taken to measure whole blood
viscosity and blood samples to determine measurements of
factions of thrombolysis and fibrinogenolysis, including
measurement of d-Dimer and b-Beta 15-42 fragments. In
addition to routine measurements of fibrinogen, plasminogen
and alpha2 anti-plasmin. Blood samples will be taken pre-
bolus and at 10, 20, 30 minutes post and at 10, 20, 30
minutes post second bolus, and at 2, 4, 8 and 24 hours.
The total volume of blood will be 175-230 mis.
Standard electrocardiographic monitoring with Holter
monitor will be performed for 24 hours, and this data will
be analysed by Reynolds Pathfinder to correlate ST segment
changes with the reperfusion data obtained from coronary
angiography.
All clinical events will be monitored and the patient's
follow up therapy will be undertaken as deemed appropriate
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by the Cardiologist.
The coronary arteriograms will be analysed blindly to
assess the achievement of reperfusion, and to assess the
relative degree. In addition, the morphological appearance
of the coronary artery following reperfusion will also be
assessed using standard techniques, as previously performed
in the European Collaborative Study for Tissue Plasminogen
Activator.
REFERENCES
1. Cercek B. Thrombolytic effect of rt-PA administered as
a bolus. Cl.Research 1987;35:55102 Abstract.
2. Eisert et al. Bolus treatment regimen of rt-PA
expedites rate of lysis without increasing risk of
bleeding. Blood 1987;70(Suppl.1):370a Abstract 1335.
3. Eisert et al. Data on file: data presented at European
Cardiac Conference Vienna 1988. Eur.Heart J.




hereby consent to receive the new thrombolytic agent called
rt-PA and to undergo the procedure of coronary
arteriography, the nature and effect of which have been
explained to me by Dr I consent to the
administration of a local anaesthetic for these purposes.
I also consent to such further or alternative procedures
which may be found to be necessary during the course of the
arteriogram.
Date Signed
I confirm that I have explained to the patient the proposed




PATIENT INFORMATION SHEET: THROMBOLYTIC THERAPY
A heart attack or a coronary thrombosis is the term used
for a condition in which the flow of blood to the heart
muscle is reduced to a degree that damage occurs. The
reduction in blood flow is usually due to a blood clot or
thrombus obstructing the arteries leading to the heart
muscle. After a period of time, damage is irreversible and
the course of the illness will follow the normal healing
process. If a patient is admitted to hospital early
enough, then treatment may be introduced which can dissolve
the blood clot and can restore flow of blood to the area of
muscle under threat of permanent damage.
The standard treatment for heart attack within the Coronary
Care Unit of Stobhill Hospital is to give this therapy to
dissolve the blood clot - that is thrombolytic treatment,
to those patients admitted in the early stage of coronary
thrombosis to obtain coronary artery flow, and to reduce
the degree of damage. This form of treatment cannot be
given to patients who have a predisposition to bleeding,
such as those with stomach or duodenal ulcers, or to
patients who have had strokes or operations in the recent
past.
Two standard drugs are available at present for
thrombolytic therapy called Streptokinase and Tissue
Plasminogen Activator. This latter drug has been shown to
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be very successful in dissolving blood clots, and has been
used in a widespread manner in both United States and
mainland Europe, as well as in the U.K. We use
thrombolytic treatment only in those cases who should
benefit, and who have no contra- indication. This
treatment is in addition to all normal forms of treatment.
Although we are studying Tissue Plasminogen Activator, its
use will not prevent the introduction of any other
treatment which is necessary for the underlying condition.
To maximise the dose of Tissue Plasminogen Activator to be
given to any patient, we are studying its effects on blood
clotting, and therefore frequent blood sampling is taken
from a small plastic tube inserted in the arm.
As a follow up to thrombolytic therapy to assess its
success and to determine if any other procedures or
treatment should be given, an x-ray test, called a coronary
arteriogram, is often helpful and we are performing this as
part of the present study. This requires the insertion of
a little plastic tube into an artery, and therefore signed
consent is required before the performance of this test.
The actual method of the test will be explained separately
by the Doctor who will perform the procedure at the time.
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FURTHER STUDIES OF BOLUS rt-PA IN PATIHITS WITH
ACUTE MYOCARDIAL INFARCTION
INTRODUCTION
Thrombolytic therapy is now established as standard therapy
for the treatment of acute myocardial infarction. Tissue
plasminogen activator has been under clinical study since
the early 1990's and is now available for routine clinical
use. Until the present time, rt-PA has been used given as
a complicated decremental infusion regime. The rationale
behind this was that the half-life of the single chain
preparation of rt-PA (Actilyse) is about 5 minutes. Recent
clinical studies, including observations by our own group
have indicated that the pharmacodynamic effects of rt-PA
exist for longer than the pharmacokinetic effects, i.e.
continued thrombolysis may occur up to 7 hours after
dosing. This has been suggested by animal studies, and has
recently been confirmed clinically. In animal studies,
Cercek (1987) and Eisert (1987) have suggested that bolus
TPA increased the rate of lysis by a factor of two-fold or
more within the first 15 minutes after injection in a dose-
dependent manner.
Clinical studies have also been performed using bolus
dosing of rt-PA in patients with acute myocardial
infarction (Eisert et al., 1988). Initial bolus dosing has
been used with 15-30mg being given, with follow on dosage
schedules up to 100-150mg. Initial clinical experience
with bolus dosing suggests that reperfusion is seen
earlier, and that the minimal luminal stenosis left after
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thrombolysis is lower in such groups. Our initial bolus
studies have been completed using an infusion regime of 35
mg followed by a further 35 mg in 30 minutes. This has
shown a high reperfusion rate and confirms that the
principle of bolus dose administration is worthy of further
study. The aim of the present study is to determine the
efficacy of an alternative regime of 20 mg, followed by two
bolus doses of 20 mg given at 20 minute intervals to a
total dose of 60 mg. This is an attempt to reduce the
initial loading dose and to reduce the total dose given to
try to reduce possible side-effects.
OBJECTIVES
1 . To assess the effect of three boluses of rt-PA on the
patency of coronary vessels at 30, 60 and 90 minutes
in patients with acute myocardial infarction by
invasive and non invasive methods.
2. To assess the pharcodynamic profile of rt-PA when
given in this dosage schedule.
3. To assess the effects of bolus rt-PA on blood
rheology.
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Twenty patients will be treated with three boluses of 20
mg, 20 mg and 20 mg. The maximum total dose of rt-PA for
generalised use as an infusion is 100 mg.
STUDY POPULATION
Inclusion Criteria
(i) Patients with acute myocardial infarction defined as:
a) cardiac pain at rest lasting from 30 minutes up to
6 hours
b) ECG changes at presentation consistent with a
diagnosis of acute myocardial infarction.
Normally this will include ST segment elevation of
at least 2 mms in two precordial leads or ST
segment elevation of 1 mm in two inferior leads.
However, patients with ECG diagnosis of posterior
myocardial infarction and right ventricular
myocardial infarction will also be included.
(ii) Males and females.
(iii) Age 18 to 75 inclusive.
(iv) Patients who have no contra-indications for
angiography.
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(v) Informed consent to participate.
(vi) No previous history on ECG of acute myocardial
infarction in same distribution.
(vii) Patients weighing over 67 kg.
Exclusion Criteria
(i) Patients with ECG abnormalities that make it
impossible to diagnose acute myocardial infarction.
This will include patients with left bundle branch
block and severe conduction defect abnormalities.
(ii) Patients with any contra-indications to thrombolytic
therapy:
Any bleeding diathesis
Major trauma or surgery within three months
Puncture of a non-compressible vessel within 10 days
Any major haemorrhage
Any patient on Warfarin or Coumarin anticoagulants
Any previous cerebrovascular accident including TIA
Any previous history of peptic ulceration
Any proliferative retinopathy
Women who are pregnant, lactating or menstruating
History of severe poorly controlled hypertension
Any additional contraindication that is felt by the




The patients will be assessed pre-study within the Coronary
Care Unit of Stobhill General Hospital. Thrombolytic
therapy has been administered as standard therapy since
1982, and this study will be conducted within the Unit
using standard monitoring facilities and general nursing
medical care as appropriate. Written informed consent will
be obtained from patients, both in terms of adminsitration
of thrombolytic therapy, and also in terms of permission
for performance of coronary arteriography. Where
appropriate, and when available, the protocol and procedure
will be discussed with any accompanying relatives.
The first bolus dose of rt-PA will be given as soon as
possible following diagnosis. Analgesia will be given as
per standard practice, and at no stage will any routine
antiarrhythmic, inotropic nor vasodilator therapy be
witheld. A second bolus dose of rt-PA will be given 20
minutes after the first bolus, and a third bolus will be
given in a further 20 minutes. Aspirin 150 mg will be
given orally after the third bolus, and at 3 hours
following dosing a bolus of heparin 5,000 units and an
infusion of 1,000 units per hour will then be commenced
with the rate of infusion being controlled using standard
coagulation screens. The second or third bolus of therapy
will not be administered if there are any contra¬
indications such as the occurrence of bleeding,
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cerebrovascular accident of if any surgical intervention is
required.
Coronary arteriography will be performed as close as
possible to 30 minutes after the commencement of rt-PA. An
angiogram of the culprit vessel will be performed and
angiography will be repeated at 60 and 90 minutes to
determine coronary artery reperfusion. If the artery
remains occluded, the responsible Consultant may give a
further 40 mg, either by the intravenous or intracoronary
route, according to what is felt best and appropriate
management for the patient. An arterial sheath will be
left in situ and coronary angiography will be repeated at
24 hours.
At all times the performance of angiography will be
undertaken only if the patient's clinical condition is
stable, and the investigation appropriate. Any formal
medical or interventional therapy can be performed at any
time at the discretion of the Consultant Cardiologist
managing the patient's overall condition.
Standard 12 lead ECGs will be performed at time zero, 2, 4,
8 12 and 24 hours following dosing. Serial cardiac enzymes
will be performed, including CPK, AST, ALT and LDH at 4, 12
and 24 hours following admission to confirm diagnosis of
acute myocardial infarction. Routine haematology and
biochemistry will be performed as required for patient
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management, and a coagulation status will be performed to
allow anticoagulation.
PHARMACOKINETIC ASSESSMENT
Serial blood samples will be taken to measure whole blood
viscosity and blood samples to determine measurements of
factions of thrombolysis and fibrinogenolysis, including
measurement of d-Dimer and b-Beta 15-42 fragments. In
addition to routine measurements of fibrinogen, plasminogen
and alpha2 anti-plasmin. Blood samples will be taken pre-
bolus and at 10 and 20 minutes following the first and
second boluses, then at 10, 20, 30, 60 minutes and at 2, 4,
8 and 24 hours following the final bolus. The total volume
of blood will be 175-230 mis.
Standard electrocardiographic monitoring with Holter
monitor will be performed for 24 hours, and this data will
be analysed by Reynolds Pathfinder to correlate ST segment
changes with the reperfusion data obtained from coronary
angiography.
All clinical events will be monitored and the patient's
follow up therapy will be undertaken as deemed appropriate
by the Cardiologist.
The coronary arteriograms will be analysed blindly to
assess the achievement of reperfusion, and to assess the
relative degree. In addition, the morphological
appearance of the coronary artery following reperfusion
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will also be assessed using standard techniques, as
previously performed in the European Collaborative Study
for Tissue plasminogen Activator.
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1. Cercek B. Thrombolytic effect of rt-PA administered as
a bolus. CI.Research 1987;35:55102 Abstract.
2. Eisert et al. Bolus treatment regimen of rt-PA
expedites rate of lysis without increasing risk of
bleeding. Blood 1987;70(Suppl.1):370a Abstract 1335.
3. Eisert et al. Data on file: data presented at European
Cardiac Conference Vienna 1988. Eur.Heart J.




hereby consent to receive the new thrombolytic agent called
rt-PA and to undergo the procedure of coronary
arteriography, the nature and effect of which have been
explained to me by Dr I consent to the
administration of a local anaesthetic for these purposes.
I also consent to such further or alternative procedures
which may be found to be necessary during the course of the
arteriogram.
Date Signed
I confirm that I have explained to the patient the proposed




PATIENT INFORMATION SHEET: THROMBOLYTIC THERAPY
A heart attack or a coronary thrombosis is the term used
for a condition in which the flow of blood to the heart
muscle is reduced to a degree that damage occurs. The
reduction in blood flow is usually due to a blood clot or
thrombus obstructing the arteries leading to the heart
muscle. After a period of time, damage is irreversible and
the course of the illness will follow the normal healing
process. If a patient is admitted to hospital early
enough, then treatment may be introduced which can dissolve
the blood clot and can restore flow of blood to the area of
muscle under threat of permanent damage.
The standard treatment for heart attack within the Coronary
Care Unit of Stobhill Hospital is to give this therapy to
dissolve the blood clot - that is thrombolytic treatment,
308
to those patients admitted in the early stage of coronary
thrombosis to obtain coronary artery flow, and to reduce
the degree of damage. This form of treatment cannot be
given to patients who have a predisposition to bleeding,
such as those with stomach or duodenal ulcers, or to
patients who have had strokes or operations in the recent
past.
Two standard drugs are available at present for
thrombolytic therapy called Streptokinase and Tissue
Plasminogen Activator. This latter drug has been shown to
be very successful in dissolving blood clots, and has been
used in a widespread manner in both United States and
mainland Europe, as well as in the U.K. We use
thrombolytic treatment only in those cases who should
benefit, and who have no contra- indication. This
treatment is in addition to all normal forms of treatment.
Although we are studying Tissue Plasminogen Activator, its
use will not prevent the introduction of any other
treatment which is necessary for the underlying condition.
To maximise the dose of Tissue Plasminogen Activator to be
given to any patient, we are studying its effects on blood
clotting, and therefore frequent blood sampling is taken
from a small plastic tube inserted in the arm.
As a follow up to thrombolytic therapy to assess its
success and to determine if any other procedures or
treatment should be given, an x-ray test, called a coronary
arteriogram, is often helpful and we are performing this as
part of the present study. This requires the insertion of
a little plastic tube into an artery, and therefore signed
consent is required before the performance of this test.
The actual method of the test will be explained separately
by the Doctor who will perform the procedure at the time.
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Objective—To examine the efficacy,
safety, and the pharmacokinetic profile of
a bolus dose administration regimen of
alteplase in the treatment of acute
myocardial infarction.
Design—An open pilot study.
Setting—District general hospital.
Patients—33 suitable consecutive
patients presenting within six hours of
the onset of symptoms who satisfied the
electrocardiographic criteria for acute
myocardial infarction.
Interventions—Two intravenous boluses
of 35 mg alteplase, 30 minutes apart.
Main outcome measures—Angiogra¬
phic coronary patency at 90 minutes and
24 hours. Plasma alteplase concentra¬
tion-time profile and pharmacokinetic
analysis.
Results—Coronary patency at 90 min¬
utes: 26 of 30 arteries (87%, 95% con¬
fidence interval (CI) 74-99%). Coronary
patency at 24 hours: 24 of 29 arteries
(83%, CI 69-97%). Mean (SD) plasma
tissue plasminogen activator (t-PA) con¬
centration reached 4434-8 (2117-8) and
4233-3 (2217-5) ng/ml within 10 minutes
of each bolus and fell to 425*8 (288-3)
ng/ml between boluses. The estimated
peak concentrations at two minutes after
boluses were 12 389 (8580) ng/ml and
10 811 (6802) ng/ml. The derived phar¬
macokinetic variables were volume of
distribution 3-11 (1*89) 1, clearance 21-3
(9-3) 1/h, half life 5 9 (1-7) minutes.
Conclusions—This simple administra¬
tion regimen achieved brief, high con¬
centrations of plasma t-PA that were
well tolerated. The regimen was as¬
sociated with a high coronary patency
rate at 90 minutes that was well main¬
tained at 24 hours.
Thrombolytic therapy is now accepted as a
standard treatment for acute myocardial in¬
farction because studies have shown that it
improves left ventricular function and reduces
mortality.1-' The benefit of thrombolysis is
improved by early treatment2 5 and the re-
establishment of coronary patency. Therefore,
the ideal thrombolytic agent- should be easily
and rapidly administered by the intravenous
route and should effectively and rapidly restore
coronary patency without adverse side effects.
The ease of administration of the agent
becomes increasingly important with the
emphasis on immediate treatment on arrival
in hospital and the possibility of starting treat¬
ment in the community.
Alteplase (recombinant tissue plasminogen
activator) is successful in restoring coronary
patency,6"11 with higher patency rates than a
conventional dose of intravenous streptokin¬
ase.6 ' At present, the recommended dosage
regimen for alteplase is a 10 mg bolus, with a
tapering dose of 90 mg infused over three
hours. This regimen was based on the
apparent short half life of alteplase in the
circulation,12 but clearly this regimen is a
cumbersome one to apply urgently.
We assessed the efficacy of two boluses of
35 mg alteplase administered intravenously 30
minutes apart in achieving angiographic
coronary patency. We also studied the phar¬
macokinetics of this regimen.
Patients and methods
Thirty three consecutive patients (23 men and
10 women, age range 40-74, mean age 56-3
years) were admitted to Stobhill Hospital
coronary care unit and recruited into the
study. Patients were eligible for inclusion if
they presented with chest pain of at least 30
minutes' duration, could be treated within six
hours of the onset of symptoms, and had
electrocardiographic evidence of acute
myocardial infarction (ST elevation > 1 mm
in two limb leads or > 2 mm in two precordial
leads). Patients were excluded if they were
over 75 years of age, had a previous infarct in
the same anatomical distribution, or had any
of the recognised contraindications to throm¬
bolytic therapy6 or coronary angiography. The
study protocol was approved by the local
research and ethics committee.
Table 1 shows the baseline characteristics
of the patients recruited. After the patients
had given their written informed consent and
the protocol had been discussed with accom¬
panying relatives, the patients were given
35 mg alteplase intravenously over 30
seconds. This dose was repeated 30 minutes
later. All patients received 150 mg aspirin
orally immediately on entry to the study and
daily thereafter. All patients were given an
intravenous infusion of glyceryl trinitrate
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Angiography not performed 3
Mean (SD) time to therapy 208(75)min
Mean (SD) time to first angiographic 49-4 (13 3) min
injection
Mean weight 73-2(12 8) kg
Dose of alteplase administered 70 mg
Mean dose of alteplase administered 0 984 (0 173) mg/kg
Cx, circumflex; LAD, left anterior descending; LMCA, left
main coronary artery; RCA, right coronary artery.
starting at 0-25 mg/h unless there was a
specific contraindication.
Coronary angiography was performed in
the coronary care unit with an image inten-
sifier (Siremobil 2N/2H) linked to a video tape
recorder (JVC CR8200E). Details of this sys¬
tem have been described elsewhere.13 The
Seldinger percutaneous approach was used
and a femoral sheath was left in situ. The
coronary angiogram was started immediately
after the second bolus of alteplase (30 minutes
after the first bolus), and the infarct related
coronary artery (as indicated by the admission
electrocardiogram) was visualised as soon as
possible after 30 minutes, then by selective
injections at 60 and 90 minutes. The degree of
perfusion was scored according to the Throm¬
bolysis in Myocardial Infarction (TIMI) scale
and reviewed by an independent experienced
cardiologist: a score of 0-1 indicated non-
patency and one of 2-3 indicated a patent
artery.6
If the artery was occluded at 90 minutes,
the study protocol allowed additional treat¬
ment to be given up to the total dose of
100 mg alteplase, as recommended by the
product licence. The other coronary arteries
were visualised in standard angiographic
projections. The femoral sheath was left in
situ and coronary angiography was repeated at
24 (8) hours after treatment to assess patency
and reocclusion.
An intravenous heparin infusion was started
in all patients 3-4 hours after onset of treat¬
ment, and the dose was titrated against the
thrombin time to a therapeutic ratio of 2:3.
No bolus of heparin was given at the start of
alteplase treatment. In all patients heparin
was stopped for a short period at the time of
the second angiogram to allow removal of the
Table 2 Angiographic details
Number ofpatients
TIMI grade First injection























femoral sheath. Venous blood samples were
collected via an indwelling venous catheter
from the first 24 patients before treatment, and
then 10, 20, 30, 40, 50, 60 minutes and 2, 4, 8,
12, 24 hours after the first bolus of alteplase,
into sodium citrate. The samples were cen-
trifuged immediately at 06C, separated, and
frozen at — 40°C. Subsequent analysis for




The infarct related artery was first visualised at
49 4 (13-3) minutes after the first bolus of
alteplase. The artery was visualised within 55
minutes in 26 of 30 (86%) patients. In three
patients an acute angiogram was not obtained:
in one because of haemodynamic instability, in
one because of death before 90 minutes, and in
one it was not possible to inject the right
coronary artery.
In three patients, although the entry criteria
were satisfied, the serial electrocardiographic
changes of acute myocardial infarction did not
occur and cardiac enzymes were normal. In one
of these patients the right coronary artery could
not be visualised and this patient is not
included in the angiographic data. In all other
patients angiographic data were obtained
within 90 minutes of start of treatment and the
results presented are the patency rates of all
patients in whom coronary visualisation was
achieved at each time point. At the first injection
of the infarct-related artery (49 4 (13-3) mins)
23 of 30 (77%, 95% confidence interval (CI) 61
to 92%) arteries were patent. At 90 minutes
this had increased to 26 of 30 (87%, 95% CI 74
to 99%) arteries (table 2).
Two patients were given a further intra-
coronary dose of 30 mg alteplase after the 90
minute angiogram. In one there was intermit¬
tent reperfusion of the index artery during the
period of angiographic observation. In the
other, after occlusion of the left main coronary-
artery, there was penetration only of the cir¬
cumflex at 90 minutes. In both patients, the
arteries were patent at the 24 hour angiogram.
One patient did not undergo the 24 hour
angiogram because of haematoma formation
after splitting of the femoral sheath. At 24
hours, 24 of 29 arteries (83%, 95% CI 69 to
97%) were patent. Seven patients improved
their angiographic appearance by at least one
grade, with three achieving reperfusion.
However, five deteriorated at least one grade
with three arteries becoming reoccluded (10%,
95% CI 0 to 22%).
ADVERSE EVENTS
The only adverse events documented in our
study group were bleeding complications. In
five patients significant haematomata developed
at the site of arterial access for coronary
angiography. Two patients suffered minor
coffeeground haematemesis and one other bled
from the gums. No patient required a blood
transfusion or specific intervention.
One patient died during the study. This
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patient had severe triple vessel disease and a
previous myocardial infarction. Shortly after
admission and treatment cardiogenic shock
developed and he died despite inotropic
support.
PLASMA t-PA CONCENTRATIONS
The mean (SD) pretreatment plasma t-PA
concentration (20-1 (4-3) ng/ml) was signifi¬
cantly higher than our laboratory normal (3 6
(1-3) ng/ml). It rose to 4434-8 (2117-8) ng/ml
within tenminutes of the first bolus ofalteplase,
fell to 425-8 (288-3) ng/ml before the second
bolus, and rose again to a peak of 4233-3
(2217-5) ng/ml within 10 minutes of the second
bolus (figure). Mean concentrations then fell
rapidly and at four hours were about twice the
pretreatment values (40-6 (28-6) ng/ml). After
this t-PA concentrations were low, variable,
and at approximately physiological values.
This introduced considerable random varia¬
tion in the pharmacokinetic fitting; therefore
the data fitted were the baseline-subtracted
concentrations confined to the four hour period
after the administration of alteplase. This
approach was adopted by others.1314
The individual declines in t-PA concentra¬
tion were fitted to one, two, and three compart¬
ment pharmacokinetic models, but a satisfac¬
tory fit was obtained only with the one compart¬
ment model. The pharmacokinetic results
derived from this model were volume of dis¬
tribution 311 (1 -89) 1 (coefficient of variation
(CV) 35-6 (26-7)%), clearance 21-3 (9-3) 1/h
(CV 14-1 (11-7)%) and half life 5-9 (1-7) min.
The coefficients of variation are means (SD) of
the coefficients of variation of the individual
fitted data and express the quality of fit of the
model (table 3). Using this model we estimated
the plasma t-PA concentrations two minutes
after the beginning of the intravenous boluses
ofalteplase, as a measure of the peak concentra-
Table 3 Pharmacokinetic variables
Variable Mean SD
Clearance (1/h) 21 4 9 3
Coefficient of variation of
estimates of clearance (%) 141 117
Volume of distribution (1) 3 11 1 89
Coefficient of variation of
estimates of volume (%) 35 6 26-7
Half life (min) 5 9 17
Gemmill, Hogg, Maclntyre, Booth, Rae, Dunn, Hillis
tions achieved with this administration
regimen. The peak concentration was 12 389
(8580) ng/ml two minutes after the first bolus
and 10 811 (6802) ng/ml after the second bolus
of alteplase.
Discussion
Our results show that a regimen of alteplase
administered intravenously as two boluses of
35 mg at an interval of 30 minutes is effective in
restoring coronary artery patency in acute
myocardial infarction. To allow comparison
with other patency studies, our primary end
point of efficacy was patency at 90 minutes after
treatment, but in addition we have angiograms
earlier in the course of treatment to assess the
time to reperfusion. At the time of first injec¬
tion, at a mean of 49 minutes after treatment,
77% of our patients had patent index coronary
arteries; this improved to 87% within 90 min¬
utes, showing that patency is achieved rapidly
and effectively.
Direct comparison with other studies of
recombinant tissue-type plasminogen activator
(r-tPA) is difficult because of several confound¬
ing factors. Other studies used different admin¬
istration regimens with widely varying doses of
two different preparations of rt-PA, with dif¬
ferent specific activities.1516 In addition,
whereas some workers studied patency others
studied reperfusion, with a difference owing to
sub-total coronary occlusion at presentation
and spontaneous reperfusion.17
Verstraete and coworkers showed patency
rates of 61% at 75-90 minutes after treatment
using 0-75 mg/kg ofdouble chain rt-PA over 90
minutes." The same group using a 40 mg
infusion of double chain rt-PA over 90 minutes
achieved a coronary patency rate of 66% at 90
minutes.18 Topol and the TAMI group
achieved a patency rate of 68% with 70 mg of
rt-PA over 90 minutes and one of 79% with a
high dose (1-5 mg/kg) of alteplase over four
hours in conjunction with a high dose of
heparin.""21 In TIMI I workers used 80 mg of
double chain rt-PA over three hours and found
a reperfusion rate of 56%.6 7 Williams et al used
the same dose of 80 mg over three hours and
found a similar reperfusion rate of 68%.8
Published reports of studies of bolus doses of
alteplase are limited. Verstraete et al using
single boluses of alteplase found that doses of
60 mg and 50 mg were associated with reper¬
fusion rates at 90 minutes of 32% and 45%
respectively, although a maximum dose of
70 mg achieved reperfusion in 72%.22 Khan et
al evaluated four boluses of double-chain t-PA
of 25 mg given over 60 minutes and showed
recanalisation in 11 of 14 patients; they sugges¬
ted that this regimen achieves coronary patency
more rapidly.23 In our study, 70 mg divided
into two boluses also achieved a high patency
rate, and would be expected to be associated
with fewer bleeding complications.24
In a recent small study Smalling et al, used
rapid intravenous infusion of a weight adjusted
dose of alteplase, and a median dose of 145 mg.
They reported a 90 minute patency rate of
84%, which was significantly higher than the
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control group who received a conventional
three hour infusion of 100 mg.25 These results
suggest that rapid administration of the throm¬
bolytic agent achieves higher patency, and that
it is the peak concentration of agent achieved
that is important—an inference supported by
our data.
The reported higher patency rates were
achieved with higher weight adjusted doses of
rt-PA. In our study the total dose of 70 mg
alteplase represents a mean dose of 0-98 mg/kg.
This contrasts with 1-5 mg/kg administered by
Topol et al20 and the fixed doses of 150 mg used
in the TIMI II study24 or 100 mg used in the
Australian National Heart Foundation Study.26
The 100 mg dose is recommended by the
manufacturers27 and is now in regular use.
Despite the lower dose we used, our patency
rate of 87% at 90 minutes compares favourably
with the published data.
Pharmacokinetic analysis of the plasma t-PA
concentration-time profile after this bolus
administration regimen of alteplase shows that
very high, short lived concentrations of t-PA
are achieved shortly after injection of the drug.
The concentration of t-PA achieved at 10
minutes (4434-8 (2117-8) ng/'ml is 34% higher
than the peak concentration attained by
Seifried et al, with 100 mg of single chain rt-PA
delivered as a 10 mg bolus and 90 minute
tapered infusion.'4 We found t-PA concentra¬
tions in excess of 2 300 ng/ml in all our patients
and predicted concentrations two minutes after
the boluses of alteplase in excess of 10 000
ng/ml. As would be expected, the period dur¬
ing which t-PA concentration was in excess of
1000 ng/ml is shorter with bolus administration
than with prolonged infusion.
Despite the short duration of high plasma
t-PA concentrations the reocclusion rate to 24
hours of three of 29 patients (10%) resembles
previous experience.18
Our patients' pretreatment t-PA concentra¬
tions were raised, but 4—8 hours after alteplase
concentrations fell to physiological values.
After four hours in all patients, t-PA concen¬
trations were low and variable,making fitting to
pharmacokinetic models difficult. To eradicate
this variable, we fitted the data for the first four
hours only and used baseline-subtracted
values. Despite taking frequent blood samples
we were unable to define multiple phases of
elimination, unlike others. Our data fitted our
chosen model satisfactorily, as reflected in low
standard deviations for each individually fitted
variable. These individual standard deviations
were expressed as coefficients of variation (CV)
of their respective estimated variable and the
CVs expressed as the mean. The mean CV of
the estimate of mean clearance was 14% and
that of the estimate ofmean volume of distribu¬
tion 36%, which indicates that the estimate of
these mean variables was reliable. Previous
studies have not reported details of the quality
of fit of their models and therefore of the
reliance that can be placed on their estima¬
tions.12 14
Our findings confirm the rapid clearance of
t-PA from the circulation, with a half life of 5-9
(1-7) minutes and modest inter-patient
variability. These closely correlate with
previous reports in patients, although they are
somewhat slower than findings in normal
volunteers with a lower total dose—possibly
reflecting diminished cardiac output and
hepatic blood flow in our patients with myocar¬
dial infarction. Our estimate of volume of
distribution of 3-1 (1-9) 1 is very similar to
previous estimates in both patients and volun¬
teers.
Some workers have found a dose related rise
in bleeding complications, in particular
intracranial bleeding.24 In our study, using a
relatively small dose ofalteplase, we saw bleed¬
ing complications in eight (24%) of 33, with five
of these being related to arterial access for
coronary angiography; there were three
episodes of minor gastrointestinal bleeding
(9%). No patients required transfusion or
specific intervention. These results are similar
to previously published data,69 10 but our small
study numbers do not allow firm conclusions to
be drawn.
Our findings show that alteplase adminis¬
tered as two intravenous boluses of 35 mg 30
minutes apart reliably produced very high
concentrations of t-PA in the plasma, which
was rapidly cleared from the circulation and
allowed a high coronary patency rate in acute
myocardial infarction. The total dose adminis¬
tered was less than that used in many studies
reporting high patency, yet reocclusion rates
were similar to those reported before. The
greater simplicity of administration and higher
efficacy of this regimen may allow alteplase
treatment to be safely started before admission
to hospital with the advantages that such earlier
administration would give.
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The pharmacokinetics of streptokinase (SK) and anistreplase in conventional dosage
regimens of 1.5 x 106 i.u. of SK infused over 60 min and 30 units of anistreplase over 5
min were studied in 24 consecutive patients presenting with acute myocardial
infarction, using a functional bioassay to assess concentrations.
! The two agents were found to have similar volumes of distribution (5.68 and 5.90 1),
but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter
terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).
■Keywords streptokinase myocardial infarction pharmacokinetics
inistreplase
introduction
The role of thrombolytic therapy in the treatment of
acute myocardial infarction is well established, and the
earlier treatment is initiated, the greater the clinical
benefits (GISSI, 1986; ISAM, 1986; ISIS II, 1987; AIMS,
1988).
The ideal thrombolytic agent would therefore be easily
and rapidly administered by the intravenous route and
have pharmacokinetic properties allowing rapid onset
of thrombolytic activity maintained for long enough
to prevent early coronary reocclusion. Currently avail¬
able agents and dosage regimens are not ideal, but
pharmacokinetic studies may facilitate the development
of optimal administration regimens.
Streptokinase binds to plasminogen (or plasmin) in
the blood to form the complex SK-glu-plasminogen
(-plasmin) which is an effective plasminogen activator
(Anderson et al., 1987). Anisoylated lys-plasminogen
streptokinase activator complex (APSAC, anistreplase,
Eminase, a trademark of Beecham Group p.I.e.) is a
pro-enzyme giving rise to the plasminogen activator
complex streptokinase-lys-plasminogen by deacylation.
The activator complexes of the two agents are of com¬
parable potency in the activation of plasminogen.
Deacylation of anistreplase occurs with a half-life of
105 min in vitro and is thought to be rate-limiting for the
removal of anistreplase from the circulation, and to be
slower than the elimination of SK-plasminogen or SK.
Previous pharmacokinetic studies are relatively few in
number, were flawed by the paucity and timing of blood
samples, and have used a variety of different assay
methods. Despite these limitations, they have suggested
that SK is rapidly eliminated with a concentration-time
profile variously fitted by mono- or bi-exponential func¬
tions (Kohler et al., 1987, Mentzer et al., 1986), while
anistreplase is eliminated from the circulation much
more slowly than SK (Been et al., 1986; Kohler et al.,
1987). In this study, we have compared the pharmaco¬
kinetic properties of these agents directly using a func¬
tional bioassay.
Methods
Twenty-four consecutive patients (18 male, six female,
age range 48 to 72 years) with acute myocardial infarc¬
tion as judged by strict ECG criteria, presenting within
6 h of onset of pain, and without contraindications to
thrombolytic therapy were treated with either a conven¬
tional dose of 1.5 x 106 i.u. of SK infused intravenously
over 60 min or 30 u of anistreplase as a 5 min continuous
intravenous injection. Blood samples were obtained
from an indwelling venous catheter at frequent intervals
up to 24 h after dosing (0,6,10,20,30,45,60,75,90 min,
2, 4, 6, 9, 12 and 24 h). They were collected into 0.1
volumes of 3.8% w/v sodium citrate, the plasma was
separated immediately at 4° C and stored at -70° C.
Total fibrinolytic activity was measured as described
by Been et al. (1986) and Nunn etal. (1987), and used as
a functional bioassay of the plasma concentrations of the
thrombolytic agents. The preparation of euglobulin
fractions has been reported in detail elsewhere (Standring
et al., 1988). In brief, plasma samples were diluted with
0.011% v/v acetic acid and the resulting precipitates
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Table 1 Pharmacokinetic parameters
Anistreplase (n = 12) SK (n = 12)
Mean (s.d.) Mean (s.d.)





Volume of distribution (I)
Model-independent (V) 5.90 (1.91) 5.68 (2.29)NS
Computer-modelled (Vss) 5.25 (1.49)
Clearance (I h~')
Model-independent (CL) 3.87 (1.52) 7.08 (2.91)*
Computer-modelled (CL) 3.72 (1.35)
Terminal phase elimination half-life (h)
Model-independently 1.16 (0.38) 0.61 (0.24)**
Computer-modelled tVl 1.15(0.38)
Time to half maximal fibrinolytic activity (h)
1.12(0.31) 0.48(0.14)**
Mean residence time (h) 1.55 (0.48) 0.76 (0.31)
tP < 0.05, *P < 0.01, **P < 0.001, NS = Not significant.
were solubilized to give a 30-fold dilution of the original
plasma. This dilution factor was found to abolish the
interference from variable amounts of endogenous
plasminogen and plasmin in the samples (Nunn et al.,
1987). Fibrinolytic activity was assayed by the lysis of
fibrin plates prepared from human fibrinogen (containing
2 |xg plasminogen mg-1 fibrinogen) incubated at 37° C
for at least 18 h. The plates were stained with bromo-
phenol blue and lysis zones were measured with an AMS
image analyser. Quadruplicate measurements were
made at each time point and typical coefficients of
variation ranged from 0.44 to 2.6% (mean 1.6%, n = 11)
for anistreplase and from 0.36 to 6.6% (mean 2.4%,
n = 10) for SK. The concentration of activator was
calculated for each patient employing the appropriate
standards diluted with autologous predose plasma, i.e.
SK for SK treated patients and anistreplase for ani¬
streplase treated patients. Standards were prepared
using the patient's own pretreatment plasma to allow for
any interpatient variability; the slopes of the standards
ranged from 1.57 to 3.26 (mean 2.42) for SK, and 1.78 to
3.07 (mean 2.47) for anistreplase. SK and anistreplase
standards gave linear responses with correlation co¬
efficients of 0.9946 (percentage coefficient of variation,
%CV 0.34) for SK (n = 12) and 0.9938 (%CV 0.21) for
anistreplase (/; = 12).
Internal standards were also included in each assay, in
pretreatment, and 10 min to 2 h post-treatment samples,
and processed concurrently. The average recovery for
samples from the entire group of 12 patients was 91% for
SK and 94% for anistreplase. The limit of reliable assay
was 0.08 x 10"8 m (3.91 i.u. ml"1) for 10 SK treated
patients and 0.04 x 10~8 m (1.95 i.u. ml-1) for the
remaining two. For anistreplase the lower limit of assay
was 0.06 x 10"8 m (7.81 X 10"5 i.u. ml"1).
Plasma SK- and anistreplase-time data were fitted by
one- or two-compartment models using non-linear re¬
gression as appropriate to each individual data set.
Modelling was performed using the computer program,
MODFIT, which employs a modified Danielson-Fletcher-
Powell algorithm (Allen, 1990). The same data sets wer
subjected to compartmental model-independent analysi
calculating AUC using the linear trapezoidal methoc
with extrapolation to infinity. Clearance (CL) anc
volume of distribution (V) were calculated by standarc
methods (Gibaldi & Perrier, 1982). The terminal phas<
half-life (fi/2) was also determined by regression analysi:
as was the time to loss of half the maximal fibrinolytii
activity from the end of the dosing period. Instantaneou:
mean residence times (MRT), which compensate for the
differences in the duration of dosing between SK anc
anistreplase, were determined by moment analysis
(Riegelman & Collier, 1980).
Pharmacokinetic parameters for anistreplase and SK




Derived pharmacokinetic parameters are summarised in
Table 1, and mean concentration-time curves are shown
in Figure 1. Concentration-time curves during and after
infusion were analysed by model-independent methods
only as the data could not be adequately fitted by a
compartmental model. The terminal phase rate constant
was determined using non-linear regression analysis
with a weighting of concentration-2.
The maximum plasma concentration (Cmax) occurred
within 1.25 h (tmax) of the start of the infusion (mean 0.9 h).
Subsequently concentrations declined rapidly to less
than 15% of Cmax in all subjects by 4 h after the start of
infusion, and in most subjects were below the limit of
reliable measurement at this time. The post peak decline
in concentration approximated to a mono-exponential
fall (maximum % CV of the regression lines was 26%) as
determined by MODFIT (Allen, 1989).



















rigure 1 Plasma concentrations of streptokinase (mean ±
,.d.) during and after intravenous infusion of 1.5 x 106 i.u. of
itreptokinase over 60 min.
Figure 2 Plasma concentrations of anistreplase (mean ± s.d.)
following intravenous injection of 30 u of anistreplase over
5 min.
The volume of distribution of SK was low, approxi¬
mating to that of plasma proteins. In conjunction with
a moderately rapid clearance this accounted for a short
terminal phase half-life.
Anistreplase
The maximum total activity of anistreplase (Cmax)
occurred within 20 min (tmax) of the start of the 5 min
intravenous injection (mean 0.15 h).
Activity fell to less than 15% of maximum by 4 h. In
six of the 12 patients, an early rapid decline phase of the
concentration-time curve could be delineated, conform¬
ing to a two-compartment model. In five subjects the
data sets conformed to a one-compartment model. In
one subject, neither model provided a satisfactory fit
and these data were analysed by model-independent
methods only. The derived parameters were similar
regardless of which model was most appropriate, and
were comparable with parameters derived from model-
independent analysis.
Pharmacokinetic parameters are summarised in Table
1 and mean total activity-time curves are shown in
Figure 2.
The volume of distribution of anistreplase and its
deacylated product was relatively low, consistent with
anistreplase and its metabolite being confined largely to
the systemic circulation. Clearance was modest and in
conjunction with a small volume of distribution resulted
in a longer elimination phase half-life (1.16 ± 0.38 h)
than that of SK.
Discussion
Thrombolytic therapy in acute myocardial infarction
achieves infarct related artery patency, limitation of
infarct size and improves mortality. Coronary reperfusion
rates are highest when the therapy is administered early
in the course of myocardial infarction (Kennedy et al.,
1985; Khalilullah et al., 1984; Lew et al.. 1986; Weinstein,
1982), and is associated with greatest clinical benefits
(AIMS, 1988; Anderson et al., 1984; GISSI, 1986;
ISAM, 1986; ISIS II; 1987, Simoons et al., 1985). For
earlier institution of therapy, a suitable thrombolytic
agent must be administered in a simple regimen allowing
easy administration, applicable even outside the hospital
environment. The ideal regimen should therefore achieve
a high early concentration, and resulting fibrinolytic
activity (short fmax and high Cmax), a slow elimination
phase, allowing maintenance of adequate concentrations
from a single 'bolus' injection (long t,/2, low CL) for an
appropriate period of time, thus minimising early re-
occlusion.
Early recommendations for the use of SK were for a
prolonged low dose infusion, but more recent usage in
myocardial infarction has adopted the now standard, but
essentially empirical dose of 1.5 X 106 i.u. over 60 min.
The recommended dose of anistreplase was based on
being equivalent to 1-1.5 x 106 i.u. of SK. Following the
administration of SK and anistreplase in their standard
treatment regimens for myocardial infarction, anistreplase
achieves a significantly earlier and higher peak concen¬
tration as would be predicted from its more rapid infusion.
In this study, we have found that SK and anistreplase
both have a low volume of distribution, approximately
twice that of plasma volume and similar to the volume
of distribution of plasma proteins (Rowland & Tozer,
1980). This would be consistent with both agents
behaving as proteins with no specific carrier mechanism.
The observed elimination phase half-life of SK of
0.61 h was similar to previous estimates based on fibrin
plate lysis assay in acute myocardial infarction (Kohler et
al., 1987) and slightly longer than estimates based on
other functional assays of 0.3 h (Martin, 1982) and 0.38 h
(Mentzer et al., 1986). These small differences may be
accounted for by variation in assay specificity and phar¬
macokinetic analysis. Claims of a considerably longer
terminal phase, with a half-life of 1.38 h (Fletcher et al.,
1958; Grierson & Bjornson, 1987), are based on radio¬
immunoassay or amidolytic assay methods for SK.
i SK infusion
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These methods do not differentiate between active and
inactive SK fragments, or take account of in vivo de-
iodination. Similarly, the amidolytic assays based on
the lysis of chromogenic substrate do not evaluate the
fibrinolytic sites of the activator molecule, and also
therefore cannot differentiate active and inactive SK
fragments, or fragments bound by circulating inhibitors
such as a2"antiplasmin. The results of previous studies
based on the lysis of bovine fibrin are also problematic,
in that this assay is particularly sensitive to endogenous
human plasminogen.
In this study, both drugs have been assayed by the
same fibrinolytic bioassay based on human fibrin plate
lysis. It has been shown that administration of either
thrombolytic agent does not completely deplete circu¬
lating plasminogen. Therefore, all of the SK present
would be in its fibrinolytically active complexed form.
Thirty-fold dilution of the euglobulin fractions eliminates
the influence of endogenous plasminogen on the assay
procedure (Fears, 1989). Therefore, this assay method
measures the functional moiety and is relevant to th
clinical application of these drugs.
We have shown that SK and anistreplase have simik
low volumes of distribution, but that SK is effective]
cleared from the circulation twice as fast as anistreplas
(7.08 vs 3.87 1 h-1, P < 0.01). In vitro studies of th
deacylation of anistreplase in human blood or plasm
have shown a deacylation half-life of 1.76 h (Ferres
1987). Our results would therefore support the concep
that the deacylation of anistreplase is the rate-limitin
step in its elimination.
Both streptokinase as a 60 min infusion of 1.5 x 10
i.u. (Verstraete et al., 1985) and anistreplase as a 5 mil
injection of 30 units (Been et al., 1985; Hillis et al., 1987
Ikram etal., 1986; Timmis etal., 1987) are well-toleratei
and effective in restoring coronary patency in acuti
myocardial infarction. In this study, we have confirmee
that anistreplase in this dosage schedule achieves earlier
higher and more prolonged levels of total thrombolytii
activity.
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